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Summary
In spite of the great efforts and progresses made over many years in the fight
against cancer, improving the treatment, whence the prognosis of this disease re-
mains one of the biggest challenges in medicine nowadays. Ever since the discovery
of X-rays by Wilhelm Conrad Ro¨ntgen in 1895, radiotherapy has played a major
role in the treatment of solid tumors for curative or palliative purposes. Radio-
therapy techniques are designed to shed ionizing radiation to induce lethal damage
in pathological tissues, while at the same time avoiding as much as possible un-
desirable side effects on nearby organs and healthy tissues. According to recent
estimates, no less than 50% of all cancer patients receive radiotherapy during their
illness, whether on its own or as an adjunct to chemotherapy, surgery or other
medical techniques. Technical and methodological advances during the last cen-
tury have allowed radiation oncologists and radiophysicists to achieve local tumor
control in a considerable number of patients diagnosed with solid tumors. How-
ever, locoregional recurrence after therapies and the treatment of disseminated
tumors remain a formidable problem in many cases. For these reasons, it is nec-
essary to improve currently used diagnosis, planning and therapeutic techniques.
In this context, the development of new mathematical models and more sophisti-
cated computer-based procedures are expected to provide significant tools towards
curing the disease whenever possible and to improve the patients quality of life in
all cases.
The present memoir aims at developing mathematical models and computer-
based procedures to assist in the decision-making process whereby actual radiother-
apy treatment plans are selected. To that end, the plan of this work is described
as follows. To introduce the main problems addressed in this work, an overview
of the key principles involved in radiotherapy is provided in Chapter 1. In the
first part of that Chapter a detailed description of the main steps in the treatment
planning process is presented. Then some of the mathematical tools used in radio-
therapy are briefly reviewed. In Chapter 2 a multi-parameter variational problem
is proposed and analyzed whose solutions provide optimal radiation dose distri-
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butions based on clinical and technological requirements. To obtain solutions of
such mathematical model, different numerical and optimization methods have been
implemented, and a detailed description of them is provided in Appendix A. In
Chapter 3 a model of heterogeneous tumor growth based on specific biological and
radiobiological properties is presented, and tumor response to different homoge-
neous and heterogeneous radiation dosimetries is investigated. Since intratumoral
heterogeneity is widely considered to be a determinant factor in tumor progression
and in particular in its recurrence after therapy, the study now performed supports
a change in the current dosimetry strategy, which aims at delivering homogeneous,
instead of heterogeneous, doses on target. In Chapter 4 a mathematical decision-
aid tool is defined to assist clinicians and radiophysicists in the choice of actual
treatment plans to be carried out, a process that to this day largely relies on the
experience of the specialists in charge. The tool now provided permits to compare
and evaluate tentative treatment plans for a same patient simulated on a commer-
cial treatment planning system. To conclude, additional results as complement to
those presented in Chapters 2 and 3 are provided in Appendices B and C respec-
tively. Finally, the main results obtained in this work as well as future research
directions are discussed in the final Chapter 5.
In summary, the work herein reported provides new mathematical models and
computer-based procedures that could be combined with current techniques to
improve radiotherapy outcomes. Such results should therefore be considered as
auxiliary instruments to prepare and deliver better treatment plans, a goal of
great importance both from scientific and social points of view.
xiv
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Resumen
Introduccio´n y Objetivos:
A pesar de los grandes avances realizados durante muchos an˜os en la lucha
contra el ca´ncer, mejorar el tratamiento, y por consiguiente el prono´stico de esta
enfermedad sigue siendo uno de los mayores retos de la medicina en la actualidad.
Desde el descubrimiento de los rayos X por Wilhelm Conrad Ro¨ntgen en 1895, la
radioterapia ha jugado un papel destacado en el tratamiento de tumores so´lidos,
ya sea con fines curativos o paliativos. En la actualidad, no menos del 50% de los
pacientes de ca´ncer reciben este tipo de tratamiento, ya sea por si solo o en com-
binacio´n con quimioterapia o cirug´ıa. Las te´cnicas de radioterapia buscan enviar
radiacio´n ionizante para inducir dan˜os letales en tejidos patolo´gicos, evitando en
la medida de lo posible dan˜os colaterales en tejidos sanos y o´rganos pro´ximos. Los
avances te´cnicos y metodolo´gicos realizados durante el u´ltimo siglo han permitido
a onco´logos y radiof´ısicos conseguir control tumoral local para un nu´mero conside-
rable de pacientes diagnosticados con tumores so´lidos. Sin embargo, la recurrencia
local tras la terapia y el tratamiento de tumores diseminados siguen representando
problemas formidables en muchos casos. Por ello es necesario mejorar las te´cnicas
actualmente usadas para el diagno´stico y la planificacio´n de tratamientos. En este
contexto se espera que el desarrollo de nuevos modelos matema´ticos y de sistemas
de ca´lculo ma´s eficaces suministren importantes herramientas para curar la enfer-
medad cuando sea posible y para mejorar la calidad de vida de los pacientes en
cualquier caso.
El objetivo de esta memoria es desarrollar modelos matema´ticos y te´cnicas
computacionales que permitan ayudar a decidir la eleccio´n de tratamientos de ra-
dioterapia. Para ello, el plan a seguir es el siguiente. En el Cap´ıtulo 1 se describen
los principios ba´sicos de la radioterapia que permiten definir el marco en el que
se formulan los problemas que se abordara´n en este trabajo. En concreto, en la
primera parte de ese Cap´ıtulo se recuerdan los fundamentos ba´sicos de la radiote-
rapia, y a continuacio´n se describen algunas herramientas matema´ticas usadas en
este campo. En el Cap´ıtulo 2 se propone y analiza una clase de problemas varia-
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cionales multiparame´tricos cuyas soluciones proporcionan distribuciones o´ptimas
de radiacio´n basadas en restricciones cl´ınicas y tecnolo´gicas. Para obtener solu-
ciones de dicho modelo, han sido desarrollados diversos me´todos nume´ricos y de
optimizacio´n, que se describen en detalle en el Ape´ndice A. En el Cap´ıtulo 3, se pre-
senta un modelo de crecimiento tumoral heteroge´neo basado en hipo´tesis precisas
de tipo biolo´gico y radiobiolo´gico, y se estudia la respuesta tumoral ante diferen-
tes dosimetr´ıas de radiacio´n, tanto homoge´neas como heteroge´neas. Dado que la
heterogeneidad intratumoral se considera un factor determinante en la progresio´n
tumoral, y en particular en la recurrencia tras la terapia, el estudio realizado su-
giere un cambio en la estrategia cl´ınica actualmente seguida, que busca administrar
dosis homoge´neas en cualquier caso. En el Cap´ıtulo 4 se propone una herramienta
de ayuda a la decisio´n para elegir el plan de radioterapia que ha de ser implemen-
tado, lo que hasta ahora se basa fundamentalmente en la experiencia del personal
que ha de tomar la decisio´n. La herramienta propuesta permite comparar y eva-
luar diferentes planes alternativos para el mismo paciente, preparados mediante
simuladores comerciales. Para concluir, en los Ape´ndices B y C se presentan re-
sultados adicionales como complemento a los presentados en los Cap´ıtulos 2 y 3
respectivamente. Por u´ltimo, los resultados obtenidos y sus posibles extensiones
futuras se discuten en el Cap´ıtulo 5.
En resumen, este trabajo propone nuevos modelos matema´ticos y procedimien-
tos computacionales que pueden combinarse con las te´cnicas actuales para mejorar
los resultados obtenidos con la radioterapia. Tales resultados pueden ser por tanto
considerados como instrumentos auxiliares para preparar y administrar mejores
tratamientos, un objetivo de gran importancia cient´ıfica y social.
A continuacio´n se describe con ma´s detalle el contenido y resulta-
dos obtenidos en cada cap´ıtulo, as´ı como las conclusiones del trabajo
realizado.
Cap´ıtulo 1:
En este cap´ıtulo introductorio se presenta una panora´mica breve y precisa del
empleo de te´cnicas de radioterapia en el tratamiento de tumores so´lidos, los fun-
damentos en que tales te´cnicas se basan y los problemas que su uso plantea en la
pra´ctica cl´ınica. En particular, se hace especial e´nfasis en los modelos matema´ticos
basados en principios radiobiolo´gicos que se utilizan a lo largo de este trabajo.
Cap´ıtulo 2:
Los pasos fundamentales en el proceso de planificacio´n en radioterapia consis-
ten en seleccionar para cada paciente diagnosticado con un tumor so´lido: i) la dosis
de prescripcio´n en el tumor, ii) restricciones en las dosis de radiacio´n suministradas
a los o´rganos de riesgo circundantes y iii) un esquema de fraccionamiento especi-
ficando el nu´mero y frecuencia de las sesiones de tratamiento. En particular, la
eleccio´n de la dosis de prescripcio´n se basa principalmente en la experiencia cl´ınica
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acumulada en el tratamiento del tipo de tumor en consideracio´n y los o´rganos de
riesgo involucrados sin ninguna referencia directa a cuantificaciones radiobiolo´gicas.
Es importante remarcar, que modelos matema´ticos desarrollados para estudiar el
efecto de la radiacio´n en la materia biolo´gica existen hace bastante tiempo, y son
ampliamente conocidos por los cl´ınicos. Sin embargo la dificultad para obtener es-
timaciones in vivo de los para´metros radiobiolo´gicos involucrados han restringido
su uso directo en la cl´ınica practica actual.
El objetivo de este Cap´ıtulo en primer lugar es proponer un modelo matema´tico
para seleccionar distribuciones de dosis de radiacio´n como soluciones de un prob-
lema variacional asumiendo que los principales para´metros radiobiolo´gicos para
el tumor y los o´rganos de riesgo circundantes involucrados son conocidos. En
segundo lugar, se realiza un ana´lisis detallado de la dependencia de tales solu-
ciones en los para´metros seleccionados, y la manera en la que el uso de tales
minimizadores podr´ıan mejorar el proceso actual de toma de decisiones para se-
leccionar dosimetr´ıas de radiacio´n, cuando (como es generalmente el caso) solo
informacio´n parcial de los para´metros radiobiolo´gicos esta disponible. Una com-
paracio´n entre las distribuciones de radiacio´n propuestas con aquellas que son
actualmente aplicadas a un nu´mero de casos cl´ınicos sugiere que las soluciones del
modelo matema´tico propuesto pueden ser de gran utilidad en el proceso de plani-
ficacio´n de radioterapia para obtener mejores planes de tratamiento. Este modelo
matema´tico puede ser aplicado a cualquier tipo de tumor con independencia de su
localizacio´n, as´ı como si diferentes regiones o varios tumores son identificados para
un mismo paciente.
Cap´ıtulo 3:
La heterogeneidad tumoral es ampliamente considerada un factor determinante
en la progresio´n de tumores y en particular en su recurrencia despue´s de las ter-
apias. Por desgracia, las te´cnicas me´dicas actuales no suministran informacio´n rel-
evante acerca de la heterogeneidad tumoral mediante me´todos no invasivos. Como
consecuencia cuando la radioterapia es utilizada como una opcio´n de tratamiento,
las distribuciones de dosis de radiacio´n son prescritas bajo la hipo´tesis que el tumor
es de naturaleza homoge´nea.
El propo´sito de este Cap´ıtulo es precisamente explorar el efecto de diferentes
dosis de radiacio´n en tumores heteroge´neos por medio de un modelo matema´tico
donde el funcionamiento de cada ce´lula es simulado de manera individual. Para
esto, se ha considerado un caso donde solo dos fenotipos tumorales diferentes esta´n
presentes, los cuales se asumen que difieren en la duracio´n del ciclo celular y sus
propiedades radiobiolo´gicas. En particular, como resultados de tales diferencias, la
distribucio´n espacial de los correspondientes fenotipos, por tanto de la resultante
heterogeneidad, se puede predecir a medida que el tumor crece. Es decir, si el
modelo de crecimiento tumoral se ejecuta desde una situacio´n donde una mayor´ıa
de ce´lulas tumorales (CC) y una minor´ıa de ce´lulas madres tumorales (CSC) esta´n
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inicialmente presentes y aleatoriamente distribuidas, entonces las CSCs quedan
concentradas en la regio´n interior del tumor a medida que este crece y mientras
que la duracio´n del ciclo celular de las CCs es menor que el de las CSCs y las CSCs
siguen siendo una fraccio´n menor respecto al nu´mero total de CCs en el tumor.
Como consecuencia, y asumiendo adema´s que las CSCs son ma´s resistentes a la ra-
diacio´n que las CCs, las distribuciones heteroge´neas pueden ser seleccionadas para
aumentar la probabilidad de control tumoral suministrando mayores dosis de ra-
diacio´n a las regiones ocupadas por las ce´lulas ma´s radioresistentes. Por otro lado,
tambie´n se obtiene que cuando se comparan con las distribuciones homoge´neas
utilizadas actualmente en la practica cl´ınica, tales distribuciones heteroge´neas pro-
porcionan mejores resultados que sus correspondientes distribuciones homoge´neas
que administran la misma dosis total.
Cap´ıtulo 4:
Los planes de tratamiento en radioterapia son seleccionados por los radiof´ısicos
y cl´ınicos de entre un pequen˜o nu´mero de planes tentativos simulados en un sistema
de planificacio´n de tratamientos. En este trabajo se propone un procedimiento de
ayuda a la decisio´n para asistir en la eleccio´n de planes de tratamiento. Esto se
hace como se describe a continuacio´n. Para cualquier plan tentativo de tratamiento
se definen tres sub-´ındices asociados a las distribuciones de radiacio´n: i) en el tu-
mor, ii) o´rganos de riesgo circundantes y iii) tejido sano respectivamente. Estos
sub-´ındices se combinan para obtener un ı´ndice global que proporciona un valor
para cada plan tentativo de tratamiento. Para esto solo se utilizan los diagramas
dosis volumen obtenidos a partir de los sistemas de planificacio´n y la dosis de pre-
scripcio´n en el tumor. Este ı´ndice global proporciona una herramienta sencilla y
fa´cil de usar para comparar diferentes planes dosime´tricos de tratamiento que son
muy similares respecto a los diagramas de dosis volumen. En particular, pequen˜as
diferencias en el nu´mero, a´ngulos de incidencia o intensidad de los ases de radiacio´n
proporcionan valores significativamente diferentes del ı´ndice global, as´ı como de
cada sub-´ındice que lo forma. Por otro lado, esta herramienta matema´tica puede
ser implementada en cualquier sistema de planificacio´n utilizado actualmente in-
dependientemente del tipo y localizacio´n del tumor, y adema´s permite comparar
planes tentativos obtenidos en diferentes sistemas de planificacio´n o desarrollados
mediante diferentes te´cnicas de irradiacio´n.
En particular, esta herramienta matema´tica permite comparar de forma cuan-
titativa diferentes planes tentativos de tratamiento definidos para un mismo pa-
ciente. Para evaluar el funcionamiento de este procedimiento el plan tentativo
sugerido por el ı´ndice global propuesto ha sido comparado con varios planes im-
plementados para tratar a pacientes diagnosticados con tumores cerebrales. Para
cada uno de estos casos cl´ınicos tres estrategias diferentes de planificacio´n fueron
consideradas de las cuales una fue seleccionada y suministrada a cada paciente
respectivamente. El valor del ı´ndice fue calculado para cada una de las estrategias
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anteriormente mencionadas y un considerable grado de consciencia fue obtenido.
Adema´s, las razones de las posibles discrepancias cuando estas ocurren fueron
discutidas. A fin de evaluar la informacio´n proporcionada por esta herramienta
matema´tica, se ha examinado tambie´n una secuencia de planes de tratamiento
hipote´ticos para un paciente diagnosticado con ca´ncer de pro´stata, y se observo´
una clara correlacio´n entre los resultados del ı´ndice global y la evaluacio´n cl´ınica
realizada por los expertos.
Conclusiones:
Desde el descubrimiento de los rayos X hace ma´s de cien an˜os, el uso de la
radiacio´n ionizante en la medicina es cada vez mayor, tanto para asistir en el
diagno´stico de enfermedades como una opcio´n de tratamiento a pacientes con tu-
mores. En particular, la radioterapia es en la actualidad una te´cnica ampliamente
utilizada para tratar tumores so´lidos. El tratamiento de estas enfermedades, y
de los pacientes diagnosticados con ca´ncer en general, representa un desaf´ıo im-
portante en te´rminos cient´ıficos y sociales. Considerables avances cient´ıficos y
tecnolo´gicos realizados en los u´ltimos an˜os han dado lugar a una reduccio´n signi-
ficativa de la incidencia de tumores. Sin embargo, la recurrencia despue´s de las
terapias, as´ı como el tratamiento de tumores diseminados o en etapas avanzadas
de desarrollos sigue siendo un problema cr´ıtico en la pra´ctica cl´ınica.
Por otro lado grandes esfuerzos han sido realizados en el desarrollo de mod-
elos matema´ticos para ayudar en el proceso de planificacio´n de tratamientos ra-
diotera´picos. En particular, se han propuesto diversos modelos basados en prin-
cipios f´ısicos y radiobiolo´gicos, que han permitido mejorar el rendimiento de la
radioterapia. Sin embargo, al preparar un plan de tratamiento en la pra´ctica ac-
tual una serie de dificultades relacionadas con la eleccio´n de la dosis de prescripcio´n
y la forma en que esta debe ser suministrada deben au´n ser superadas.
En esta memoria se han propuesto varios modelos matema´ticos y me´todos
basados en ordenadores para ayudar a los cl´ınicos y radiof´ısicos en el proceso de
planificacio´n de tratamientos. En primer lugar, en el Cap´ıtulo 2 se propone un
modelo matema´tico para seleccionar distribuciones de dosis o´ptimas como solu-
ciones (minimizadores) de un problema de optimizacio´n considerando restricciones
cl´ınicas y te´cnicas. Para estudiar este modelo matema´tico, se han considerado dife-
rentes casos cl´ınicos, donde se realizo´ una comparacio´n de las distribuciones de dosis
o´ptimas con las suministradas a cada paciente. Como resultado, cuando se com-
para con las dosimetr´ıas aplicadas, las distribuciones de dosis o´ptimas propuestas
representan mejores opciones de tratamiento, y por lo tanto pueden ser consider-
adas distribuciones o´ptimas contra las cuales los planes tentativos de tratamiento
pueden compararse durante el proceso de planificacio´n de la radioterapia. Por
otro lado, el ana´lisis de la dependencia de los para´metros del modelo en tales min-
imizadores permite proponer una estrategia para seleccionar las distribuciones de
dosis de radiacio´n, bajo el supuesto de que los para´metros radiobiolo´gicos para los
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tumores y o´rganos en riesgo implicados so´lo se conocen parcialmente, una situacio´n
que es bastante comu´n en la pra´ctica cl´ınica.
En el Cap´ıtulo 3 se investigo´ el efecto de la heterogeneidad del tumor en los
resultados obtenidos con la radioterapia. Para ese fin, se considera un modelo
matema´tico con el que se simula el crecimiento de tumores heteroge´neos en los
cuales dos fenotipos de ce´lulas tumorales esta´n presentes las cuales se diferencian
en sus respectivas propiedades biolo´gicas y radiobiolo´gicas. En particular, como
consecuencia de esas diferencias, la distribucio´n espacial de tales fenotipos y por
lo tanto de la heterogeneidad tumoral resultante se puede predecir a medida que
el tumor avanza en su desarrollo. El uso de dicha informacio´n de heterogeneidad
y los efectos de diferentes tratamientos heteroge´neos han sido investigados. Se ha
demostrado que dosimetr´ıas heteroge´neos se pueden seleccionar para mejorar el
control tumoral al aumentar las dosis de radiacio´n suministradas en la regio´n ocu-
pada por el fenotipo de ce´lulas tumorales ma´s radioresistentes. En consecuencia, se
ha observado que tales dosimetr´ıas heteroge´neas proporcionan mejores resultados
que sus respectivas homoge´neas las cuales son utilizadas actualmente en la pra´ctica
cl´ınica.
En el Cap´ıtulo 4 se ha propuesto una herramienta matema´tica de ayuda a la
decisio´n para comparar y evaluar planes tentativos de tratamiento en radioterapia.
Esta herramienta utiliza so´lo los datos extra´ıdos de los histogramas dosis volumen
que ofrecen los sistemas de planificacio´n de tratamientos y la dosis de radiacio´n
prescrita en el tumor. En particular, para evaluar la informacio´n proporcionada
por esta herramienta se investigaron una serie de casos cl´ınicos en retrospectiva.
Adema´s, un programa informa´tico ha sido implementado, con el que los me´dicos y
radiof´ısicos pueden comparar y analizar los diferentes planes tentativos. Es notable
destacar que esta herramienta puede ser incorporada fa´cilmente en cualquier sis-
tema de planificacio´n de tratamientos y ser utilizada para evaluar cualquier te´cnica
de radioterapia que proporciona histogramas de dosis volumen de los planes ten-
tativos siendo simulados.
En resumen, esperamos que los modelos matema´ticos propuestos en este tra-
bajo proporcionen herramientas u´tiles en la pra´ctica cl´ınica de la radioterapia, un
objetivo que ha estado siempre presente durante este estudio.
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Chapter1
Treatment planning process and
mathematical modeling in radiation
therapy
“. . . For the birth of something new, there has to be a happening. Newton saw an
apple fall; James Watt watched a kettle boil; Ro¨ntgen fogged some photographic
plates. And these people knew enough to translate ordinary happenings into some-
thing new . . .”
Alexander Fleming (1881-1955)
1.1 Introduction
Despite advances made over the years, cancer is at the top of the mortality statistics
in developed countries together with heart diseases [1]. For instance, in United
States the five-year relative survival rate (age standardized) for individuals aged
15 and older, and for all tumor locations is about 65.9%, while for brain tumors
is only 26.1% [2]. Cancer incidence worldwide amounted to about 14.1 million
reported cases with 8.2 million deaths in 2012 [3]. Unfortunately, cancer impact
is expected to keep on rising, with an estimated 21.6 million incidences and 13.1
million deaths in 2030 [3]. For these reasons a significant improvement on cancer
2therapies is most needed to improve these sober predictions.
Radiotherapy, the use of ionizing radiation to destroy pathological tissues, cur-
rently plays an important role in the treatment of solid tumors. It is widely used
both for curative (when therapy results in improved survival) or palliative (when
cure is not possible and the aim pursued is symptomatic relief) purposes. More
than 50% of all cancer patients receive radiotherapy at some point during the course
of their illness, whether on its own or in combination with surgery, chemotherapy,
immunotherapy or any other medical technique [4], [5], [6].
The clinical use of radiotherapy is based on our knowledge about radiobiology,
which is the scientific field concerned with the effect of ionizing radiation on living
matter. Research on this topic started almost immediately after the discovery of
X-rays by Wilhelm Conrad Ro¨ntgen in 1895 (see for instance [7], [8]), which was
received with extraordinary interest by the scientific community. Actually, within
months of that discovery different medical systems were designed to use X-rays
for diagnosis, and to treat skin lesions and hair diseases as well as cancer tumors
[9], [10], [11]. However, at the beginning of the 20th century, radiotherapy was
applied by means of relatively low-voltage machines and was mainly used to treat
superficial tumors. Moreover, there was no accurate method of calculating the
radiation dose emitted and delivered, and poor knowledge about radiobiological
effects led to high morbidity, unexpected side effects and low tumor control [12].
Such outcomes prompted scientists to develop new techniques to deliver radiation
and to investigate its effects on living tissues, specifically on healthy and malignant
cells. See for instance [13], where a detailed description of advances in radiation
physics, radiobiology and radiotherapy between 1895 and 1950 is provided.
The goal of any radiotherapy technique is to control or destroy tumor cells
while at the same time keeping as low as possible unwanted side effects to the
surrounding organs and healthy tissues [14], [15]. To a large extent, the success
of radiotherapy relies on the fact that healthy cells recover better from radiation
injury than cancer cells, since normal cells possess more efficient repair mechanisms
than malignant ones [4]. This fact notwithstanding the effect of radiation in healthy
tissues, that need to be spared, cannot be easily dismissed. In fact, it is not possible
to deliver radiation from an external source to an internal tumor without inflicting
3some damage to surrounding organs at risk (OARs). Indeed, ionizing radiation
has to inevitably pass through healthy tissues on its way to the target in this
case. However, due to the scientific and technological advances made over the
last years, ionizing radiation can be used nowadays to treat deeper tumors with
high precision and comparatively low side effects to neighboring organs. Powerful
and sophisticated treatment techniques have been developed, which yield highly
satisfactory results when applied to solid tumors caught at an early stage of their
development. Some examples of these techniques are 3D Conformal Radiotherapy
(3D-CRT), Intensity Modulated Radiation Therapy (IMRT) and Image-Guided
Radiotherapy (IGRT) (see [16] and references therein for further details). On the
other hand several types of ionizing radiation are currently used in clinical centers
as for instance photons (gamma rays) and charged particles (electrons, protons,
neutrons, carbon ions, etc.) delivered through particle accelerator devices (mainly
Linear Particle Accelerators, LINAC) [17]. However, tumors at an advanced or
disseminated stage remain out of control in most cases.
In current practice, to prepare a radiotherapy treatment plan a number of key
issues have to be dealt with. To begin with, the tumor and critical healthy regions
have to be identified as accurately as possible. To do this, use is made of medical
imaging techniques, a field which has experienced impressive progress but where
much improvement is still needed [18]. In particular, high-resolution methods for
precisely identifying tumor are still lacking. As a consequence, clinicians usually
select a security area around identified tumor regions, and refer to this enlarged
volume as the Planning Target Volume (PTV) [14], [15]. This becomes the desig-
nated region to be irradiated. Having done this, a suitable radiation dose has to
be prescribed and delivered on the PTV along a specified number of therapeutic
sessions, which constitutes the so-called fractionation scheme.
Once the PTV and OARs have been sufficiently identified by means of med-
ical imaging techniques, clinicians and radiophysicists are faced with the task of
selecting and delivering an appropriate radiation dose distribution The choice of
that distribution is made according to two general, and often conflicting, princi-
ples. First, it should be large enough over the PTV to achieve high tumor control,
and at the same time it has to affect as little as possible neighboring OARs [19].
4In many cases the radiation doses selected to achieve tumor control are close to
the maximum values tolerated by neighboring healthy tissues. Therefore, the level
of normal tissue morbidity will often limit the tumor control rate that may be
achieved [20]. However, tolerance doses are not fixed, well-known values. In fact
they differ for each organ and type of tissue. To this day, no procedure has been
found to simultaneously achieve those goals in an optimal way. As a consequence,
a given patient may well be assigned a different dosimetry plan depending on the
clinical center where he/she is treated.
In addition to the previous considerations, when selecting a prescription dose
over a PTV, additional issues have to be addressed. Among them, tumor hetero-
geneity is particularly relevant. Evidence accumulated during last years strongly
suggests that tumor heterogeneity, that is the presence of several different tumor
phenotypes in a given tumor, is a key factor in the development of resistance to
radiotherapy [21], [22], [23]. As a consequence, increasing attention is being paid to
“dose painting”, a technique consisting in delivering different radiation dosimetries
to different regions within a given tumor, so that irradiation be boosted in more
radioresistant regions (for instance, hypoxic, quiescent, etc.) [24], [25], [26]. This
strategy, which is in sharp contrast with the still prevailing homogeneous radia-
tion dose delivery approach [14], [15], has been made possible by the availability of
high-precision linear particle accelerators, and looks particularly promising in those
cases where current techniques fail to provide sufficient tumor control. However, in
order for dose painting to show its full power, detailed information is needed about
the internal structure of the tumor to be irradiated. Such information should ide-
ally be provided by medical imaging techniques. These however are not yet able to
distinguish different radiosensitivity regions except in a few cases, commonly re-
lated to hypoxia effects. In view of current technical limitations, the question thus
arises of providing tools to i) obtain as much information as possible about inter-
nal spatial tumor heterogeneity before a dosimetry is prescribed, ii) simulate the
effects of dose painting therapies which take into account whatever heterogeneity
data are available, and iii) compare such simulations with those corresponding to
standard homogeneous dose distributions currently delivered in clinical practice.
Once the choice of a prescription dose has been made, the question remains of
5how to accurately deliver it on the PTV. To do that, a standard strategy consists in
using several radiation beams that converge at the PTV, which is therefore arrived
at along a variable number of incidence angles and intensities. In general, the choice
of the beam configuration is made by selecting one among several tentative cases
simulated by means of treatment planning systems (TPS), computer simulators
which are incorporated at the particle accelerator to be used [14], [15], [19]. Any
such case is called a tentative treatment plan. The plan to be delivered is selected
among these alternatives, but to this day no standard protocol for quantitatively
comparing tentative plans has been agreed upon. In spite of this, during the last
decades a number of quantitative indexes (also termed as figures of merit) have
been proposed to assist in the selection of dosimetry plans (cf. for instance [27],
[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38] and [39]). Generally speaking,
any such index assigns a score to a tentative plan according to its compliance with
a specified criterion. However, the search for a single, optimal index to quantify
and evaluate the quality of a radiotherapy treatment plan has been unsuccessful
as yet.
In the next sections further details on the process of radiotherapy planning will
be provided. These will yield a useful background for the mathematical problems
to be discussed in this memoir, which will be introduced as well.
1.2 Radiotherapy treatment planning process
The purpose of this Section is to briefly describe the main principles and techniques
involved in the radiotherapy treatment planning process as well as their application
in current clinical practice.
The path followed by any radiotherapy-prescribed patient can be summarized
as follows. The process begins with the diagnosis of a solid tumor with the help
of medical imaging techniques, for which radiotherapy is considered advisable.
To proceed further, an accurate distinction between tumor and nearby organs is
a crucial task, because over-dosage of radiation can lead to severe side effects,
while under-dosage reduces the probability of tumor control. Once the medical
images have been analyzed, clinicians and radiophysicists should decide what type
6of radiotherapy technique should be applied, the prescription radiation dose on the
tumor, the fractionation scheme and the precise manner in which radiation should
be delivered. These decisions depend on the type, stage and location of the tumor
as well as on its radiosensitivity (response to radiation), the radiation tolerance
of surrounding OARs, and the clinical history of the patient among other factors.
Then a number of tentative treatment plans are simulated in a treatment planning
system (TPS), a simulator incorporated to the linear particle accelerator that will
be used. Finally, after comparing the tentative plans thus obtained, that which is
expected to yield better results is selected and delivered.
1.2.1 Anatomical structures definition: medical imaging
techniques
The development of medical imaging techniques began immediately after the dis-
covery of X-rays by Ro¨ntgen in 1895. He noticed that these invisible rays can
provide images of the interior of solid objects after they pass through them. Ever
since, medical imaging techniques have become a key source of information in the
design of radiotherapy treatment plans. The application of state-of-the-art ra-
diotherapy techniques requires accurate tumor and organs delineation, as well as
the intrinsic characterization of the tissues, facts which are strongly dependent on
imaging techniques [40], [41]. For instance, Computed Tomography (CT) and Mag-
netic Resonance Imaging (MRI) provide anatomical information (see Figure 1.1),
whereas Positron Emission Tomography (PET) allows to keep track of metabolic
activity. In addition, different imaging techniques can be combined to create more
complete and comprehensive images than none of them can offer alone. An exam-
ple of that is the PET-CT technique, where functional images obtained by PET
can be displayed together with anatomic imaging obtained by CT scanning (see
Figure 1.2).
7Figure 1.1. (Left) Magnetic Resonance Imaging (MRI) image compared with a Com-
puted tomography (CT) image (right) for a same patient. Notice that MRI is better
suited to distinguish soft tissues than CT, which is more appropriate to visualize dense
tissues such as bones. [This image is used under permission of the Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain].
8Figure 1.2. (Left) Computed tomography (CT) image compared with a combined
PET-CT image (right) for a same patient. Notice that PET-CT scan reveals abnormal
metabolic activity. [This image is used under permission of the Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain].
Once a patient is diagnosed with a solid tumor for which radiotherapy is pre-
scribed, clinicians and radiophysicists carefully analyze the available medical im-
ages in order to delineate the tumor and nearby OARs. This process is prone to a
number of inaccuracies. On the one hand, these volumes are manually contoured
on a 2D slice-by-slice basis, although modern treatment planning systems are able
to automatically accomplish parts of this task for various critical structures. How-
ever, in almost all cases sharp identification of tumor boundaries remains a major
challenge. For such reasons, the International Commission on Radiation Units
(ICRU) has proposed several tumor and organ at risk volume definitions to assist
in this part of the treatment planning process [14], [15].
The first such term is the gross tumor volume (GTV) commonly defined as “the
gross palpable or visible/demonstrable extent of location of malignant growth” [15].
Due to inaccuracies inherent in tumor delineation, a clinical target volume (CTV)
is next defined as follows: “is the tissue volume that contains a demonstrable GTV
9and/or sub-clinical microscopic malignant disease, which has to be eliminated. This
volume thus has to be treated adequately in order to achieve the aim of therapy, cure
or palliation” [15]. In this case, CTV is usually drawn with an empirical margin
added to the GTV of approximately 1 millimeter in order to consider different areas
of spread of the tumor, which current imaging techniques are not able to detect.
On the other hand, the planning target volume (PTV) is a new concept introduced
specifically for the treatment planning process, which should include the CTV and
accounts for uncertainties in patient positioning and alignment of treatment beams.
“The planning target volume (PTV) is a geometrical concept, and it is defined to
select appropriate beam arrangement, taking into consideration the net effect of
all possible geometrical variation, in order to ensure that the prescribed dose is
actually absorbed in the CTV ” [15]. In Figure 1.3 a representation of a CTV and
the corresponding PTV for a patient diagnosed with a brain tumor is provided.
Figure 1.3. From left to right a CT image of a patient diagnosed with a brain tumor
and the delineation of the CTV (purple) and the corresponding PTV (red). [This image is
used under permission of the Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain].
The process of contouring a tumor and the surrounding OARs is a crucial task
during planning. In fact, small errors in this process may result in low tumor
control and undesirable side effects to the patient. For that reason, low-resolution
(corresponding to low-dose irradiation) images are sometimes taken in the course
of treatment prior to every new therapeutic session. In fact, this strategy helps
in a correct positioning of the patient before each session, so that a prescribed
radiation dose will be delivered where required.
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On the other hand, tumor heterogeneity is widely considered to be a determi-
nant factor in radiotherapy outcomes [21], [22], [23]. Unfortunately, to this day only
partial information can be derived about that feature by means of non-invasive,
medical imaging techniques. Currently available information can be mainly used
to distinguish various level of oxygen pressure within the tumor related to hy-
poxia processes [24], necrotic areas, or highly proliferating regions detected by
means of PET techniques [42]. While undoubtedly important, such information
is not enough to design therapies whose results could significantly improve those
obtained by current standard procedures. As a consequence, when radiotherapy is
used, radiation dosimetries are selected under the assumption that the malignancy
targeted is of a homogeneous nature. Further improvements in imaging techniques
are still required to increase the spatial and functional resolution of the internal
tumor structure. Any additional information in this respect could be translated
into a more efficient dosimetry planning.
In this work, a mathematical model has been proposed in an attempt to gain
insight about the influence of tumor heterogeneity in radiotherapy treatment re-
sponse. More precisely, in Chapter 3 a mathematical model is presented to in-
vestigate i) how the internal structure of a tumor could be predicted from the
knowledge of key biological properties of the different phenotypes involved and ii)
the way in which suitable heterogeneous radiation therapies can then be prepared
that clearly outperform homogeneous dosimetries as those currently in use.
1.2.2 Selecting the prescription radiation dose and frac-
tionation schemes
For any given patient, once the PTV and OARs have been delineated, radiation
oncologists and radiophysicists prepare a treatment plan. To that end, the number
of therapeutic sessions (fractionation scheme) and the prescription radiation dose
(Dp) on the tumor should be specified. In particular, Dp depends on the type,
location, stage and radiosensitivity of the tumor considered. Moreover, the radia-
tion dose distribution to be applied should satisfy a set of clinical constraints on
the dose prescribed on the PTV and on the maximum radiation deemed accept-
able over neighboring OARs. These clinical requirements are selected by radiation
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oncologists according to their clinical experience, without explicit reference to any
underlying radiobiological or physical theory.
Selecting suitable clinical constraints is a key question. For instance, a high
and homogeneously delivered radiation dose on the PTV, and a zero dose outside
is obviously a desirable choice. However, this high-precision dosimetry is out of
question due to limitations in the radiation equipment resolution. The prescrip-
tion dose distribution has therefore to be selected by achieving a suitable balance
between radiation doses delivered on PTV and on nearby OARs. In particular, a
maximum and minimum dose as close as possible to Dp is sought on the PTV to
achieve sufficient tumor control, while at the same time strict maximum limits on
the doses on the surrounding OARs are always wanted. Dose-volume constraints
may be also required on the volume fraction of the PTV and/or OARs that receives
a dose above/below a given threshold value.
To address these issues, in Chapter 2 a mathematical model to find optimal
radiation dose distributions satisfying clinical and technical requirements is formu-
lated and discussed. The proposed dose distributions are given as solutions of a
multi-parameter optimization problem of a variational nature, where high tumor
control and low radiation doses on OARs are simultaneously sought-for.
Once the radiation dose distribution to be applied has been selected, a frac-
tionation scheme should be defined. This process consists in dividing the total
radiation dose into smaller fractions distributed on different sessions, so that at
the end the total prescription dosimetry is delivered [14], [15]. The main motiva-
tion for dose fractionation is related with the concept of the 5 R’s of radiotherapy:
repair, repopulation, redistribution, re-oxygenation [43] and more recently, intrin-
sic radioresistance [44]. All of these are biological and radiobiological effects that
occur in the time interval between treatment sessions. In particular, a fractiona-
tion protocol allows healthy cells time to recover, and thus benefits from the fact
that tumor cells have generally less efficient repair mechanisms. In fact, there is
a dependence of tumor radiosensitivity on the cell cycle phases, as well as on the
level of cell oxygenation. For instance, since hypoxic cells are more resistant to
radiation than well-oxygenated cells [45], fractionation also permits that tumor
cells reoxygenate and enter into other cell cycle phases, where they become more
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radiosensitive [46]. In addition to these cellular processes, fractionation is also sup-
ported by clinical experience related to the radiation tolerance of nearby OARs.
As to the number of sessions in which a selected dosimetry is delivered, different
fractionation protocols are currently used in radiotherapy, according to the amount
of radiation per fraction and to the number of treatment sessions per day [47]. For
instance, hyperfractionated schemes prescribe more than one session per day with
low radiation doses. Hypofractionated dosimetries give large radiation doses per
session instead, but fewer sessions are scheduled than in the former case. Some
brain tumors are usually treated with a very high radiation dose in a single session.
This technique is known as Stereotactic Radiosurgery, which in some clinical cases
can provide acceptable results in terms of tumor control. It should be noted that
for similar tumors fractionation schemes may vary between different clinical centers
and even between individual radiophysicists in a same center, although in general
standard protocols achieved by consensus are widely (if not universally) followed.
For instance, in current clinical practice a standard fractionation scheme for adults
diagnosed with brain tumors as Meningioma, or Glioblastoma Multiforme (GBM)
consists in 1.8Gy to 2.0Gy per day, 5 days a week along 28-30 sessions with weekend
interruptions [48], [49]. Here Gy stands for Gray, a standard unit for absorbed
ionizing radiation dose (1 Gy being 1 Joule per Kilogram) [50].
1.2.3 Radiation delivery
Radiation may be delivered externally or internally depending on the type of ra-
diotherapy technique selected. In the case of external beam radiotherapy (EBRT)
the radiation is sent to the tumor from an external machine. On the other hand,
internal radiotherapy or Brachytherapy consists in the implantation of small radi-
ation sources known as seeds in or as near as possible to the tumor. Furthermore,
radiation can also be delivered as radioactive tracers (generally short-lived iso-
topes linked to chemical compounds), which emit gamma rays from within the
body. These isotopes can be administered by injection, inhalation or orally, as in
the case of thyroid and mouth cancers.
External beam radiotherapy EBRT, the technique underpinning the models
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studied in this work, is applied by means of linear particle accelerators (LINAC),
which are able to deliver radiation even at deeply-seated tumors (see Figure 1.4).
In combination with sophisticated techniques of treatment, LINACs have enabled
radiation oncologists and radiophysicists to significantly reduce side effects while
at the same time improving the precision and efficiency of the therapy. In partic-
ular, treatment plans are applied to a patient positioned on a computer-controlled
couch that can rotate, while LINAC delivers ionizing radiation from a gantry that
can turn around a central axis. This enables variable positioning of couch and
gantry, so that radiation beams can be focused on the PTV center to achieve a cu-
mulative radiation effect, so that the exposure of nearby healthy tissues and OARs
is significantly reduced. For each beam incidence angle (defined by the position of
couch and gantry) the LINAC delivers radiation, which passes through a multi-leaf
collimator (MLC). This device that consists of a number of pairs of metal leaves
moving along channels into the path of radiation to block out different parts of
the beam. This allows radiation beams to better fit to the shape of the tumor (see
Figure 1.5).
Figure 1.4. A linear particle accelerator (LINAC). [This image is used under permission of the
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain].
14
Figure 1.5. A multi-leaf collimator (MLC).
On the other hand, delivery of radiation is particularly difficult in areas that
keep moving during a treatment session, such as the thoracic and abdominal regions
affected by breathing. In those cases, immobilization of patients is important,
particularly in the case of small tumors, where a slight shift in position can move
the target out of the beams path. For this reason, several devices are currently used
to prevent movement (i.e. molds, masks and stereotactic head or body frames).
These are custom-made individually to fit the patient body or head, and are used
during each treatment session. Moreover, different techniques may also be applied
to keep track of the medical images obtained before any session treatment starts,
including low-resolution images, skin markers, laser lights, infrared cameras, X-rays
positioners, etc.
Several modalities of external beam therapy are currently used in clinical prac-
tice (see [15], [51], [52] and references therein) and some of them are briefly de-
scribed as follows:
◦ Three-Dimensional Conformal Radiation Therapy (3D-CRT) uses
computers and advanced imaging techniques (such as CT, MRI and/or PET scans)
to create 3D digital data sets of the tumor and adjacent organs. These data are
used to deliver highly “conformed” (focused) radiation beams to a tumor by means
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of multi-leaf collimators (MLC) and field shaping blocks. Since radiation beams
are very precisely focused, nearby healthy tissue receives little radiation. In 3D-
CRT, the planning process is directly determined, meaning that radiophysicists
decide the beam configuration (number, incidence angles, shapes and weights of
radiation beams) and the TPS provides the resulting dose distribution.
◦ Intensity Modulated Radiation Therapy (IMRT) is an advanced form
of 3D-CRT that allows radiation to be shaped to fit complex tumor geometries (for
instance, concave tumor shapes surrounding organs at risk as the spinal cord or
the brain stem). To do that, each radiation beam can be decomposed into many
“beamlets” and the intensity of each beamlet can be adjusted individually. This
intensity modulation is achieved by moving the leaves in the MLC during the course
of treatment, which produces radiation fields with non-uniform intensities. In
IMRT dose distributions are inversely determined. This means that radiophysicists
select the clinical requirements to be met, and then the TPS produces, by means
of different optimization algorithms, a series of beam intensities as close as possible
to the desired prescription goals. IMRT technique allows higher radiation doses to
be delivered to the tumor, potentially increasing tumor control or eradication.
◦ Image-Guided Radiation Therapy (IGRT) consists in using medical
imaging (such as CT, ultrasound or X-rays) before or during the course of a treat-
ment session to improve the precision and accuracy of radiation delivery. This
technique is used to treat tumors in areas that are prone to movement while breath-
ing, as thoracic cavity for example. In general, all patients undergo at least a CT
scan as part of the treatment planning process, but further imaging test are seldom
performed during treatment. The imaging information obtained allows radiophysi-
cists to compare earlier images (obtained during the simulation) with the images
taken just before treatment session starts. Then, any necessary adjustments re-
garding the patient position and/or treatment plan (beam configuration) can be
made in order to better fulfill clinical requirements. In particular, IGRT is often
used in conjunction with IMRT or any other advanced modality of high-precision
radiotherapy.
In standard fractionated radiation therapy the same prescribed radiation dose
distribution is applied in each treatment session. However, changes occurring be-
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tween sessions are receiving increasing attention. Since variations in tumor size
during treatment can have dosimetric impact, advanced radiotherapy protocols
that utilize IMRT and IGRT further stress the need for periodic plan adaptation,
which is often referred to as Adaptive Radiation Therapy (ART). Session dosime-
tries in ART will thus be reconsidered after evaluation of tumor changes resulting
from the previous sessions. However, efficient tools are yet to be developed to allow
for better tumor control resulting from sequential feedback on the evolution of the
tumor as treatment proceeds.
1.3 Mathematical modeling in radiotherapy
As in many medical fields, mathematical modeling plays an important role in
radiotherapy. In fact, several mathematical models, based on physical and ra-
diobiological principles, have been developed to estimate and improve treatment
outcomes. The topics addressed by these models includes estimating the radiation
effects on healthy and malignant tissues, quantifying tumor control and side effects
on critical structures, improving the accuracy and precision of radiation delivery
techniques, optimizing the treatment planning process, assisting in the decision-
making process and comparing different tentative treatment plans. This Section
is devoted to a brief description of the mathematical models in radiotherapy that
are pertinent for the purpose of this work.
1.3.1 Estimating the effect of ionizing radiation on cells:
the Linear Quadratic model
To understand the effect of ionizing radiation on cells, it is crucial to know the
mechanisms by which ionizing particles interact with living tissues, and in par-
ticular the differences in radiation response between malignant and healthy cells.
In general, ionizing radiation produces harmful effects on all types of cells.
The action of ionizing particles on cell structures is of a stochastic character. This
means that an ionizing particle that hits at a cell may, or may not, produce a mea-
surable effect. When the latter occurs, it will produce a damage whose importance
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may be highly variable. In particular, radiation damage on cells depends on the
amount and type of radiation, the exposure time and the nature of the irradiated
tissue. Most importantly, radiation can damage the cell DNA (Deoxyribonucleic
Acid), which plays a crucial role in cell activity and viability [45], [47]. More
precisely, changes induced in the DNA structure may result in chromosomal aber-
rations and genetic mutations with various effects, from modifications in normal
cell behavior to cell death. At the molecular level, the two most important lesions
in the genome induced by radiation are related with the number and location of
strand breaks in the double DNA helix (see Figure 1.6). More precisely, these
lesions are single-strand breaks (SSB) and double-strand breaks (DSB). SSB may
be repaired in a comparatively easy way by using the remaining intact strand as
a template to restore the original genetic information. However, DSBs are more
difficult to repair, and often result in cell death, even when produced in a smaller
proportion than SSB [47], [53].
Figure 1.6. Representation of single-strand breaks (SSB) and a double-strand break
(DSB) induced by ionizing radiation in the DNA structure. From top to bottom, i)
representation of the undamaged strands of the DNA, ii) a single break in one strand,
iii) two single strand breaks in two different locations and iv) a double-strand break.
[Reproduced from E. J. Hall et al. “Radiobiology for the radiologist” 2006, see reference [47]].
To this day, the most widely used mathematical tool to measure the effects of
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ionizing radiation on cell populations is the so-called Linear Quadratic (LQ) model
(cf. for instance [53], [54], [55], [56]). Interestingly, the LQ model was heuristically
deduced from empirical data of cell survival curves [57]. Only years after its formu-
lation was the LQ formula derived as an asymptotic limit of a dynamical system
describing the kinetics of radiation damage production, repair and misrepairs [58].
The LQ model states that for a given cell aggregate (either malignant or
healthy), the surviving fraction of cells after receiving a radiation dose D is given
by
SF (D) = e−(αD+βD
2), (1.1)
The linear and quadratic terms in the exponent of (1.1) are respectively related
to cell damage induced by single and double DNA strand breaks. The positive
parameters α and β in (1.1) (the so-called radiosensitivity parameters) depend of
the specific cell line under consideration. It has been suggested that SF (2), the
surviving cell fraction after receiving a radiation dose of 2.0Gy, is an important
figure to predict the effects of radiation on a given tumor (see [53], [59] and [60] for a
comparison with other commonly used radiobiological models). According to that
principle, low (respectively high) values of SF (2) would indicate good (respectively
poor) expected results for a given radiotherapy treatment. However no rationale
for that fact (nor any precise determination of the corresponding threshold values
of SF (2)) has been substantiated as yet.
Obviously, a precise knowledge of radiosensitivity parameters α and β is a pre-
requisite to obtain useful clinical information from the LQ model. Unfortunately,
the task of estimating such parameters meets a number of significant difficulties.
As a matter of fact, most values reported in the literature are obtained upon irra-
diation either of in vitro growing cells taken from tumor samples or of cultures of
healthy cell lines. A major drawback towards direct clinical use of the LQ model
is that there is no consensus on the values of these parameters for many of the
cell lines (either malignant or healthy) studied, and there are many tumor lines
and healthy tissues for which such parameters have not even been reported as yet.
Therefore, use of values of the radiosensitivity parameters α and β should be made
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with extreme caution.
On the other hand, the LQ model has been extended to include relevant aspects
involved in radiotherapy as for instance repopulation, the time course between
treatments, dose-rate effects and hypersensitivity (see [56] and references therein).
Further details will be omitted here, and the reader is referred instead to [61] for
a comprehensive review on this topic.
1.3.2 Optimization in radiotherapy
Optimization techniques have been extensively used with successful results in many
medical fields, and particularly in radiotherapy (see for instance [62], [63], [64],
[65]). In this context the term optimization can be used for different purposes. For
instance, at a general level optimization may be considered as a process leading to
selecting a treatment plan that maximizes the probability of tumor control with
comparatively low side effects in the nearby organs at risk and healthy tissues.
In technical terms, the search for such a treatment plan is often divided into a
sequence of steps, many of which involve large-scale mathematical programming
problems that require particular optimization techniques to be solved.
Clearly, such techniques depend on the type of objective functions that need
to be optimized at any step of the process. These are often divided into those of
a physical or biological nature. In a recent AAPM group report [66] the following
can be read:
“. . . Until recently, the quality of a radiotherapy treatment (RT) plan has been
judged by physical quantities, that is, dose and dose-volume (DV) parameters,
thought to correlate with biological response rather than by estimates of the bi-
ological outcome itself. It is widely recognized that the DV criteria, which are
merely surrogate measures of biological responses, should be replaced by biological
indices in order for the treatment process to more closely reflect clinical goals of
RT. Developments in our understanding of advantages and limitations of existing
dose-response models begin to allow the incorporation of biological concepts into a
routine treatment planning process . . .”
As observed above, physical optimization methods look for radiation dose dis-
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tributions satisfying criteria as high tumor coverage and low dose deposition on
organs at risk, but the biological response to radiation of the tumor and organs at
risk is not explicitly taken into account [62], [67], [68]. For instance, under-dosing
a very small volume of the tumor might not have a significant effect on the objec-
tive value of a physical-based treatment plan, but tumor control might be largely
diminished in that case. On the other hand, radiobiological methods focus on the
biological and radiobiological effects resulting from the radiation dose distributions
selected [69], [70], [71], [72]. For instance, tolerance to radiation of the OARs and
tumor radiosensitivity will be now given priority with respect to dose conformity
over PTV, which is a constraint of a physical nature.
Optimization techniques in radiotherapy are relevant both for direct and inverse
planning, which were briefly mentioned in the context of the external beam radi-
ation therapies considered in Section 1.2.3. The forward optimization approach,
which is mostly used nowadays in clinical practice, is a trial-and-error process
where radiophysicists change the radiation beam configuration: incidence angles,
intensities (fluence), number of beams... and consequently the resulting radia-
tion dose distribution, in an attempt to satisfy some prescribed clinical criteria
[73], [74], [75], [76], [77], [78]. Availability of high computer power in commer-
cial TPS has turned inverse planning into a competitive alternative. In this last
procedure, which is usually harder to handle from a mathematical point of view,
predetermined clinical criteria are used as an input to produce the radiation beam
configuration that satisfies as much as possible the prescription goals [79], [80],
[81], [82], [83].
Commonly used optimization methods for forward and inverse planning are
linear and nonlinear programming, mixed-integer programming and dynamic pro-
gramming (see [62], [74], [76], [77], [84], [85], [82], [83] for further details). Variables
used by such optimization methods include number, intensities and incidence an-
gles of radiation beams (see Figure 1.7), beam modulation through a multi-leaf
collimator (MLC) and parameters related to fractionation schemes (number of
treatment sessions, radiation dose per session, patient positioning, etc.). Solving
these optimization problems remains in many cases is a formidable challenge due
to the huge size of its solution space.
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Figure 1.7. Representation of two different radiation beam configurations on a treat-
ment planning system over a CT scan (left) and in a three-dimensional reconstruction of
the head of the same patient (right). [This image is used under permission of the Hospital Universitario
Puerta de Hierro Majadahonda, Madrid, Spain].
Radiobiological optimization is one of the main research directions of this work.
Specifically, in Chapter 2 an optimization model to select optimal radiation dose
distributions based on radiobiological principles is described. The model includes
in its formulation compliance with current clinical and technical restrictions. More-
over a procedure is proposed to use it as comparison standard when only partial
information on radiosensitivity parameters is available.
1.3.3 Assessing and comparing treatment plans
In radiotherapy, for any patient diagnosed with a solid tumor the treatment to be
applied is expected to achieve high tumor control and to induce little side effects
on neighboring critical regions. To achieve those goals, a number of tentative
treatment plans (usually two or three) are simulated (or a unique plan is defined
and successively modified) on a commercial treatment planning system (TPS) until
the result is found close enough to clinical prescription. In general, the tentative
plans considered differ only from each other in small variations in the number,
incidence angles or intensity of radiation beams converging on the tumor. To this
day no standard, computerized system seems to be in use to assist in such decision
process, which largely relies on the clinical experience of the radiophysicists in
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charge. Moreover, such choice, even when made by experienced specialists, is
subject to considerable uncertainty due to the absence of quantitative standards
to grade and evaluate alternative plans.
For any tentative treatment plan being considered, commercial TPSs provide
a 3D view of the tumor and organs at risk obtained by different medical imaging
techniques (see Figure 1.7 in Section 1.3.2), dose volume histograms (DVHs) for
each anatomical structure involved, and the isodose curves over the whole treat-
ment domain. A cumulative DVH is a plot of the volume of a given structure that
receives at least a certain radiation dose. For instance, stating that V (D = y) = x
means that x% of the total volume under consideration receives at least the y% of
a normalized dose value (see Figure 1.8). On the other hand, the isodose curves
are closed lines bounding regions where radiation dose is larger or equal than a
given value (see Figure 1.8). Out of all tentative plans considered, the choice of
the actual treatment plan is then made upon comparison (by inspection) of the
DVHs and isodose curves for each tentative plan considered, independently of any
subsequent radiobiological calculations.
Figure 1.8. Representation of a normalized dose volume histogram (DVH) for a PTV
(left) and isodose curves corresponding to a maximum radiation dose for a brain tumor
(right). [This image is used under permission of the Hospital Universitario Puerta de Hierro Majadahonda,
Madrid, Spain].
The underlying evaluation and comparison process just described is highly sub-
jective and prone to inaccuracies. For this reason, several quantitative indexes (also
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termed as figures of merit) have been proposed to assist in the selection of tenta-
tive plans. For instance, some well-known figures of merit in radiotherapy planning
are the Homogeneity Index (HI) and the Conformity Index (CI). In particular, HI
basically computes the ratio between the maximum dose and the prescription dose
in the PTV, so that values close to 1 correspond to largely homogeneous dose dis-
tributions within the target [27], [29], [32]. On the other hand, CI can be defined
as the ratio between two particular isodose regions within the PTV. For instance,
typical choices are the volume fraction of the PTV receiving the prescription dose
and the total PTV volume (see also [27], [28], [30], [31], [32]).
Besides HI and CI, different indexes have been proposed to assess dosimetry
plans paying attention to dose coverage, conformity and dose gradient as separate
or global scores [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37] and [38].
However, most of such figures have been reported to suffer from limitations. In
particular, the models proposed may introduce false positives (see [27], [29], [32]
for a detailed discussion on HI and CI), may not be sensitive to small modifications
sequentially introduced, they often depend on many parameters (cf. for instance
[31], [33], [37], [39]), provide ambiguous scoring due to averaging effects [34] and
are generally not easy to implement [38]. Furthermore, in some of these cases no
value normalization is performed, which renders difficult the interpretation of the
results obtained.
Clearly, any figure of merit permits to evaluate a tentative plan according to
its compliance with a criterion specific to that figure. In the absence of widely
accepted quantitative criteria as a standard, different persons may possibly make
different choices from the same set of DVHs, isodose curves and radiobiological
features. As a consequence, different clinicians may suggest different actions for a
given patient, which makes difficult to properly estimate applied therapies from a
statistical point of view.
Bearing these facts in mind, in Chapter 4 a mathematical tool is proposed to
assist clinical personnel when it comes to estimate the consequences of modifica-
tions, however small, on any tentative treatment plan under consideration. The
proposed user-friendly decision-support tool is easy to handle and uses exclusively
the information of DVHs for each structure defined in a treatment plan and the
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corresponding prescription dose on the tumor. The figure proposed is intended to
better understand the differences between the alternatives being considered, and
no attempt is made to modify the priorities made by the person who has to apply
the treatment.
1.4 Discussion
In most clinical cases, cancer is a threatening disease and any improvement in
the diagnosis, planning and treatment techniques will result in great benefits for
patients. This is a compelling reason to pay more attention to mathematical mod-
eling and computer-based techniques, which could be helpful to predict and pro-
vide relevant quantitative clinical information. In consequence, many researchers
worldwide are developing advanced mathematical methods to contribute to the
fight against cancer, a goal towards the studies conducted in this memoir intend
to contribute.
In this Chapter basic principles and techniques involved in the radiotherapy
treatment planning process have been described in connection to the main problems
that will be addressed in this work. In particular, a brief description of medical
imaging modalities used for diagnosis and therapeutic purposes, the principles
followed to select the prescription dose distribution and fractionation schemes in
current clinical practice, and the most used radiation delivery techniques has been
briefly recalled. On the other hand, some of the mathematical models used in
radiotherapy have been reviewed. More precisely, the basic Linear Quadratic model
describing the effect of radiation on tissues has been has been recalled. Moreover,
some aspects of radiotherapy optimization as well as some of the figures of merit
proposed to evaluate and compare the quality of different tentative treatment plans
have been also reviewed.
The main goal of this memoir is to provide new mathematical and computer-
based tools to assist in the decision-making process in radiotherapy treatment
planning process, a brief description of which has been presented. More precisely,
the issue of whether an optimal radiation dose distribution can be determined
under given clinical and technological constraints is addressed in Chapter 2. To
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this end, a theoretical definition of radiation dose distributions, given as the so-
lution of a suitable multi-parametric variational problem is proposed. The choice
proposed will be shown to be suitable for personalized patient treatment, since it
allows for assigning different radiation dosimetries for different clinical priorities.
On the other hand, increasing attention is being paid to tumor heterogeneity as
a key factor in tumor prognosis. Unfortunately, current clinical and experimental
techniques are unable to probe deeply enough into tumor heterogeneity by non-
invasive procedures. In Chapter 3 a mathematical model of tumor growth with
spatial intratumoral heterogeneity is investigated. Specifically, a simplified situa-
tion is assumed, where only two tumor cell phenotypes are present, which strongly
differ in their respective cell cycle duration and radiosensitivity properties. It is
shown that such difference in phenotype behaviours permit to predict the internal
distribution of both phenotypes as tumor grows. As a consequence, heterogeneous
radiation dosimetries could be planned which are shown to yield better results
in terms of local tumor control than the homogeneous ones currently pursued in
clinical practice. On the other hand, a decision-aid tool based the prescription
radiation dose and on the DVHs obtained from a TPS has been proposed in Chap-
ter 4 to estimate any tentative treatment plan. In this manner, different plans
can be compared and evaluated in a quantitative way. Finally, in Chapter 4 some
concluding remarks and future research directions are discussed.
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Chapter2
Selecting radiation therapy dose
distributions by means of
constrained optimization problems
“. . . Mathematics is one of the most significant manifestations of the love of
wisdom. On the one hand, there are no boundaries in mathematical thought and
imagination, but on the other hand there is the reality that the world is made of
things both visible and invisible and that mathematics is the unique science with
the capacity to pass from the observations of visible things to the imagination of
things invisible. This is perhaps the secret of the strength of mathematics . . .”
Ennio De Giorgi (1928-1996)
2.1 Abstract
The main steps in planning radiotherapy consist in selecting for any patient diag-
nosed with a solid tumor i) a prescribed radiation dose on the tumor, ii) bounds on
the radiation side effects on nearby organs at risk and iii) a fractionation scheme
specifying the number and frequency of therapeutic sessions during treatment. In
particular, the choice of a prescription radiation dose and bounds on the radiation
doses are mostly based on clinical experience accumulated on the specific type of
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tumor and organs at risk involved, without any direct reference to quantitative
radiobiological assessment. Interestingly, mathematical models for the effect of
radiation on biological matter exist long since, and are widely acknowledged by
clinicians. However, the difficulty to obtain accurate in vivo measurements of the
radiobiological parameters involved has severely restricted their direct application
in current clinical practice.
The goal of this Chapter is first to propose a mathematical model to select radi-
ation dose distributions as solutions (minimizers) of suitable variational problems,
under the assumption that key radiobiological parameters for tumors and organs at
risk involved are known. Second, by analyzing the dependence of such solutions on
the parameters involved, the manner in which the use of those minimizers could
improve current decision-making processes to select clinical dosimetries is then
discussed, when (as is generally the case) only partial information on model ra-
diosensitivity parameters is available. A comparison of the proposed radiation dose
distributions with those actually delivered in a number of clinical cases strongly
suggests that solutions of the proposed mathematical model can be instrumental
in deriving good quality tests to select radiotherapy treatment plans in rather gen-
eral situations. This model can be applied for any type of tumor regardless of its
location, as well as if different intratumoral regions or several tumors are identified
for a same patient.
2.2 Introduction
A crucial step in planning radiotherapy is the choice of the radiation dose distri-
bution to be delivered during treatment to a patient diagnosed with a solid tumor.
Standard clinical practice requires radiation dose distributions to be as close as
possible to a prescribed radiation dose (Dp) homogeneously distributed over the
Planning Target Volume (PTV), while unwanted side effects on surrounding organs
at risk (OARs) and healthy tissues (HT) should be kept as low as possible. Ad-
dressing such often conflicting goals is the aim of the dosimetry planning process,
where the number and frequency of therapeutic sessions, clinical constraints on the
radiation dose reaching nearby OARs and the Dp on the tumor are selected, and
the manner in which the resulting treatment plan has to be delivered is specified.
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In particular, selecting Dp depends on the type, location and size of each tu-
mor under consideration and on its expected radiosensitivity (that is, its estimated
resistance to radiation). As a matter of fact, sparing radiation delivery to critical
structures is the most important limiting factor in radiotherapy treatments [53].
Indeed, an important consideration is that the radiation dose selected to achieve
tumor control should depend on that tolerated by nearby organs and healthy tis-
sues. Therefore, normal tissue morbidity will often set a limit to the cure rate
that may be achieved [20]. On the other hand, radiation does not affect different
organs in the same way. In fact, its effect will depend of the organ architecture
(serial, parallel or combination of them) and the intrinsic radiosensitivity among
other factors. As consequence, estimating the effect of radiation on anatomical
structures (both pathological and physiological) is thus a key feature in the ra-
diotherapy planning process. To this day, the accepted theoretical foundation for
that purpose is the Linear Quadratic (LQ) model (see Section 1.3.1 in Chapter
1 and [53], [54], [55], [56]). Since the LQ model is an essential ingredient in the
optimization problem formulated in this Chapter, some of its main features are
recalled as follows.
According to the LQ model, for any given cell aggregate, the surviving fraction
of cells (either malignant or healthy) after a radiation dose D has been delivered
there can be estimated by means of equation (1.1) in Chapter 1. Radiosensi-
tivity parameters are thus specific for any anatomical or pathological structure
considered, and this represents a major obstacle towards their efficient clinical use,
particularly in the case of malignancies. As a matter of fact, and in spite of in-
trinsic variability between patients, extensive (although by no means exhaustive)
data have been gathered for the values of α and β in healthy human tissues [88],
[89]. However, in what concerns tumors, the situation is less satisfactory (see for
instance [90] for Glioblastoma Multiforme (GBM) tumor cell lines and [91] for
prostate carcinoma cell lines). To begin with, most data available have been gath-
ered from in vitro grown cell cultures obtained from animal trials or from patient
samples, and it is widely accepted that in vivo values might considerably differ
from their in vitro counterparts. Furthermore, an additional difficulty to ascer-
tain their precise values is represented by tumor heterogeneity [21], [22]. In fact,
most developed tumors contain different tumor subpopulations, each possessing
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different sensitivity properties to radiotherapy (or to other therapies) [23]. To this
day, no efficient, non-invasive technique exists which could sort out neither the
spatial distribution of such subpopulations within a tumor, nor their different ra-
diosensitivity parameters. Thus, in spite of equation (1.1) being considered as a
cornerstone in theoretical radiobiology, in current clinical practice radiation doses
prescribed on tumors are selected without making direct use of such formula to
estimate radiation effects.
However, indirect albeit highly significant use of the LQ model has found a
relevant place in current clinical practice in the context of dose fractionation [55],
[60]. Fractionation schemes were introduced to facilitate recovery in organs and
healthy tissues affected by radiation and led to the concept of Biological Effective
Dose (BED) (see for instance [53], [92]), which is defined as follows. Suppose that
a total radiation dose D is prescribed on a tumor, which is equally distributed into
a number of n sessions, at any of which a single dose d is delivered. Assuming
that treatment session effects are independently accumulated, the quantity in the
exponent of equation (1.1) (usually termed as the log cell kill) will read
E = n(αd+ βd2).
Thus, when d is small and n large, the main contribution to E is contained in
its linear part. BED is then defined as follows
BED =
E
α
= D
(
1 +
d
(α/β)
)
. (2.1)
Therefore, when tumor cell repopulation between treatment sessions is ne-
glected, BED represents the radiation dose required for a given effect if the total
dose D were delivered by means of small doses per fraction. As a consequence,
BED quantitatively estimates the biological dose delivered to a tissue characterized
by a given (α/β) ratio, by means of a particular combination of dose per fraction
d and total radiation dose D. Notice that BED does not depend on α and β sepa-
rately, but on their ratio (α/β), which is the dose at which cell killing by the linear
and quadratic terms in (1.1) are equal. Clearly, for any fixed dose D, the same
BED can be achieved with different fractionation schemes. Clinical experience
accumulated on fractionation effects over years led to a classification of tissues (in-
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cluding tumors) into Early-responding (ER) and Late-responding (LR) ones [47],
[93]. Roughly speaking, ER tissues show only limited changes when a dose is frac-
tionated into a number of treatment sessions, a common clinical practice, whereas
LR tissues display large changes due to fractionation. Using the definition of BED
in (2.1), it turns out that such effects are respectively associated with large (in
the case of ER tissues) and small (for LR tissues) values of the ratio (α/β) [53],
[94]. In spite of acknowledging that precise values of (α/β) ratios are rarely known
in human tissues, for each particular type of tumor clinicians use some accepted
figures for such ratio when selecting the particular fractionation scheme to be car-
ried out. For instance, it is common to take α/β = 10Gy for early responding
tissues and most tumors, and α/β = 2Gy − 3Gy for late responding ones. These
values are usually arrived at in a statistical way from data obtained from clinical
practice (see for instance [95], [96] for (α/β) ratios reported for different organs
and tumors).
As argued in Chapter 1, to minimize collateral damage on OARs and HT, a
standard radiotherapy strategy consists in selecting several radiation beams that
converge at the PTV, which is therefore arrived at along a variable number of
incidence angles, with possibly different intensities along each beam configuration.
In general, the choice of any such configuration is made by selecting one among
several tentative cases simulated by means of treatment planning systems (TPS)
[15], [53]. Current practice consists in simulating a (usually small) number of
tentative plans corresponding to different beam configurations. After comparing
the plans thus obtained, that which is expected to yield better results is selected.
As a matter of fact, simulated tentative plans usually differ from each other in
small variations in the number, incidence angles or intensity of radiation beams
converging on the PTV. Indeed, the choice of the treatment plan to be applied in
any particular case relies mainly on a personal decision by the responsible clinician
according to his/her own professional experience.
To remedy the uncertainties surrounding this decision process, during the last
decades a number of quantitative figures of merit have been proposed to assist in
this planning process (see Section 1.3.3 in Chapter 1 for further details). More pre-
cisely, some well-known figures of merit in radiotherapy are the Homogeneity Index
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(HI) and the Conformity Index (CI) (see [27], [29], [32] for a detailed discussion
on HI and CI). The conventionally used HI is usually defined as follows
HI =
DM
Dp
, (2.2)
where DM is the maximum radiation dose delivered in the PTV, and Dp is the
prescribed radiation dose. In most clinical cases, good homogeneity, corresponding
to HI close to one, is often sought for [29]. On the other hand, the CI proposed by
the Radiation Therapy Oncology Group (RTOG) [27] is given as
CI =
VRI
V
, (2.3)
where VRI is the volume of a (selected) reference isodose and V is the volume
of the planning target, so that a value of CI close to one is considered to provide
a good conformation with respect to the reference isodose considered (see [32]
for a review). In addition to these, several indexes have been proposed to assess
dosimetry plans, however figures of merit (2.2) and (2.3) have been widely used to
compare radiation effects in tumors in current clinical practice.
In this Chapter mathematical modeling and computer simulations are used to
select radiation dose distributions according to the information about radiosen-
sitivity parameters available in each given clinical case. Mathematical models of
tumor growth and therapy have been extensively studied during last years: see for
instance [97], [98], [99], [100], [101], [102], [103], as well as the reviews [104], [105].
Radiotherapy modeling has been reviewed in [56], [62] and specific issues of that
field have been studied in [106], [107], [108], [109], [110], [111], [112]. In particular,
the impact of radiation on the spatio-temporal dynamics of tumor spheroids has
been discussed in [112] (see also [113]), where the effect of radiation on cell cycle
synchronization is discussed, as well as in [109], where radiosensitivity parame-
ters identification has been addressed. The impact of re-oxygenation in tumor
sensitivity is discussed in [114]. An image-based kinetic algorithm to model tu-
mor response to therapy has been described in [115], and specific models for the
response of brain tumors to a given radiation dose (including in particular dose
fractionation effects) have been proposed and discussed in [116], [117].
33
Let us now describe more in detail the plan and structure of this Chapter. To
begin with, a mathematical model to obtain optimal radiation dose distributions
satisfying clinical and technical requirements has been proposed and discussed.
More precisely, in Section 2.3 a multi-parameter variational problem is formulated
whose minimizers provide optimal choices for a radiation dose distribution when all
radiosensitivity parameters α and β of the LQ model are known (see related works
[106], [110]). In particular, the functional to be minimized represents a weighted
sum of radiobiological effects, directly related to PTV coverage and OARs and HT
sparing, evaluated according to the LQ model. In addition, standard clinical and
technological constraints are also accounted for. The situation considering volu-
metric constraints on the fraction of a PTV and/or OARs that receive a radiation
dose above of a given threshold value is also investigated, since these are issues of
great clinical interest [15].
Then, in Section 2.4 theoretical results related to existence and uniqueness
properties of solutions are provided. When doing so, in Section 2.5 the dependence
of previously obtained minimizers on radiosensitivity parameters is explored to
propose a strategy to select a dose distribution when the ratio (α/β) (but not the
separate values of α and β) are known for tumors present. Roughly speaking (see
that Section for details), suitable volumetric constraints on OARs are imposed and
then increase the weight assigned to the PTV dosimetry in the functional to obtain
a dose distribution whose radiobiological effects could hardly be improved, even if
the precise values of α and β for the tumor involved were known. Moreover, when
compared with actual dosimetries delivered in some clinical cases reported, the
radiation dose distribution thus selected is shown to be a better option. Therefore,
the dosimetry thus selected can be considered an optimal choice against which
tentative treatment plans should be compared during the radiotherapy planning
process. This Chapter is then concluded with a final Section 2.6, where the main
results of this work are summarized and future research directions are highlighted.
Finally, in Appendices A and B the numerical discretization of the proposed model
and additional computer simulations of the clinical cases considered are provided
respectively.
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2.3 A theoretical model: radiation dose distribu-
tions as minimizers of a variational problem
In this Section a mathematical model that provides radiation dose distributions ac-
cording to precise radiobiological principles is formulated. To begin with, consider
a three-dimensional domain Ω ⊂ R3 where different radiosensitivity cell popula-
tions may coexist, and Ωi = Ω1, . . . ,Ωn (1 ≤ i ≤ n) and Ωj = Ωn+1, . . . ,Ωm
(n + 1 ≤ j ≤ n + m) denote the subset of Ω occupied by tumor and organs at
risk/healthy tissues respectively. Thus, Ω =
n⋃
i=1
Ωi
n+m⋃
j=n+1
Ωj, where the sets Ωi and
Ωj are mutually disjoint. The effect of radiation in each of these regions will be
estimated by means of the LQ model (1.1), namely
SFk(D(x)) = e
−(αkD(x)+βkD(x)2), k = 1, . . . , n+m, (2.4)
where D(x) is the amount of radiation delivered at any point x ∈ Ω and (αk, βk)
are the radiosensitivity parameters of the regions considered. In the sequel, tumor
regions (respectively, OAR and HT regions) will be indexed by i (respectively, by
j).
For a given set Ωk ⊂ Ω, (k = 1, . . . , n+m), XΩk(x) represents the characteristic
function defined as follows
XΩk(x) =
1 if x ∈ Ωk0 otherwise . (2.5)
Let us now consider the following multi-parameter variational problem: find
D(x) defined in Ω, such that D(x) minimizes the following functional
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J(D(x)) =
n∑
i=1
wi
∫
Ω
XΩiSFi(D(x)) dx +
n+m∑
j=n+1
wj
∫
Ω
XΩj (1− SFj(D(x))) dx
+ a
∫
Ω
|∇D(x)|2 dx,
(2.6)
subject to the following constraints
|∇D(x)| ≤ C1 in Ω, (2.7)
C2 ≤ D(x) ≤ C3 in Ω, (2.8)
Cmk ≤ D(x) ≤ CMk in Ωk, k = 1, . . . ,m+ n, (2.9)
|{x ∈ Ωi : D(x) > CVi}| ≥ δi|Ωi|, i = 1, . . . , n, (2.10)
|{x ∈ Ωj : D(x) ≥ CVj}| ≤ δj|Ωj|, j = n+ 1, . . . , n+m, (2.11)
where wk (respectively, C1, C2, C3, Cmk , CMk , CVk and a) for (k = 1, . . . ,m+n)
are given positive (respectively, nonnegative) real numbers, the functions XΩi and
XΩj are defined in (2.5), SFi(D(x)) and SFj(D(x)) represent the surviving cell
fraction given by the LQ model of the ith and jth region respectively (see equation
(2.4)), and where |·| in (2.10) and (2.11), when applied to a measurable set, denotes
its volume.
A solution (if any) D(x) of functional (2.6) subject to constraints (2.7)–(2.11),
henceforth referred to as (P) for short, is called a minimizer function of the cor-
responding problem. Concerning the meaning of the various terms in (2.6) and
constraints (2.7)–(2.11), a few remarks are in order. To begin with, it should be
noticed that the quantities
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∫
Ω
XΩiSFi(D(x)) dx =
∫
Ωi
SFi(D(x)) dx ≡ |Ωi(D(x))|
∫
Ω
XΩj(1− SFj(D(x))) dx =
∫
Ωj
(1− SFj(D(x))) dx ≡ |Ωj(D(x))|
for i = 1, . . . , n and j = n+1, . . . , n+m, represent the volume of the malignant
and healthy regions Ωi and Ωj after receiving a dose D(x) respectively, so that for
instance, |Ωk(D(x))| ≤ |Ωk| for (k = 1, . . . ,m + n). The first and second term in
the right of (2.6) represent a weighted estimate of the changes in the surviving cell
fractions of the subsets occupied by each tumor and organ at risk/healthy tissue
after irradiation. In particular, the first term in the right of (2.6) represents a
tumor control term, and can account for possible tumor heterogeneity. On the
other hand, the second term there represents organs at risk side effects. As a
matter of fact, one may aim at achieving different effects in different regions by
appropriately selecting the weight parameters wk for (k = 1, . . . , n+m) in (2.6).
On the other hand, (2.7) is a constraint related to the resolution limit achieved
by the radiation equipment being used (for instance, linear particle accelerators),
whereas (2.8)–(2.11) corresponds to minimum and maximum radiation bounds
over the regions considered, and are added to meet clinical requirements (where
obviously one has to impose C2 ≤ Cmk , CMk , CVk ≤ C3, for (k = 1, . . . , n+m)). In
addition, when a > 0, the last term in (2.6), provides a global gradient bound that
complements the pointwise bound in (2.7). Notice that constants in this model
have to be compatible, in the sense that the class of admissible, differentiable
functions D(x) satisfying (2.7)–(2.11) should be nonempty, an assumption to be
retained henceforth. Moreover, for ideal cases of the volumetric constraints (2.10)
and (2.11), a good selection is to fix values of CVi = C3 − , for (i = 1, . . . , n) and
CVj = C2 + , for (j = n+ 1, . . . ,m), where  > 0 is sufficiently small, and where δi
(i = 1, . . . , n) (respectively, δj (j = n + 1, . . . ,m)) for 0 ≤ δi, δj ≤ 1 should be as
close to 1 (respectively, to 0) as possible (say for instance, δi ≈ 0.9 and δj ≈ 0.1). In
this formulation, the sets Ωi and Ωj are assumed to be time-independent. Indeed,
this is a reasonable hypothesis if repopulation effects are assumed to occur at a
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much slower time scale than that corresponding to radiation delivery.
2.4 Theoretical results of the variational prob-
lem
The problem (P) just stated can be studied by means of classical methods in the
Calculus of Variations (see for instance [118], [119]). In particular, the existence
of at least one minimizer can be readily obtained under very general assumptions.
The proposed problem has bounded solutions with generalized bounded deriva-
tives. More precisely, they belong to the space W 1,∞(Ω) of all bounded functions
D(x) on Ω that satisfy a Lipschitz property, namely
|D(x)−D(y)| ≤ K|x− y|, ∀x,y ∈ Ω,
for a suitable constant K. The notation W 1,∞0 (Ω) is used for the subclass
of functions in W 1,∞(Ω) that vanish on the boundary ∂Ω of Ω (see for instance
[120] for properties of such spaces). In particular, for the problem consisting of
minimizing (2.6) under constraints (2.7)–(2.9) one has the following result.
Theorem 1. Let D0(x) be any given function in W
1,∞(Ω), where Ω is a bounded,
open set in Rd (d ≥ 1) with Lipschitz boundary ∂Ω. Then, there exists at least one
D(x) ∈ W 1,∞(Ω) such that the functional (2.6) achieves its minimum in the set
K = {D(x) ∈ W 1,∞(Ω) : (D(x)−D0(x)) ∈ W 1,∞0 (Ω)
and (2.7)-(2.9) hold
}
.
Any such function D(x) is said to be a minimizer of (2.6) in K.
Proof. It is readily seen that the functional given in (2.6) is lower semicontinuous
(l.s.c) on the space W 1,∞(Ω) endowed with the uniform convergence. Thus, exis-
tence of at least one minimizer follows from the fact that the associated functional
J∗(D) = J(D) + IK(D), (2.12)
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where K is as in the statement of the Theorem 1 and IK(D) = 0 when D ∈ K,
IK(D) = +∞ otherwise, is also l.s.c on W 1,∞(Ω) with respect to the uniform
convergence, since K is compact for the uniform convergence. Then a minimizer of
(2.12) (hence for the problem under consideration consisting of minimizing (2.6)
under constraints (2.7)–(2.9)) exists by classical results, (cf. for instance [118],
[119]).
Besides constraints (2.7)–(2.9), a common clinical requirement consists in im-
posing volumetric constraints on the percentage of a tumor region (respectively,
an organ at risk or healthy tissue) that is expected to receive no less (respectively,
no more) than a threshold radiation dose. Let us now suppose that the volumet-
ric constraints (2.10), (2.11) are compatible in the sense recalled above. Then a
variational problem as that considered in Theorem 1 continues to have minimizers
when volumetric constraints are imposed in addition to those already considered
in (2.7)–(2.9). More precisely, there holds.
Theorem 2. Let Ω, Ωi, Ωj and D0(x) be as in Theorem 1, and assume that in
addition to (2.7)–(2.9), compatible volumetric constraints (2.10)–(2.11) are im-
posed. Then, there exists at least one D(x) ∈ W 1,∞(Ω) such that the functional
(2.6) achieves its minimum in the set
K̂ = {D(x) ∈ W 1,∞(Ω) : (D(x)−D0(x)) ∈ W 1,∞0 (Ω),
D(x) satisfies (2.7)− (2.9), (2.10) and (2.11)}.
Proof. It is quite similar to that of Theorem 1. In particular, the functional
J∗(D) = J(D) + IK̂(D) (2.13)
is l.s.c on the space W 1,∞(Ω) endowed with the uniform convergence, since K̂
is compact for that convergence. This yields the existence of minimizers of (2.13)
(hence for the problem under consideration consisting of minimizing (2.6) under
constraints (2.7)–(2.11)).
Therefore, from Theorems 1 and 2 the existence of at least one minimizer of the
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problem (2.6)–(2.11) has been obtained. However, to achieve uniqueness, suitable
restrictions on the upper and lower bounds in (2.8) have to be imposed, which
turn out to be related with the radiosensitivity parameters of the corresponding
structures. In particular, there holds.
Theorem 3. Let Ω, Ωi and Ωj be as in Theorems 1 and 2. Then for any choice
of positive (respectively, nonnegative) constants wk for (k = 1, . . . , n+m) (respec-
tively a) and for any compatible choice of constants in (2.7)–(2.11), the variational
problem (P) consisting of minimizing (2.6) under constraints (2.7)–(2.11) has a
unique minimizer provided that
C2 > max
1≤i≤n
{
− αi
2βi
+
√
1
2βi
}
,
C3 < min
n+1≤j≤n+m
{
− αj
2βj
+
√
1
2βj
}
,
(2.14)
where (αi, βi) (respectively, (αj, βj)) are the radiosensitivity parameters of the
regions Ωi (1 ≤ i ≤ n) (respectively, Ωj (n+ 1 ≤ j ≤ n+m)).
Proof. Uniqueness for the problem under consideration consisting of minimizing
(2.6) under constraints (2.7)–(2.11) is guaranteed whenever the functional in (2.6)
happens to be strictly convex. To achieve this result, it suffices to show that, when
finite, the integrand in (2.6) is strictly convex as a function of ∇D(x) and D(x).
In view of the particular form of (2.6), one just needs to show that
∂2
∂D2
SFi(D(x)) > 0, (1 ≤ i ≤ n),
∂2
∂D2
(1− SFj(D(x))) > 0, (n+ 1 ≤ j ≤ n+m).
(2.15)
A quick computation reveals that
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∂2
∂D2
SFi(D(x)) = e
−(αiD(x)+βiD(x)2)((αi + 2βiD(x))2 − 2βi)
=
(
e−(αiD(x)+βiD(x)
2)
)
· 4β2i
(
D(x)2 +
αi
βi
D(x) +
α2i − 2βi
4β2i
)
≡ 4β2i
(
e−(αiD(x)+βiD(x)
2)
)
gi(D(x)).
(2.16)
Therefore, in order to satisfy the first set of inequalities in equation (2.15), one
needs to have gi(D(x)) > 0 for (1 ≤ i ≤ n), such that
D(x) >
1
2
−αi
βi
±
√(
αi
βi
)2
−
(
α2i − 2βi
β2i
)
⇓
D(x) >
1
2
(
−αi
βi
±
√
2
βi
)
,
which certainly holds provided that
D(x) > Dmi =
{
− αi
2βi
+
√
1
2βi
}
, for (i = 1, . . . , n). (2.17)
From equation (2.16) it also follows that the second inequality in equation
(2.15) is satisfied whenever one has
D(x) < DMj =
{
− αj
2βj
+
√
1
2βj
}
, for (j = n+ 1, . . . , n+m). (2.18)
Putting together equations (2.17) and (2.18) the result follows. Therefore, the
integrand in (2.6) is strictly convex when inequalities (2.14) are satisfied. This
in turn implies the strict convexity of J(D(x)) in (2.6), whereupon uniqueness
follows.
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Remark 1. The case a = 0 is admissible in Theorem 3, since the constraint
|∇D(x)| ≤ C1 in (2.7) then provides enough compactness to pass to the limit in
the corresponding functional.
Remark 2. Theorems 1 and 3 can be considered to yield existence and uniqueness
in cases where constraints (2.9) are imposed on some specified open subsets of Ω.
For instance, for (k = 1, . . . , n + m), let Ωk be a family of open sets such that
Ωk ⊂ Ω and the sets Ωk are mutually disjoint. Let Cmk and CMk be nonnegative
constants such that C2 ≤ Cmk ≤ CMk ≤ C3 for (k = 1, . . . , n + m), and consider
now the minimization problem (P
′
) consisting in solving (P) under the following
additional conditions
Cmk ≤ D(x) ≤ CMk in Ωk, k = 1, . . . , n+m. (2.19)
Then, under the assumption that constants C1, C2, C3, Cmk and CMk are com-
patible (that is, assuming that there exist differentiable functions D(x) in Ω satisfy-
ing (2.7)–(2.8) and (2.19)) there exists a unique solution of the new minimization
problem (P
′
) provided that conditions (2.14) hold.
2.5 Planning under radiobiological uncertainty
This Section is devoted to discuss how to use the minimizers of the model previously
formulated as a guide to select appropriate radiation dose distributions when only
partial information about tumor radiosensitivity parameters is available. To begin
with, the manner in which radiotherapy treatment plans are currently selected in
clinical practice is briefly recalled.
2.5.1 How are clinical radiation dosimetries planned?
For any given patient diagnosed with a solid tumor, once the number and frequency
of therapeutic sessions, volumetric and dose constraints on the PTV and/or OARs
have been established, and the radiation dose to be delivered on the PTV has
been prescribed, radiophysicists are required to prepare a treatment plan as close
as possible to the previously defined requirements. To that end, they simulate a few
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different tentative treatment plans on a treatment planning system (TPS), oper-
ating on the same linear particle accelerator (LINAC), which will deliver radiation
to the patient.
For any such tentative plan, the TPS being used provides cumulative dose-
volume histograms (DVH) for each structure involved, as well as isodose curves
over the whole treatment domain. A DVH summarizes 3D dose distributions in
a 2D graphical format and isodose curves are closed lines bounding regions where
radiation dose is larger or equal than a given value (see Figure 1.8 in Chapter
1). After comparing the tentative plans thus prepared, that which is expected to
be closer to the clinical prescription requirements is selected and delivered to the
patient. Such comparison, and therefore the resulting choice of a treatment plan, is
made mainly by inspection of the DVHs and isodose curves for each tentative plan
considered. A key point to be noticed is that tentative plans usually differ from
each other in small variations in the number, incidence angles or intensity of the
radiation beams converging on a PTV. As a consequence, the corresponding DVHs
and isodose curves for different tentative plans may look quite close to each other.
This makes it difficult, even to a trained eye, to tell by mere inspection which one
may yield better results. To illustrate this issue, Figure 2.1 shows actual DVHs
corresponding to two tentative treatment plans for a same patient.
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Figure 2.1. Superposed dose volume histograms (DVHs) of two tentative treatment
plans (solid and dashed lines respectively) for a same patient. Same color arrows corre-
spond to the same tentative plan. Notice that the plan pointed in light blue is better for
the OARs indicated, but worse for the PTV in the case considered.
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At this juncture, it is worth remarking on the values assigned to tentative plans
in Figure 2.1 by figures of merit as Homogeneity Index (HI) and Conformity Index
(CI) recalled at the introductory Section 2.2. Let us denote by A (respectively by
B) the plan corresponding to solid (respectively dashed) lines in Figure 2.1. One
readily checks that the maximum radiation dose received by the PTV is about
1.77Gy for plan A and 1.74Gy for plan B. Accordingly, the corresponding HI
in (2.2) is equal to 0.98 for plan A and 0.96 for plan B. Moreover, the CI in
(2.3) measured with respect to the reference isodose corresponding to 95% of the
prescription radiation dose (1.8Gy) is equal to 0.91 for plan A and 0.84 for plan
B respectively. Therefore, if attention is paid on effect achieved on the PTV,
it appears that plan A is better than plan B, both in terms of radiation dose
homogeneity and conformity on the tumor.
On the other hand, the maximum radiation dose received by the Hypothalamus,
Optic Chiasm and left Optic Tract is equal to 1.68Gy, 1.75Gy and 1.69Gy for plan
A, and 1.65Gy, 1.71Gy and 1.66Gy for plan B respectively. Moreover, 15% of
the volume of such organs received at least a radiation dose of 1.35Gy, 1.73Gy
and 1.58Gy for plan A, and 1.33Gy, 1.69Gy and 1.54Gy for plan B respectively.
Therefore, out of the two cases considered, plan B is better than plan A with
respect to OARs sparing.
In general, no direct reference to the radiobiological effects induced by each
tentative treatment plan is made when the dosimetry to be applied is selected.
However, information about radiosensitivity of the anatomical structures involved
is implicitly used whenever a fractionated radiation dosimetry is prescribed, a stan-
dard therapeutic choice for most tumors. Indeed, as discussed at the introductory
Section 2.2, a fractionated scheme depends among other factors on the characteri-
zation of the tumor considered as ER or LR tissue, which is known to be correlated
with the respective (α/β) ratio.
2.5.2 Numerical simulations for minimizers. Comparison
with a clinical case
To proceed further, in this Section the solutions of the theoretical model formulated
in Section 2.3 are considered and the way in which efficient numerical approxima-
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tions to them can be obtained is described.
Since solutions to the variational problem described in Section 2.3 cannot be
represented in a closed form, to analyze their performance an efficient numerical
approximation for them has to be provided, so that their corresponding DVHs and
isodose curves could be readily obtained. Furthermore, to be able to compare with
actual clinical cases, such numerical approximations need to be obtained under the
same technical requirements satisfied by linear particle accelerators used to treat
the patients selected. Therefore, to obtain suitable numerical solutions of model
(2.6)-(2.11) a first step consists in data processing from the particular TPS used
in each case.
Then, to illustrate these results let us discuss how the solution of the proposed
variational problem compares with a clinical case of a patient diagnosed with a
centrally-located brain tumor (Meningioma), where the PTV and several surround-
ing OARs have been delineated by clinicians and radiophysicists (see Figure 2.2
and 2.3). This is part of a larger study conducted over ten patients diagnosed with
Meningioma, which are reported in Appendix B. Such type of tumors have been
selected since, due to its internal location, they are surrounded by several OARs
that have to be spared as much as possible. In this case, technical data were ob-
tained from the TPS used, iPlan RT Dose 4.1.1, BrainLAB AG Germany. These
data were retrieved in the form of DICOM (Digital Imaging and COmmunication
in Medicine) files, a standard for handling and transmitting information in medi-
cal imaging [121]. These files have been interpreted through appropriate software
(CERR, Computational Environment for Radiotherapy Research, see [122] for
further details).
Having done this, a three-dimensional Delaunay triangulation [123] of the whole
domain of simulation (considered as healthy tissue, namely Brain tissue), the OARs
involved and the PTV as defined by radiophysicists and clinicians in the same
treatment planning system is created (see Figure 2.2). For that purpose an open-
source C++ library (CGAL, The Computational Geometry Algorithms Library,
[124], [125]) has been used, which provides easy access to efficient and reliable
computational geometric algorithms. It should be noted that in the corresponding
numerical simulations the same points defined in the TPS and the same defini-
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tion of each structure involved have been considered. In this way, minimizers are
obtained in the same domain, and under the same conditions, that were assumed
during the actual treatment planning process.
Figure 2.2. From left to right a three-dimensional domain reconstruction for the clinical
case considered, the three-dimensional Delaunay triangulation created over the whole
domain of simulation, and the representation of the PTV and OARs involved.
Figure 2.3. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
To approximate the minimizers of the model given by (2.6)-(2.11), the finite
element method has been used (see for instance [126], [127], [128] and [129]). That
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is, the key idea is look for a minimizer D(x) that is a continuous function in Ω
and linear in every tetrahedron of the three-dimensional triangulation implemented
(see Appendix A where a detailed description of the numerical discretization and
computational implementation is provided). This last property implies that its
value on every tetrahedron is defined by the value at its vertices, and the fact that
D(x) is continuous implies that the value at a vertex is unique, independently of
how many tetrahedrons the vertex belongs to. In fact, denoting by x1, . . . , xnv the
vertices of the triangulation (the domain points defined in the TPS), and writing
for simplicity, d1 = D(x1), . . . , dnv = D(xnv), it is customary to express D(x) as
follows
D(x) = d1ϕ1(x) + . . .+ dnvϕnv(x), x ∈ τ, (2.20)
where for i = 1, . . . , nv, ϕi(x) denotes the nodal basis function (continuous in
Ω and linear in every tetrahedron) associated to vertex xi, which takes value one
on the vertex xi and zero on the remaining vertices (see for instance Section 1.4 in
[127], Section 2.3 in [128] and Section 1.4 in [129]). Therefore, substituting (2.20)
in the model (2.6)-(2.11), then the problem of finding the minimizer D(x) reduces
to a nonlinear constrained optimization problem (see Chapter 15 in [130]) in the
variables d1, . . . , dnv (see also Appendix A).
Solving this optimization problem requires the computation of the integrals in
(2.6) and their partial derivatives with respect to d1, . . . , dnv . This can be done
by summing the contributions to the integrals on every tetrahedron, contributions
which can be computed in a standard and well-established way (see Section 1.8
in [127], and Section 2.2.3 and 2.3.3 in [128]). Observe also that since D(x) is
linear in every tetrahedron, constraints (2.8) and (2.9) reduce to C2 ≤ dl ≤ C3 and
Cmk ≤ dl ≤ CMk for l = 1, . . . , nv and k = 1, . . . , n + m, respectively. Similarly,
since ∇D(x) is constant on every tetrahedron, constraint (2.7) reduces to requiring
that in each tetrahedron τ is expressed as follows(∑
xl∈τ
dl∇ϕl
)2
≤ C21 , l = 1, . . . , nv.
Again, it is easy to compute ∇ϕi in every tetrahedron following standard pro-
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cedures as in Section 2.2 in [128]. Concerning the volumetric constraints (2.10) and
(2.11), it should be noted that their computation reduces to estimate the fraction
of volume that receives a radiation dose higher than CVk of those tetrahedrons in
the triangulation which belong to the region considered. In particular, to do that
three general cases should be considered: i) the value of D in the four vertices is
larger than CVk for k = 1, . . . ,m + n, ii) the value of D is larger than CVk in one
vertex and smaller in the remaining three vertices and iii) the value of D is larger
than CVk in two vertices and smaller in the other two vertices. For instance, let us
consider only one tetrahedron, then for the case i) the portion of volume that re-
ceives a radiation dose higher than CVk is precisely the volume of this tetrahedron,
while for ii) and iii) is the portion of its volume receiving a radiation dose higher
than CVk . Therefore, volumetric constraints (2.10) and (2.11) can be computed
from an iterative process over each tetrahedron in the region considered based in
the cases described above (see Appendix A for further details).
To numerically solve the corresponding nonlinear constrained optimization
problem, the C++/Fortran open-source optimization package (IPOPT, Interior
Point OPTimizer) has been used, which is a numerical library for large-scale
nonlinear optimization [131]. Since this package does not include linear algebra
routines, IPOPT has been coupled with PARDISO solver [132], [133], which is
a high-performance and memory-efficient C++ library for solving large sparse
symmetric and non-symmetric linear systems of equations on shared-memory and
distributed-memory multiprocessors.
2.5.3 The case of equally important anatomical structures
Let us continue with the study started in Section 2.5.2, which corresponds to a pa-
tient treated with Intensity Modulated Radiation Therapy (IMRT) [15], [19]. The
radiosensitivity parameters required for application of the LQ model for different
OARs involved in this clinical case are given in Table 2.1 (see also [89]). Since ap-
propriate data are not always available, non-reported radiosensitivity parameters
have been selected as follows: i) Hypothalamus parameters have been taken equal
to those of the Brain Stem, which are known and ii) Optic Tracts parameters are
assumed equal to those of the Optic Nerve. While such assignment has been made
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according to anatomical proximity, it should be stressed that the results that fol-
low do not depend on the precise values taken for such parameters. Actually, the
process to be described below will be shown to be robust with respect to changes
in all radiosensitivity parameters involved.
Organ α/β(Gy) α(Gy−1) β(Gy−2)
Brain Tissue 2.1 0.0499 0.0238
Brain Stem 2.1 0.0491 0.0234
Eye 1.2 0.0686 0.0572
Retina 3.0 0.0439 0.0146
Optic Nerve 3.0 0.0586 0.0195
Optic Chiasm 3.0 0.0251 0.0084
Table 2.1. Radiosensitivity parameters of the Linear Quadratic (LQ) model (2.4).
Values of (α/β), α and β for OARs and HT (Brain tissue) are provided (see [89]).
Concerning the PTV, and in line with what has been said at the introductory
Section 2.2, for Meningioma (a well-known late responding tissue [134], [135]) a
value of the ratio α/β = 3.7Gy has been considered. This is consistent with the
conventional radiotherapy fractionation scheme selected to treat this type of tu-
mors, that is a total prescription dose of 50.4Gy, delivered in 28 diary treatment
sessions 5 days a week with weekend interruptions, which corresponds to a prescrip-
tion dose (Dp) of 1.8Gy per session [48], [136]. Thus, the constants in constraints
(2.8) and (2.9) were selected as C2 = Cmk = 0.0Gy and C3 = CMk = 1.8Gy for
(k = 1, . . . , n+m), in agreement with clinical requirements considered for this clin-
ical case. On the other hand, the bound of the gradient in (2.7) (C1 = 3.0Gy/cm)
was estimated from the TPS data used to simulate the tentative plans prepared
for that patient, and was accordingly imposed in numerical simulations. To do
that, the maximum change of the radiation gradient in the applied radiation dose
distribution simulated in the TPS for the whole treatment domain was computed,
which has a dimension of about 17.37cm × 23.31cm × 20.83cm. In this way, it is
possible to ensure that the resulting simulation keeps to clinical requirements, and
satisfies the same operational restrictions that the linear particle accelerator actu-
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ally used in that radiotherapy treatment applied. However, it is not assumed that
values of radiosensitivity parameters α or β are separately known for the tumor
type considered. Therefore, the impact of various possible choices of such param-
eters (compatible with the restriction α/β = 3.7Gy) on the radiobiological effects
induced by the corresponding minimizer in the PTV, OARs and HT is explored. It
should be noticed that in the simulations described in this Chapter the parameter
a in (2.6) has been assumed equal to zero (see [110] where different results of a
related, two-dimensional model considering a > 0 has been described).
To do this, the PTV is supposed homogeneous and assume that shrinkage of
tumor region and sparing OARs are deemed equally important by clinicians, so
that all weights w1 and wj (2 ≤ j ≤ m + 1) in (2.6) are taken equal to one.
Consider first the case where no volumetric constraints (2.10) and (2.11) are im-
posed. Then, results describing the performance of the minimizer of (2.6)-(2.9) for
different values of α when α/β = 3.7Gy are reported in Table 2.2 and Figure 2.4.
Parameter α = 0.95Gy−1 α = 0.85Gy−1 α = 0.70Gy−1 α = 0.40Gy−1 α = 0.25Gy−1 α = 0.10Gy−1
SF2 0.05 0.07 0.12 0.29 0.46 0.73
DPTV 100% 1.1403Gy 1.1584Gy 1.1946Gy 1.2127Gy 1.1765Gy 0.9955Gy
PTVDp 52.57% 54.07% 55.79% 57.50% 55.75% 46.87%
CIDp95% 0.67 0.68 0.71 0.73 0.70 0.62
Brain Tissue* 1.1584Gy 1.1765Gy 1.2127Gy 1.2489Gy 1.1946Gy 1.0679Gy
Optic Nerve (L)* 0.6878Gy 0.6937Gy 0.7240Gy 0.7582Gy 0.7059Gy 0.5611Gy
Optic Nerve (R)* 0.3439Gy 0.3620Gy 0.3982Gy 0.4344Gy 0.3863Gy 0.3077Gy
Hypothalamus* 0.7421Gy 0.7602Gy 0.7964Gy 0.8326Gy 0.7783Gy 0.6154Gy
Optic Chiasm* 1.0860Gy 1.1122Gy 1.1503Gy 1.1765Gy 1.1484Gy 1.0317Gy
Optic Tract (L)* 0.7421Gy 0.7602Gy 0.7964Gy 0.8145Gy 0.7783Gy 0.6878Gy
Optic Tract (R)* 0.6697Gy 0.6878Gy 0.7582Gy 0.7964Gy 0.7240Gy 0.4887Gy
Table 2.2. Dependence of induced radiobiological effects on the values of α for α/β =
3.7Gy when w1 = wj = 1 for (2 ≤ j ≤ m+ 1). SF2 represents the surviving cell fraction
at 2.0Gy on the PTV given by the LQ model (2.4). (DPTV 100%) Maximum radiation
dose received at least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving
the prescribed radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose
corresponding to 95% of the prescription radiation dose on the PTV. (*) Maximum
radiation dose received by the OARs considered.
Concerning the results presented in Table 2.2, a few remarks are in order. To
begin with, in all these simulations the HI is equal to 1. This is due to the fact that
the maximum radiation received by the PTV is equal to the prescription radiation
dose (1.8Gy). On the other hand, for the applied treatment plan the maximum
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radiation on the PTV and the HI are equal to 1.77Gy and 0.98 respectively. In
addition the maximum radiation dose received at least by 100% of the PTV in
the applied treatment plan is 1.63Gy, while for simulations described in Table
2.2 such value ranges from 0.99Gy to 1.21Gy. Moreover, the CI for the isodose
corresponding to 95% of the prescription radiation dose for values of α considered
in Table 2.2 ranges from 0.62 to 0.73, which are smaller than that obtained with the
applied treatment plan (CI equal to 0.95). Therefore, in spite that the radiation
dose delivered at the PTV with the applied treatment is smaller than that provided
in these simulations, the radiation coverage of the PTV for the applied treatment
plan is higher than that achieved with the simulations in Table 2.2.
On the other hand, the maximum radiation dose delivered with the applied
treatment plan to the Brain tissue, left Optic Nerve, right Optic Nerve, Hypotha-
lamus, Optic Chiasm, left Optic Tract and right Optic Tract are equal to 1.75Gy,
1.58Gy, 1.51Gy, 1.53Gy, 1.73Gy, 1.52Gy and 1.57Gy respectively (to be compared
to values on Table 2.2). Therefore, simulations described in Table 2.2 deliver less
radiation to OARs (see Figure 2.4) than the actually implemented treatment plan.
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Figure 2.4. Maximum radiation dose received by some OARs considered in Table 2.2.
Maximum radiation dose received at least by 100% of the PTV is also shown. Parameters
considered as in Table 2.2.
Summing up, concerning tumor control, simulations in Table 2.2 do not perform
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better than the treatment plan applied to the patient, although less radiation dose
is delivered on the OARs with them than was achieved with the applied treatment
plan. From this result follows that, to improve minimizers performance, an increase
in the weight corresponding to the PTV dosimetry in (2.6) should be required. This
strategy will be explored in detail in the following sections.
As a matter of fact, the results presented in Table 2.2 and Figure 2.4 suggest
a strategy to select an optimal radiation dose distribution as a standard for com-
parison with tentative treatment plans. Namely, the first step may be to fix the
maximum damage considered acceptable in OARs, and then select the value of
α for which damage inflicted at the PTV is larger. Then, no matter what the
precise value of α for that patient is, a radiation dose distribution that cannot be
improved under the assumptions made on OARs damage is eventually obtained.
In particular, this point will be addressed in detail in Section 2.5.6. Before doing
it, though, some remarks on the meaning of the corresponding simulations are in
order.
2.5.4 Uniqueness of minimizers revisited. (Pseudo)-
minimizers
The simulations described in the previous Section 2.5.3 were done according to the
process sketched in Section 2.5.2. When doing so, a basic theoretical background is
provided in Theorems 1, 2 and 3 in Section 2.4. However, while the existence result
therein obtained is quite general, the uniqueness conditions in (2.14) of Theorem
3 are not satisfied by all values of α considered in Table 2.2. In particular, for the
ratio α/β considered, there is a threshold value αc of α such that for values below
that threshold inequalities in (2.14) are no longer compatible with the choices of
clinical bounds C2 and C3 made so far. In particular, and since αc = 0.54Gy
−1, it
is not possible to take C2 = 0.0Gy in (2.14) if α is small enough, as depicted in
Figure 2.5.
Therefore, if an α value below that threshold is selected, it is not possible to
guarantee any longer that the numerical algorithm will converge to a minimizer of
the proposed variational problem. However, in all cases examined, the algorithm
used does converge to a radiation dose function when it runs over the discretized
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Figure 2.5. Uniqueness threshold for minimizers (see Theorem 3 in Section 2.4). For
the ratio α/β = 3.7Gy, the value of the lower bound C2 in (2.14) is represented in terms
of α. Notice that C2 = 0.0Gy cannot be imposed for values of α below αc = 0.54Gy
−1,
which is indicated by an arrow.
mesh used by the TPS where the actual dosimetry was implemented. Thus, a func-
tion D(x) is numerically computed in that case that need not be an approximation
to a minimizer, but still will be shown to provide a better treatment choice when
compared with the actual dosimetry delivered. In particular, such D(x) will be
referred as a pseudo-minimizer of the variational problem under consideration. In
the sequel, all numerical approximations will correspond either to actual minimiz-
ers (when uniqueness requirements are met) or to pseudo-minimizers when they
fail to do so. For the ease of notation, the term minimizer will be often used in
either case.
2.5.5 Increasing the weight on PTV dosimetry
To explore how the proposed variational model can be fine-tuned to suit different
clinical priorities, let us next consider the case where weights wj (2 ≤ j ≤ m+1) in
(2.6) are kept equal to one over the OARs involved, whereas w1, the corresponding
coefficient over the PTV dosimetry, is allowed to increase. More precisely, to see
how sensitive the results are to different choices of w1, let us assume as before that
α/β = 3.7Gy, select this time the value α = 0.10Gy−1, and compute the minimizer
of (2.6)-(2.9) for increasing values of w1. Table 2.3 contains the values obtained
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in such cases, and Figure 2.6 shows how radiobiological effects on some OARs and
the PTV described in Table 2.3 change as w1 increases.
Parameter w1 = 1.0 w1 = 2.5 w1 = 5.0 w1 = 7.5 w1 = 10
wj = 1.0 wj = 1.0 wj = 1.0 wj = 1.0 wj = 1.0
DPTV 100% 0.9955Gy 1.2670Gy 1.4480Gy 1.5104Gy 1.5565Gy
PTVDp 46.87% 61.68% 73.96% 80.30% 83.46%
CIDp95% 0.62 0.77 0.88 0.92 0.94
Brain Tissue* 1.0679Gy 1.3213Gy 1.4661Gy 1.5267Gy 1.5746Gy
Optic Nerve (L)* 0.5611Gy 0.8145Gy 1.0136Gy 1.0317Gy 1.0859Gy
Optic Nerve (R)* 0.3077Gy 0.5068Gy 0.5792Gy 0.7240Gy 0.7783Gy
Hypothalamus* 0.6154Gy 0.8688Gy 1.0498Gy 1.1222Gy 1.1583Gy
Optic Chiasm* 1.0317Gy 1.2127Gy 1.2851Gy 1.3575Gy 1.3936Gy
Optic Tract (L)* 0.6878Gy 0.9231Gy 1.0498Gy 1.1946Gy 1.2115Gy
Optic Tract (R)* 0.4887Gy 0.8145Gy 0.9593Gy 1.0136Gy 1.1221Gy
Table 2.3. The effect of increasing radiation weight over PTV when weights over OARs
are kept constant and equal to one, where α = 0.10Gy−1 and α/β = 3.7Gy. (DPTV 100%)
Maximum radiation dose received at least by 100% of the PTV. (PTVDp) Percentage of
the PTV receiving the prescribed radiation dose (1.8Gy). (CIDp95%) Conformity Index
(CI) for the isodose corresponding to 95% of the prescription radiation dose on the PTV.
(*) Maximum radiation dose received by the OARs considered.
A quick glance at Table 2.3 reveals that radiation coverage on the PTV increases
with w1 and the same happens with the maximum radiation dose received at least
by 100% of the PTV. Moreover, the radiation delivered over all OARs considered
is higher than in the case where w1 = 1, although still less than that corresponding
to the applied treatment plan (see Section 2.5.3).
Let us now select the PTV weight equal to its largest value in Table 2.3 (w1 =
10) and explore how the values reported in the previous Tables 2.2 and 2.3 change
with α. As it turns out, the radiation coverage now obtained over the PTV is
similar to that provided in the applied treatment plan, but less radiation doses
on the OARs are delivered than in the applied treatment (see Section 2.5.3). The
corresponding results are represented in the Table 2.4.
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Figure 2.6. Dependence of radiobiological effects for some OARs and the PTV in
the cases considered in Table 2.3. Maximum radiation dose received by some OARs
is represented. Maximum radiation dose received at least by 100% of the PTV is also
shown.
Parameter α = 0.95Gy−1 α = 0.85Gy−1 α = 0.70Gy−1 α = 0.40Gy−1 α = 0.25Gy−1 α = 0.10Gy−1
DPTV 100% 1.5928Gy 1.6108Gy 1.6389Gy 1.6691Gy 1.6443Gy 1.5565Gy
PTVDp 84.66% 86.93% 89.86% 92.73% 91.83% 83.46%
CIDp95% 0.96 0.97 0.98 0.99 0.98 0.94
Brain Tissue* 1.6109Gy 1.6289Gy 1.6470Gy 1.6731Gy 1.6525Gy 1.5746Gy
Optic Nerve (L)* 1.1041Gy 1.1583Gy 1.1765Gy 1.2127Gy 1.1946Gy 1.0859Gy
Optic Nerve (R)* 0.7844Gy 0.7964Gy 0.8145Gy 0.8507Gy 0.8507Gy 0.7783Gy
Hypothalamus* 1.1946Gy 1.2126Gy 1.2488Gy 1.2670Gy 1.2489Gy 1.1583Gy
Optic Chiasm* 1.4118Gy 1.4167Gy 1.4298Gy 1.4480Gy 1.4313Gy 1.3936Gy
Optic Tract (L)* 1.2127Gy 1.2307Gy 1.2569Gy 1.3032Gy 1.2952Gy 1.2115Gy
Optic Tract (R)* 1.1765Gy 1.2015Gy 1.2341Gy 1.2851Gy 1.2670Gy 1.1221Gy
Table 2.4. The impact of changing α for a comparatively large value of w1 = 10 when
wj (2 ≤ j ≤ m + 1) are kept equal to one, and α/β = 3.7Gy. (DPTV 100%) Maximum
radiation dose received at least by 100% of the PTV. (PTVDp) Percentage of the PTV
receiving the prescribed radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for
the isodose corresponding to 95% of the prescription radiation dose on the PTV. (*)
Maximum radiation dose received by the OARs considered.
An inspection of Table 2.4 reveals that if α = 0.40Gy−1 is now selected, the cor-
responding pseudo-minimizer provides the higher effect on the PTV, and delivers
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less radiation doses on the OARs involved than the applied treatment. A compar-
ison of the results obtained with this choice (α = 0.40Gy−1, w1 = 10, wj = 1 for
2 ≤ j ≤ m + 1) and those corresponding to the actually applied treatment plan
can be seen in Figure 2.7.
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Figure 2.7. Top: A comparison of the applied radiation dose distribution (left) and the
minimizer dose distribution (right) obtained from model where w1 = 10, wj (2 ≤ j ≤
m + 1) are kept equal to one and α = 0.40Gy−1. From left to right the radiation dose
distributions (3D) over the OARs, HT and the PTV. Bottom: Dose volume histograms
(DVHs) of the applied (left) and minimizer (right) dose distributions for each OAR, HT
and the PTV.
At this juncture it should be remarked that the better performance of the mini-
mizer considered when compared to the actual treatment delivered is not restricted
to the particular choice of α made. Actually, a similar pattern is displayed when
other values of α are selected instead (see Table 2.4). Details corresponding to
some of those alternative choices can be found in the Appendix B.
56
2.5.6 Volumetric constraints and alternative treatment
planning strategies
In general, the dosimetry obtained in the previous case when w1 = 10, wj = 1 for
2 ≤ j ≤ m+ 1 and α = 0.40Gy−1 might be too harsh on OARs compared to what
was obtained with the simulations in Section 2.5.3 for w1 = wj = 1 (see Tables 2.2
and 2.4). This is due to the fact that, in the case just considered, obtaining large
radiation coverage over the PTV was assigned the highest priority, and side effects
were not given a similar importance. In many clinical settings, however, clinicians
insist on enforcing strong sparing effects over OARs. This can be done for instance
by considering multiple pointwise constraints as in (2.9). A detailed study on the
performance of a related, two-dimensional model considering such constraints has
been described in a previous work (see [110] for further details).
An alternative which is very appealing to clinicians consists in imposing volu-
metric constraints on the dose delivered to the PTV and/or OARs as those con-
sidered in (2.10), (2.11) and discussed in Theorem 2. Remarkably, considerable
volumetric constraints are obtained as a token from the pointwise constraints on
the radiation dose imposed in Theorem 1. For instance, in the numerical sim-
ulation discussed above for the case w1 = 10, wj = 1 (2 ≤ j ≤ m + 1) and
α = 0.40Gy−1 (see Figure 2.7 and Table 2.4), where no volumetric constraints
were a priori imposed, no more than 15% of the Hypothalamus, right Optic Tract
and Optic Chiasm receive a radiation dose higher than 0.83Gy, 0.92Gy and 1.25Gy
respectively (see Figure 2.7). However, when more stringent volumetric constraints
are needed, one has to explicitly include such requirements in the statement of the
variational problem under consideration, and then make use of Theorem 2. As an
example, below is reported a result for the case where parameter values C1, C2, C3,
(α/β), α, w1 and wj (2 ≤ j ≤ m + 1) are as in the case under consideration, and
the following volumetric constraints (2.10), (2.11) are considered: no more than
15% of the Hypothalamus and right Optic Tract should receive a radiation dose
higher than 0.70Gy, and no more than 15% of the Optic Chiasm should receive a
radiation dose higher than 0.80Gy.
DVHs and 2D slices of isodose curves of this numerical simulation when volu-
metric constraints are imposed and a comparison with the previous one without
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volumetric constraints, are displayed in Figure 2.8 when w1 = 10, wj = 1 for
2 ≤ j ≤ m+ 1 and α = 0.40Gy−1.
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Figure 2.8. Isodose curves in a 2D slice and dose volume histograms (DVHs) of the
minimizer radiation dose distributions discussed in the previous Section 2.5.5 without
volumetric constraints (left) and that simulated in this Section 2.5.6 with volumetric
constraints (right) for each OAR, HT and the PTV. In both cases w1 = 10, wj = 1 when
2 ≤ j ≤ m+ 1 and α = 0.40Gy−1.
A quick glance at Figure 2.8 reveals that the minimizer obtained under volu-
metric constraints provides a lower effect on PTV than that obtained when such
restrictions are ignored. For instance, the maximum radiation dose received at
least by 100% of the PTV and the percentage of the PTV receiving the prescribed
radiation dose (1.8Gy) are respectively equal to 1.6691Gy and 92.73% for the sim-
ulation without volumetric constraints, and equal to 1.1946Gy and 82.92% for that
with volumetric constraints. However, the former has lower side effects on OARs
than the second minimizer, as expected from the volumetric constraints required.
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Since it is not possible to obtain arbitrarily large tumor coverage and arbitrarily
small OARs irradiation at the same time, the following strategy for dosimetry
selection is suggested by the results shown in this Section 2.5.4. For simplicity, let
us restrict in the following to the case where PTV is considered homogenous, as is
the situation in current clinical practice:
1) Once a value of the ratio (α/β) had been selected in agreement with the
diagnosed tumor type and fractionation scheme chosen, select arbitrarily one value
of α, set all weights w1 and wj (2 ≤ j ≤ m+ 1) in (2.6) equal to one as a standard
to start with, and impose pointwise constraints in (2.7)-(2.9) according to TPS
resolution capabilities (in the case of (2.7)) and following clinical prescriptions (in
the case of (2.8) and/or (2.9)). Then select volumetric constraints (2.10) and/or
(2.11) deemed suitable on OARs, HT and the PTV involved. These volumetric
constraints (2.11) will impose at once a limit on the side effects retained admissible.
Notice that stringent pointwise and volumetric restrictions need not always be
imposed in all OARs considered. On the other hand, in some clinical settings
different levels of priority for OARs sparing could be considered. In that case
different values for weights wj (2 ≤ j ≤ m + 1) in (2.6) should be selected. As
a matter of fact, the larger the number of OARs subject to such constraints, and
the stronger the requirements thereby imposed, the lower the maximum effect on
PTV turns out to be.
2) If the minimizer obtained after solving the variational problem under the
conditions listed in Step 1 provides enough tumor coverage, let us proceed to Step
3 below. If however further impact on PTV is needed, allow w1 to increase while
keeping all other weights wj (2 ≤ j ≤ m+1) as before. As w1 grows, it may happen
that a value for that parameter is reached so that tumor coverage saturates, in that
no further impact is achieved when is w1 further increased. Then, let us keep the
value of w1 for which saturation is first observed, and continue to Step 3.
Alternatively, it may occur that the desired tumor coverage cannot be achieved
by increasing w1 unless the choice of pointwise and/or volumetric constraints im-
posed in Step 1 is weakened. If this is the case, a compromise has to be achieved
between both requirements. For instance, a large enough value of w1 may be
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considered, which is still compatible with the restrictions considered in Step 1, or
reduce the constraints imposed on some of the OARs previously considered.
3) After Step 1 and Step 2 have been fulfilled, let us next provide simulations
for the minimizers corresponding to various values of α, keeping the ratio (α/β)
and the remaining model parameters constant as in Step 1. Out of them, which
yields better coverage of the PTV and less side effects on the OARs under the
pointwise and volumetric constraints retained must be eventually selected. Then,
this radiation dose distribution will be defined as optimal in that clinical case, and
propose it as a standard with respect to which tentative treatment plans should
be compared.
The previous argument naturally leads to an important question. Namely, one
may wonder how can we tell which of two given tentative plans simulated on a
TPS is closer to a given dosimetry, as that resulting from Step 1 to Step 3 above.
A way in which this can be done is by means of figures of merit as the indexes HI
or CI recalled before. More precisely, one could state that a tentative plan is close
to the optimal dosimetry suggested if the difference between the respective indexes
HI and/or CI (or any other figure of merit reported) is small enough. The issue
of deciding which figure of merit is more adequate to account for actual clinical
requirements is far from being settled, and is currently being the subject of active
research. In particular, in Chapter 4 this issue is addressed in detail where a
decision-aid tool is proposed.
2.6 Discussion
In this Chapter the possibilities offered by mathematical modeling and computer
simulations to assist radiophysicists and clinicians to improve current decision-
making processes to treat solid tumors by means of radiotherapy have been ex-
plored. To this end, more attention has been paid on a key aspect, namely how to
obtain a theoretical radiation dose distribution that provides a standard against
which tentative plans should be compared.
To address such issue, the case when radiosensitivity parameters for tumor and
neighboring organs at risk are known have been first considered, and a theoretical
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definition of a radiation dose distribution based on current radiobiological criteria
has been proposed. Such dose distribution is given as the solution of a suitable
variational problem recalled in Section 2.3. It should be noted that such prob-
lem includes among its hypotheses common clinical requirements (as bounds on
maximum and minimum dosage over the anatomical structures considered) on one
hand, as well as technical constraints on the clinical linear particle accelerators
(for instance, their operative resolution) on the other. Therefore, the dosimetry
obtained from the study of that problem could be computed on treatment plan-
ning systems (TPS) for linear particle accelerators currently in use. Moreover, the
choice proposed is suitable for personalized patient treatment, since it allows for
computing different dosimetries for different therapeutic priorities.
Then, this theoretical result has been used to propose a possible strategy to
assist in the choice of clinical dosimetries when only partial information on ra-
diosensitivity parameters for the PTV is available, as is often the case in current
clinical practice. Specifically, the case of a homogenous tumor (i.e. consisting of a
single tumor cell population), for which only the ratio (α/β) is known, has been
discussed. In many cases a value for such ratio is suggested from clinical experience
resulting from the use of different fractionation schemes to treat a particular type
of tumor. Conversely, when such ratio has been obtained experimentally (usually
in vitro) the corresponding result can be used to select a type of fractionation
scheme suitable for the tumor under consideration. In that case, a strategy con-
sisting in Step 1 to Step 3 has been implemented in the previous Section 2.5.6
to eventually obtain an optimal radiation dose distribution with which tentative
plans simulated over the corresponding TPS should be compared.
The way in which this comparison should be done deserves a detailed study,
which goes beyond the scope of this Chapter. Actually, TPS are not equipped with
sophisticated decision-aid tools to quantify the radiobiological impact of modifica-
tions, whether large or small, on the tentative plans considered. To this it should
be added that current operational limitations establish a tough limit on the number
of tentative treatment plans that can be prepared for a single patient. However,
selection procedures can be implemented at once without introducing new tools or
principles in the field. Indeed, one may pick up any of various quantitative esti-
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mators that are used in radiotherapy for that purpose. For instance, the standard
Homogeneity Index (HI), defined as the ratio between the maximum and minimum
radiation dose over a given anatomical structure could be considered, and decide
that, out of the number of tentative plans simulated, the best one is that for which
the value of the HI over the PTV is closer to the corresponding value for the min-
imizer obtained after Step 1 to Step 3 before. The novelty here is that minimizers
of the proposed optimization problem suggest a reference value for HI (that of the
radiation dose distribution arrived at by means of this approach) to compare with.
Even in so simple a form, easy to translate into a user-friendly software, such a
procedure could be helpful in current decision-making processes.
To illustrate this method, the proposed radiation dose distributions have been
compared with that actually delivered in ten clinical cases; see Section 2.5 for
a thorough study of one of these cases, and the Appendix B for a description
of results for the remaining nine patients considered. In all cases such studies
were performed keeping to the same specifications of the linear particle accelerator
which was actually used, as well as to the clinical requirements (say, on maximum
and minimum radiation dose per session) specified by clinicians. Moreover, it
is apparent from the previous discussion that both the proposed mathematical
model in Section 2.3, and the proposed strategy for dosimetry selection presented
in Section 2.5.6 are robust with respect to changes in all model parameters involved.
To conclude, some remarks on the assumptions made, as well as on future
research directions are commented as follows. In Section 2.3 the PTV has been
assumed homogeneous since that was the assumption made by clinicians in the
treatments provided. However, this approach could be extended to deal with het-
erogeneous tumors as soon as sufficient information on in vivo tumor heterogeneity
is available (see [110] for a previous work related to such issue). As a matter of fact,
in the absence of such information, which is still out of reach in current clinical
practice, standard radiotherapy protocols all over the world continue to consider
tumors as homogeneous in structure, as in the cases herein considered. This model
can be easily extended for the case where different PTVs are defined for a same
patient. Moreover, radiation dose distributions can be simulated for any type of
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tumor regardless of its location insofar information on radiosensitivity parameters
of nearby critical structures are known.
A second and far reaching question concerns the way in which tentative plans
could be prepared to better fit a theoretical radiation dose distribution. Clinical
technology seems to have reached a sufficient level of sophistication to permit a
major breakthrough in this respect. However, a key limitation stems from the
fact that only limited information on radiosensitivity parameters for tumors is
currently available [53], and without a comprehensive library of such parameters
no theoretical link can be directly established between experimental dosimetries
and radiobiological effects. While this issue requires of sustained experimental
exploration, mathematical methods can nevertheless help in making appropriate
decisions under considerable parametric uncertainty. The approach presented in
Section 2.3 could provide a step in this direction. Needless to say, new decision
strategies should be developed to further enhance the efficiency of optimization
protocols as those described in this Chapter.
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Chapter3
Estimating dose painting effects in
radiotherapy: a mathematical model
“. . . A great discovery solves a great problem, but there is a grain of discovery in
the solution of any problem. Your problem may be modest, but if it challenges your
curiosity and brings into play your inventive faculties, and if you solve it by your
own means, you may experience the tension and enjoy the triumph of discovery . . .”
George Po´lya (1887-1985)
3.1 Abstract
Tumor heterogeneity is widely considered to be a determinant factor in tumor
progression and in particular in its recurrence after therapy. Unfortunately, cur-
rent medical techniques are unable to deduce clinically relevant information about
tumor heterogeneity by means of non-invasive methods. As a consequence, when
radiotherapy is used as a treatment of choice, radiation dosimetries are prescribed
under the assumption that the malignancy targeted is of a homogeneous nature.
The purpose of this Chapter is precisely that of exploring the effects of different
radiation dose distributions on heterogeneous tumors by means of an individual
cell-based model. To that end, a case is considered where two tumor cell pheno-
types are present, which have been assumed to strongly differ in their respective
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cell cycle duration and radiosensitivity properties. In particular, as a result of such
differences, the spatial distribution of the corresponding phenotypes, whence the
resulting tumor heterogeneity can be predicted as growth proceeds. That is, if
the model of tumor growth starts from a situation where a majority of ordinary
cancer cells (CCs) and a minority of cancer stem cells (CSCs) are initially present
and randomly distributed, then CSCs become concentrated at an inner region as
tumor grows, as long as CSC cycle is significantly longer than that of CCs and
CSCs remain a small fraction of the total tumor population. As a consequence,
and assuming also that CSCs are more resistant to radiation than CCs, heteroge-
neous dosimetries can be selected to enhance tumor control by boosting radiation
in the region occupied by the more radioresistant tumor cell phenotype. It is also
shown that, when compared with homogeneous dose distributions as those being
currently delivered in clinical practice, such heterogeneous radiation dosimetries
fare always better than their homogeneous counterparts.
3.2 Introduction
Technical and methodological advances have allowed radiation oncologists to
achieve local tumor control in a considerable number of patients. However, lo-
coregional recurrence (LRR) remains a problem in many clinical settings. For
example, a recent study in patients with Stage III lung cancer found a 5-year LRR
rate of 31% [137]. In Glioblastoma Multiforme (GBM), the most common and
aggressive malignant primary brain tumor, LRR approaches 90% [138]. In such
critical cases, radiotherapy usually results in an initial shrinkage of malignancies,
followed by a subsequent growth recovery that cannot be checked even by resorting
to larger radiation doses.
The onset of radioresistance, and its resulting poor prognosis, is strongly cor-
related with the development of significant intratumoral heterogeneity. For that
reason, there is growing interest in the clinical significance of tumor heterogeneity.
In different works have been recently demonstrated extensive genetic variations
in tumor cells due to intratumoral evolution [139], [140]. Moreover, tissue-level
heterogeneity due to variations in vascular density and blood flow has been long
since evident in clinical medical imaging (see for instance Figure 3.1). In recent
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years, accumulating evidence suggests that tumor heterogeneity is a key factor in
the development of therapeutic resistance and therefore in radiation therapy out-
comes [21], [22], [23]. As a consequence, increasing attention is being paid to “dose
painting” (or “dose sculpting”), a technique which consists in prescribing different
radiation dosimetries to different regions within a given tumor, so that irradiation
be boosted in more radioresistant (for instance, hypoxic, quiescent, etc.) regions
[24], [25].
Figure 3.1. CT scan of lung showing a cancer in the right upper lobe (circled) with
regions of necrotic (dead) and viable tissue (Courtesy of Dr. Robert Gatenby).
The work reported in this Chapter intends to yield some insight into these
issues. More precisely, in the sequel a mathematical model for heterogeneous tu-
mor growth is formulated, and the effects of various radiation dose distributions
on it are investigated by means of computer simulations. Specifically, a situation
where two tumor cell phenotypes, cancer cell (CC) and cancer stem cell (CSC), are
present at an early stage, when the tumor consists of about 105 cells in total has
been considered. Concerning CCs and CSCs, the following assumptions are made
i) CSCs represent only a small percentage of the total number of cells at that stage
(say, about 15%), ii) CSCs have a significantly longer cell cycle duration than CCs
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and can replicate indefinitely, while CCs can perform only a limited number of
cell divisions, and iii) CCs and CSCs show quite different resistance to radiation,
CSCs being more radioresistant than CCs. These biological and radiobiological
features have been reported in the literature, specifically for Glioblastoma Multi-
forme (GBM), where there is mounting evidence of CSCs presence in GBM tumors
(cf. for instance [23], [141], [142], [143]). Growth of the heterogeneous tumor thus
resulting is simulated by means of an agent-based model in which each cell is
individually represented [144], [145]. Tumor growth is kept track of until a size
of approximately 106 cells is attained, which roughly corresponds to a spheroid
of about 1 cubic millimeter in size, a typical volume in multi-cellular spheroids
(MCS) in vitro growth. At that stage, different (homogeneous and heterogeneous)
radiation dose distributions are simulated using the Linear Quadratic (LQ) model
[53], [54], [55], [56], and their effects compared.
An interesting consequence of i) and ii) above is then shown to be that, as
tumor grows, most of the CSCs concentrate themselves within the tumor core,
irrespective of their initial distribution at an earlier stage. This fact, which will be
described to be inversely correlated with cell migration rates, when migration is not
inhibited by cell-cell adhesion (which is the case, for instance, after cells undergo
an epithelial-mesenchymal transition (EMT) [146]), is then used together with iii)
to simulate the effects of different radiation dosimetries to achieve tumor control,
or in the case where this cannot be obtained, to compare tumor heterogeneity (seen
as an indicator of malignancy in terms of the proportion of CSCs) before and after
treatment has been delivered. In this context, it will be shown that for a given
amount of radiation, heterogeneous dose distributions, where different radiation
doses are delivered at different regions of the tumor according to the presence of
more radioresistant cells there, invariably fare better than homogeneous ones when
sufficient information about tumor spatial heterogeneity is available. In the case
herein reported, such information will be shown to follow from assumptions i) and
ii) above. It should be noticed that hypotheses i), ii) and iii) are amenable to
experimental validation, at least in vitro.
This work can be considered as a preliminary step towards analyzing preclini-
cal models where larger tumors (of the order of cubic centimeters) should be dealt
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with, several tumor cell phenotypes would simultaneously be present (possibly as
a consequence of mutations) as tumor expands, and vascular networks, immune
response, and hypoxic and necrotic effects are also taken into account. While the
case herein considered is still far from that situation, the simplicity of the set-
ting selected allows to stress the consequences derived from the minimal number
of biological and radiobiological assumptions made on the tumor cell phenotypes
involved. This last is particularly relevant in view of the scarcity of in vivo biolog-
ical parameter measures available. Scaling results up to larger tumor sizes, as well
as increasing phenotypic and anatomical complexity appear as feasible within the
same approach, but only after key biological data retrievable by non-invasive prob-
ing had been identified, and their impact on tumor growth elucidated, an objective
toward this work intends to contribute.
It should be noted that considerable attention is being currently paid to math-
ematical modeling as a tool towards designing patient-tailored and adaptive ther-
apies; see for instance [146], [147], [148], [149], [150], [151], [152], [153], [154] and
[155]. In particular, radiotherapy modeling and simulations have been addressed
in [54], [56], [107], [108], [112], [156], [157], [158] and [159], as well as in [111], [116]
and [117] where GBM cases are considered. Mathematical models and computer
simulations on the impact of the presence of CSCs in tumor therapies have been
discussed in [107], [160] and more recently in [111], where focus is made in a GBM
case. It is worth to be stressed, however that in the cases previously mentioned,
the total number of cells simulated (and thus the resulting structural complexity)
remained way below that of the computer simulations arrived at in this work.
In summary, in Sections 3.3 and 3.4 the tumor growth mechanism considered
and the mathematical model thereof are described respectively. In Section 3.5 the
effects of different homogeneous and heterogeneous radiation dose distributions on
tumors resulting from different model parameter sets are investigated. Finally, a
discussion on the results obtained and their clinical implications make then the
content of the concluding Section 3.6.
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3.3 Tumor cell phenotypes assumptions
In this Section the assumptions made on the tumor cell phenotypes considered
are described in details. To begin with, for definiteness model parameter values
corresponding to Glioblastoma Multiforme (GBM) cell lines have been used [90],
[161], [162]. More precisely, a heterogeneous tumor where two different phenotypes
coexist at an early stage is considered, where it is assumed a preponderant (ap-
proximately 85% of the total tumor volume) proportion of a tumor cell phenotype
denoted as CC (cancer cell) coexisting with a second tumor cell phenotype CSC
(cancer stem cell), randomly distributed, that roughly represents 15% of the total
population at that stage. Both phenotypes CC and CSC are supposed to possess
markedly different biological and radiobiological properties.
3.3.1 Cell cycle duration
The duration of cell cycle for CCs is significantly shorter than that of CSCs. In
particular, CCs are assumed to divide every 26 hours. Then, for tumor cell pheno-
type CSC three cases have been considered, corresponding respectively to a CSC
cycle duration of 96 hours (four days), 72 hours (three days) and 48 hours (two
days). Moreover, CCs are assumed to divide a maximum of 15 times, while CSCs
are able to replicate indefinitely.
Concerning the cell cycle duration property, it is currently assumed that CSCs
proliferate at a slower pace than ordinary cancer cells (see for instance [142], [163],
[164], [165], [166], [167], [168], [169], [170] and [171]). Actually, as observed in
the references previously quoted, slow-cycling is to be expected from CSCs since
such cells belong to tumor phenotypes that are highly resistant to current thera-
pies (radiotherapy, chemotherapy or combined) and these are targeted at killing
cycling cells. On the other hand, recent in vivo experiments in a mouse model
of Glioblastoma to identify and isolate CSCs through genetically engineered mice
demonstrate the presence of a small pool of slow-cycling and highly tumorigenic
cells that retain long-term self-renewal ability [170], [172]. It should be remarked
that cell cycle durations of 24h-26h for GBM have been reported [90], [111], [173],
although considerably different cell cycle durations, which in particular include the
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values herein considered for CSCs, have been noticed as well [90], [174]. Concern-
ing the assumption on the maximum number of CCs replications (see for instance
[175]), the value 15 has been selected [107], [176], [177], but the results obtained
continue to hold if this number is slightly changed. Actually, an arbitrary increase
in CSC cycle duration is always compatible with such results, as long as CC cycle
duration continues to be significantly faster.
In the course of tumor growth, each of the previous tumor cell phenotypes may
transiently enter in a quiescent, non-proliferating stage, due to contact inhibition.
Moreover, replication of CCs is always supposed to be symmetric. On the other
hand, CSCs have been assumed to sustain either symmetric or asymmetric division,
in which case one CSC and one CC will result from replication. Evidence for
asymmetric division for CSCs, has been reported in [178], [179], [180]. Since reliable
estimates about actual probabilities of asymmetric division pa do not seem to be
available as yet, computer simulations will be performed for different choices of
that model parameter, namely pa = 0.75, pa = 0.50 and pa = 0.25 (cf. for instance
[107], [176]).
3.3.2 Response to radiation
When irradiated, CSCs are significantly more resistant to radiation than CCs. As
a matter of fact, CSCs have been described as a comparatively small subpopulation
that is highly radioresistant [141], [143], [176], [181]. Radioresistance and surviving
cell fractions are estimated by means of the standard Linear Quadratic (LQ) model
(see Section 1.3.1 in Chapter 1 and [53], [54], [55], [56]) given by
SF (D) = e−ξ(αD+βD
2), (3.1)
where ξ is a parameter introduced, as in [107], to distinguish the different
radiosensitivities of the proliferating and quiescent states for CCs and CSCs. Ac-
tually, cells in a quiescent state (in the G0 cell cycle phase) are known to be more
resistant to radiation than their non-quiescent counterparts [182].
It should be noticed that, when estimating the impact of radiation according
to the LQ model, what matters is the particular combination of α and β that ap-
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pears in (3.1), which provides the surviving cell fractions, rather than the separate
values of α and β by themselves. For definiteness, in the sequel α = 0.48Gy−1,
β = 0.02Gy−2 and ξp1 = 1.00 for proliferating CCs have been taken. These ra-
diosensitivity parameters have been reported in [162], where in vitro estimates on
surviving cell fractions at 2.0Gy, SF (2), can be found for different GBM cell lines
(see also [183]); similar values for α and β have been recently proposed in [111].
In particular, SF (2) = 0.36 for proliferating CCs in this case (to be compared to
the value SF (2) = 0.44 corresponding to α and β parameters proposed in [111]).
For quiescent CCs, ξq1 = 0.85 has been taken, so that the corresponding value
is SF (2) = 0.42. For proliferating CSCs the value ξp2 = 0.30 (SF (2) = 0.73) is
considered, whereas for quiescent CSCs the value ξq2 = 0.20 (SF (2) = 0.81) is
selected. Also, such surviving cell fraction ranges at 2.0Gy have been observed
and reported in the literature (cf. [111], [183], [184]). It should be remarked that
the results described in this Chapter continue to hold when the values selected
for the radiosensitivity parameters α and β undergo considerable variations, which
in particular include the ranges considered in the references quoted above. As a
matter of fact, once these assumptions are made, the proposed model is shown to
be quite robust with respect to changes in its parameters.
3.4 A three-dimensional (3D) model of stochas-
tic tumor growth
Different mathematical models of tumor growth and its radiation response have
been reported in the literature. For instance, tumor growth models and radiation
effects with continuous and discrete populations have been reviewed in [104], [185],
[186] (see also [112], [156], [157], [158], [187], [188], [189], [190] for more details).
On the other hand, the effects of different radiation dosimetries have been con-
sidered in [107], [112], [156], also in [110], [111] for fractionated radiotherapy and
in [106] for a case of stereotactic radiosurgery. However, little seems to be known
concerning mathematical modeling and computer simulations on the effects of het-
erogeneous radiation dose distributions on heterogeneous tumors, as in the case
herein examined.
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The model of tumor growth implemented in this Chapter is as follows. Within
the growing tumor, both tumor cell phenotypes, CC and CSC, will be subject
to the same kinetic rules. More precisely, following [144], [191], [192], a three-
dimensional cellular automata (CA) model for tumor growth is developed, where
each cell is considered as an individual agent. In particular, each cell (whether
CC or CSC) occupies a single node in a 3D unstructured lattice (a lattice with no
rotational or translational symmetry [192]) thus avoiding symmetry artifacts. Cell
division, migration, apoptosis (programmed death) and lysis (removal of debris)
have been included and are represented by stochastic processes. Accordingly, each
kinetic rule is characterized by a rate, and the governing equation to be solved
is a multivariate master equation (see equation (3.2)). Figures 3.2 and 3.3 show
a sketch of the processes included and a scheme describing the possible actions
that a cell is able to perform in the mathematical model respectively (for further
details, see Appendix C). Nutrient-limited growth is not accounted for in this
model. This issue, as well as others, could be included at the expense of increasing
complexity by adding degrees of freedom in the computer simulations, but they are
not expected to play a significant role in a tumor cell colony of the size considered,
which may be assumed to be fully oxygenated [191]. At any rate, for tumors of
the size considered in this work the assumption made is not unlikely. For instance,
NIH3T3 cells form tumors of size larger than 1cm3 without apparent necrotic core
even though micro-lesions may be observed [191].
As to the rules of the model of tumor growth, proliferation is only possible
for cells located at a node having at least one free neighbor in the lattice. In the
case that all neighbor sites are occupied, a cell enters in a quiescent state due to
contact inhibition. However, quiescence is abandoned, and cells return to their
normal state, as soon as one of the surrounding nodes becomes free. Proliferation,
apoptosis, migration and lysis are modeled as stochastic processes occurring with
certain rates. A Poisson process has been assumed for each individual stochastic
process and a master equation for the change of the probability of the multi-cellular
configuration at time t (denoted by the variable Z) in terms of the multi-cellular
configuration in another state Z
′
at time t
′
is then used. It reads as follows
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Figure 3.2. Cell processes mimicked in the model of tumor growth. Schematic
representation of the cell processes considered in the model of tumor growth (symmetric
and asymmetric division, migration, death by radiation, apoptosis (programmed death)
and lysis (removal of debris)). Notice that CSCs can perform all these cell processes,
while replication of CCs is always supposed to be symmetric. See Appendix C for further
details.
dP (Z, t|Z ′′ , t′′)
dt
=
∑
Z′
rZ′→ZP (Z
′
, t|Z ′′ , t′′)− rZ→Z′P (Z, t|Z
′′
, t
′′
), (3.2)
where p(Z, t|Z ′′ , t′′) denotes the conditional probability of finding the multi-
cellular configuration Z at time t given the configuration was Z
′′
at time t
′′
, rZ→Z′
being the transition rate from configuration Z to Z
′
. Notice that the master
equation (3.2) is a balance equation. Indeed, the first term on the right of (3.2)
is a gain term that summarizes all transitions that increase the probability of
finding the corresponding multi-cellular system in configuration Z. On its turn,
the second term in the right describes transitions that move the system away from
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Figure 3.3. Scheme showing the possible actions that a cell is able to perform
in the model of tumor growth. As long as the population size is below a prescribed
maximum N , it is first tested whether a cell is dead. If so, it undergoes lysis at a certain
rate. Alive cells are classified according to CSCs and CCs; CCs die and are subject to
lysis with a certain rate once they have performed the maximum number of cell divisions
prescribed. CCs not having yet reached the maximum number of cell divisions and CSCs
can undergo apoptosis. Those cells that do not go through apoptosis can migrate if free
space is available. If they do not migrate and have sufficiently advanced in the cell cycle,
they divide. If those cells have not yet reached the end of G2-phase, then they continue
to progress in the cell cycle. Cells with no free space available at neighboring sites can
only progress in the cell cycle. Concerning radiation effects, cells are picked randomly
and killed according to the corresponding surviving cell fraction estimate. See Appendix
C for details on the technical implementation of the model algorithm.
Z, and thus represents a loss term. Equation (3.2) can be numerically solved if the
initial condition p(Z, t = 0) = δ(Z0) is given, where Z0 denotes the initial multi-
cellular (in this case, tumor cells) configuration. A configuration is determined by
the spatial distribution of cells and the state of each cell (proliferating, quiescent,
etc.). In this model both CCs and CSCs are able to migrate with the same rate.
Migration is mimicked by a hopping process allowing any cell to move from one
lattice site to a free neighbor lattice site. In case several free neighbor lattice sites
exist, one of them is randomly chosen. In this work, two different migration rates
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(kmig) have been considered, a comparatively low rate (0.025h
−1) in the range
obtained from the cell diffusion constant [144] as outlined in the Appendix C, and
a higher rate (1.75h−1) as estimated in vitro in [111] for a GBM cell line. These will
be respectively referred to as low and high migration rates in the sequel. It should
be stressed that in this model is only considered the case where the motion of a cell
from one lattice site to another does not depend on the contact energy between
neighboring cells, but only on the availability of space. In that case, the higher
the migration rate, the stronger the cell dispersion is. If however cell-cell adhesion
would be considered, migrating cells would tend to fill holes and cavities [192], and
migration will lead instead to tumor compactification. Thus, it is assumed that in
the current setting this case is substantially included in very low migration cases.
On the other hand, CCs and CSCs undergo programmed cell death (apoptosis)
(see for instance [107]). Disposal of cellular debris resulting from apoptosis is
carried out by a lysis process [193], for which a lysis rate klys = 0.035h
−1 (about
30h) has been assumed. This is about 10-fold less than phagocytosis (digestion
of cellular debris by macrophages) observed in vivo in [194], but within the range
reported for in vitro cultures 0.002h−1 for Hybridoma VO 208 cell line [195] to
0.07h−1 for Fibrobacter succinogenes [196].
The master equation (3.2) has been numerically solved by means of the so-called
Gillespie algorithm [197], (also called kinetic Monte-Carlo algorithm or Bortz-
Kalos-Lebowitz algorithm [198], see Appendix C for more details). Notice that
one advantage of using a lattice model is the possibility of extending the same
formalism at larger scales by permitting more than one cell to occupy a single lat-
tice site [191]. In order to simulate the resulting biological effect when a radiation
dose D is delivered, the surviving cell fraction is computed for each tumor cell
phenotype according to the LQ model (3.1), taking into account the state of each
cell, proliferating or quiescent. Surviving cells are randomly selected out of the
total cell number involved. In the next Section it is shown a typical starting point
(about 105 cells) in the computer simulations to be described below, as well as the
resulting tumor once a size of about 106 cells has been reached under the kinetic
rules just described, and before the radiotherapy treatment is applied. For conve-
nience of the reader, in Table 3.1 all parameter values used in this mathematical
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model to simulate the tumor growth and radiation response are provided.
Description Symbol Value/Range Source
Migration rate kmig 0.025h
−1 / 1.75h−1 [144], [111]
Apoptosis rate kapt 4.17× 10−4 h−1 [107]
Lysis rate klys 0.035h
−1 (Assumed)
Radiosensitivity (LQ model) α 0.48Gy−1 [162]
Radiosensitivity (LQ model) β 0.02Gy−2 [162]
Radiosensitivity (LQ model): Proliferating (CC) ξp1 1.00 [183],[184]
Radiosensitivity (LQ model): Quiescent (CC) ξq1 0.85 [183],[184]
Radiosensitivity (LQ model): Proliferating (CSC) ξp2 0.30 [183],[184]
Radiosensitivity (LQ model): Quiescent (CSC) ξq2 0.20 [183],[184]
CC cycle duration τcc 26h [90]
CSC cycle duration τcsc 48h, 72h, 96h (Assumed)
Asymmetric division probability (CSC) pa 0.75, 0.50, 0.25 (Assumed)
Maximum number of cycle divisions (CC) −−− 15 [107],[176]
Table 3.1. Model parameters used in computer simulations of tumor growth
and radiotherapy treatments. Values for those parameters not found in the literature
were assumed (see detailed explanation for lysis rate). In the remaining cases (asym-
metric division probability and CSC cycle duration) some values were assumed, and the
impact of different parameter sets on the resulting effects was subsequently analyzed.
3.5 Results: computer simulations of tumor
growth and radiotherapy
In this Section the impact of different irradiation strategies in tumors that grow
according to the process previously described is analyzed and compared by means
of computer simulations. To begin with, a standard protocol is simulated in ho-
mogenous tumors where only CCs are present. While doing so, heterogeneous
tumors are considered and several homogeneous and heterogeneous radiation dose
distributions are simulated using standard fractionation protocols. To conclude, a
case of hyperfractionation as well as protocols with low total radiation doses are
also investigated.
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3.5.1 Standard fractionation protocols
As a reference case, let us first consider the effect on a fully monoclonal tumor
(containing only CCs) of a therapeutic irradiation protocol, consisting of 30 sessions
of 2.0Gy, each being homogeneously delivered on the tumor. According to standard
radiotherapy scheduling, sessions are distributed into 6 weeks, each week including
five sessions from Monday to Friday separated by 24 hours intervals, and with a
72 hours interval from Friday to next Monday in the following week (with weekend
interruptions). The total radiation dose delivered with this treatment is thus 60Gy.
This is currently considered a standard radiotherapy treatment for most GBM
tumors [49], [199], [200]. The corresponding process is illustrated in Figure 3.4,
both for the cases of low and high migration rate, under current assumption that
migration is not inhibited by cell-cell adhesion. Figure 3.4 shows that tumor prior
to treatment grows from week 1 to approximately week 5 for the low migration case,
and just in one week in the case of high migration, until a size of about 106 cells is
attained. Notice that the growth time of the tumor decreases with the migration
rate due to the decreasing effect of contact inhibition inside the tumor. Then
radiation therapy treatment starts, and accordingly tumor cell number diminishes
during the first week (with small re-growth between each daily session and weekend
interruptions, as represented by the knots in the straight line in the plot, see Figure
3.4). The pattern just described is reproduced until tumor eradication is achieved
at the end of the radiotherapy treatment in these cases.
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Figure 3.4. Standard radiotherapy treatment in a homogeneous tumor for
the low and high migration cases. Cell growth curves are shown corresponding to
homogeneous tumor growth for the low and high migration cases when only CCs are
present (see respectively (A) and (C)). Tumor growth is allowed unchecked from a size
of about 105 cells until about 106 cells are present, which approximately occurs at day
30 (respectively at day 7) since the beginning of the process. Then, a homogeneous
treatment corresponding to 30 sessions of 2.0Gy each is delivered. In all cases, sessions
are scheduled along 6 weeks separated by 24 hours intervals except for weekends, where
a 72 hours interval is allowed. Radiotherapy treatment is thus completed 40 days af-
terwards its beginning (about 70 and 47 days since the initial stage respectively). Data
corresponding to 20 simulations (with different seeds of a random number generator) are
presented. Notice that the vertical coordinate is represented in a logarithmic scale. In
(B) and (D) tumor stages are represented when radiation therapy is started (about 106
cells in total) for the low and high migration cases respectively. Depicted in dark and
light green are proliferating and quiescent CCs. Dead cells are represented in black.
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A heterogeneous tumor containing the two tumor cell phenotypes is now con-
sidered. Starting from an initial configuration where 105 cells are present, out of
which approximately 85% are CCs and 15% are CSCs, tumor growth is allowed
until a size of about 106 cells is reached (see Figures 3.5 and 3.6). Then the impact
of homogeneous and heterogeneous radiation dose distributions is modeled, and
computer simulation results are compared in the cases where asymmetric division
probabilities pa for CSCs are pa = 0.75, pa = 0.50 and pa = 0.25, the CSC cycle
duration is taken to be 96h, 72h and 48h, and the low and high migration rates are
considered. The results obtained will show that the standard irradiation protocol
described before fails now to achieve tumor control in any of the cases considered.
To compare the dynamics of the tumor resulting after irradiation with respect to
its pre-treatment stage, computer simulations are stopped once the pre-treatment
population size of about 106 cells is again obtained.
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Figure 3.5. Simulated growth of a heterogeneous tumor with the low mi-
gration rate. Depicted in dark and light green (respectively, dark and light red) are
proliferating and quiescent CCs (respectively, proliferating and quiescent CSCs). Dead
cells are represented in black. (A) An initial stage where about 105 cells, distributed into
tumor cell phenotypes CC (85%) and CSC (15%), are present. (B) Tumor stage when
radiation therapy is started (about 106 cells in total). In the middle image, the location
of the inner region where 100% of CSCs are concentrated is shown for the case when
pa = 0.25 and CSC cycle duration equal to 96h. A 3D transversal cut is performed in
the middle of solid figures (A) and (B) (left), so that its interior could be seen (middle
and right) respectively. (C) Representation of the transversal cut showed in (B) for a
slice of two cell diameters. Notice the little space existing between cells.
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Figure 3.6. Simulated growth of a heterogeneous tumor with the high mi-
gration rate. Depicted in dark and light green (respectively, dark and light red) are
proliferating and quiescent CCs (respectively, proliferating and quiescent CSCs). Dead
cells are represented in black. (A) An initial stage where about 105 cells, distributed into
tumor cell phenotypes CC (85%) and CSC (15%), are present. (B) Tumor stage when
radiation therapy is started (about 106 cells in total). In the right image, the spatial
distribution of CCs and CSCs is shown for the case when pa = 0.25 and CSC cycle
duration equal to 48h. A 3D transversal cut is performed in the middle of solid figure
(B) (left), so that its interior could be seen (right). (C) Representation of the transversal
cut showed in (B) for a slice of two cell diameters. Notice the comparatively large (with
respect to Figure 3.5) space observed between cells.
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As shown in Figure 3.5, for pa = 0.25, CSC cycle duration equal to 96h and the
low migration rate, the more radioresistant tumor cell phenotype CSC is confined
within an inner, smaller region when irradiation is started. Such spatial CSCs
distribution is neither a priori imposed, nor a consequence of the specific CSC
cycle duration or the asymmetric division probability considered (see Table 3.2).
It is due instead to the difference of the CSC and CC cycle durations. Indeed,
a robust emerging feature is now observed. Namely, due to asymmetric division
CSCs produce a certain fraction of CCs. Both CCs and CSCs then compete for
resources including free space at the tumor border [144], [201]. For sufficiently
small micro-motility, that competition is controlled by cell replication. As CCs
proliferate faster than CSCs, they have a selective advantage in the competition
for free space and will eventually outcompete the CSCs in the border region of the
tumor, if (as it happens in this case) to achieve such dominance less replications
are needed than the maximum number that CCs can perform. The precise timing
depends on the relation of the cell cycle duration for CSCs vs. CCs, pa, and the
fraction of CSCs in the initial population at 105 cells (notice that this fraction
would itself be determined by pa and CSC cycle duration if the 10
5 cells would
already have emerged by replication from a single initial CSC).
Therefore, for a low migration rate, CSCs will be contact-inhibited by the fast
proliferating CCs. As a consequence, CSCs will remain confined in an inner region
in that case. Actually, on assuming a cell diameter of 20µm, the diameter of the
tumor in all cases is then of about 2680µm (with a standard deviation of 56µm
over 20 simulations performed for each parameter set considered) and the volume
of this inner region where 100% of CSCs are located varies from the 15% to 25% of
the total tumor volume, when asymmetric division probability and the CSC cycle
duration are allowed to change (see Table 3.2, and Figures in the Appendix C).
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pa = 0.75 pa = 0.50 pa = 0.25
τcsc Diameter CSCs Diameter CSCs Diameter CSCs
96h 1426.3 µm 16871 1488.6 µm 18718 1513.5 µm 20448
[41.07 µm] [56.12] [43.24 µm] [71.33] [53.70 µm] [77.30]
72h 1473.6 µm 17125 1539.3 µm 19366 1587.8 µm 21092
[40.85 µm] [67.50] [58.67 µm] [102.07] [40.45 µm] [85.48]
48h 1498.1 µm 17785 1595.9 µm 19829 1682.2 µm 21953
[47.21 µm] [62.45] [73.16 µm] [88.98] [47.74 µm] [140.16]
Table 3.2. Estimates of the tumor inner region diameter and number of
CSCs before irradiation for the low migration case. Diameter is that of an inner
sphere where 100% of CSCs are located. CSCs number is computed before radiation
therapy treatment starts. Within brackets the corresponding standard deviations are
also provided. Data corresponding to 20 simulations (with different seeds of a random
number generator) for each case considered. See also Figures in the Appendix C for
further details.
On the other hand, when the high migration rate is considered, CSCs are not
fully concentrated in an inner region of the tumor (see Figure 3.6 for pa = 0.25
and CSC cycle duration equal to 48h). However, it is possible to define an inner
region where at least 80% of CSCs are located (see Figure 3.7). When asymmetric
division probability and CSC cycle duration are allowed to change in the parameter
range considered, this inner region approximately represents between 21% to 40%
of the volume where 90% of cells, both CCs and CSCs, are located (see Table 3.3,
and Figures in the Appendix C). In this case, the diameter of the tumor for all
cases is about 5294µm (with a standard deviation of 778µm over 20 simulations
performed for each parameter set considered). In Tables 3.2 and 3.3 the number of
CSCs just before treatment starts is shown, so that its dependence with migration
rate, asymmetric division probability and CSC cycle duration can be observed.
Actually, the number of CSCs existing before treatment starts is a key factor to
estimate tumor resistance to radiation therapy, as will be described below.
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Figure 3.7. Spatial distribution of CSCs for a heterogeneous tumor with the
high migration rate. From left to right tumor stage when radiation therapy is started
(about 106 cells in total) with the high migration rate, 3D transversal cut in the middle
of the tumor, region where 80% of CSCs are located (yellow) and region where 90% of
total cells (CCs and CSCs) are located (yellow and blue). (A) For the case pa = 0.75
and (B) for pa = 0.25 considering CSC cycle duration equal to 48h. Depicted in dark
and light green (respectively, dark and light red) are proliferating and quiescent CCs
(respectively, proliferating and quiescent CSCs). Dead cells are represented in black.
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pa = 0.75 pa = 0.50 pa = 0.25
τcsc Diameter CSCs Diameter CSCs Diameter CSCs
96h 1857.4 µm 20454 1986.9 µm 27916 2035.6 µm 35087
[74.72 µm] [256.53] [51.30 µm] [811.67] [77.80 µm] [1066.54]
72h 1906.2 µm 21178 2043.1 µm 28847 2158.7 µm 37686
[54.46 µm] [322.63] [78.51 µm] [861.47] [94.21 µm] [859.31]
48h 1983.8 µm 21944 2139.3 µm 30119 2294.8 µm 41629
[69.64 µm] [506.92] [81.17 µm] [872.98] [62.60 µm] [1040.65]
Table 3.3. Estimates of the tumor inner region diameter and number of CSCs
before irradiation for the high migration case. Diameter is that of an inner
sphere where 80% of CSCs are located. CSCs number is computed before radiation
therapy treatment starts. Within brackets the corresponding standard deviations are
also provided. Data corresponding to 20 simulations (with different seeds of a random
number generator) for each case considered. See also Figures in the Appendix C for
further details.
Bearing these facts in mind, it turns out that tumor control can be obtained in
all cases when a radiation boost is applied at such internal regions. More precisely,
in the case of low migration tumor control can be achieved for CSC cycle durations
equal to 96h and 72h, when 2.5Gy (for the case pa = 0.75), 2.9Gy (for pa = 0.50)
and 3.3Gy (for pa = 0.25) are respectively delivered within the largest inner sphere
containing 100% of CSCs, and 2.0Gy is delivered in the rest of the tumor, according
to the former standard fractionation protocol (5 days a week along 30 sessions at 24
hours intervals except for weekends). However, when CSC cycle duration is equal
to 48h, tumor eradication is not possible with these heterogeneous therapies under
the same conditions. In that case, to obtain tumor control, the dose delivered in
the inner region has to be raised to 2.7Gy, 3.4Gy and 3.9Gy respectively (see Table
3.4 and the Appendix C). Notice that these radiation doses increase as asymmetric
division probability decreases.
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Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 96h −−− 2.0Gy − 2.5Gy(1) 2.10Gy(1) 2.5Gy
[63.0Gy] [63.0Gy] [75.0Gy]
72h −−− 2.0Gy − 2.5Gy(2) 2.10Gy(2) 2.5Gy
[63.0Gy] [63.0Gy] [75.0Gy]
48h 2.0Gy − 2.5Gy(3) 2.0Gy − 2.7Gy(4) 2.10Gy(3) / 2.12Gy(4) 2.7Gy
[63.0Gy] [63.6Gy] [63.0Gy] / [63.6Gy] [81.0Gy]
0.50 96h −−− 2.0Gy − 2.9Gy(5) 2.15Gy(5) 2.9Gy
[64.5Gy] [64.5Gy] [87.0Gy]
72h −−− 2.0Gy − 2.9Gy(6) 2.17Gy(6) 2.9Gy
[65.1Gy] [65.1Gy] [87.0Gy]
48h 2.0Gy − 2.9Gy(7) 2.0Gy − 3.4Gy(8) 2.19Gy(7) / 2.30Gy(8) 3.4Gy
[65.7Gy] [69.0Gy] [65.7Gy] / [69.0Gy] [102Gy]
0.25 96h −−− 2.0Gy − 3.3Gy(9) 2.23Gy(9) 3.3Gy
[66.9Gy] [66.9Gy] [99.0Gy]
72h −−− 2.0Gy − 3.3Gy(10) 2.27Gy(10) 3.3Gy
[68.1Gy] [68.1Gy] [99.0Gy]
48h 2.0Gy − 3.3Gy(11) 2.0Gy − 3.9Gy(12) 2.32Gy(11) / 2.47Gy(12) 3.9Gy
[69.6Gy] [74.1Gy] [69.6Gy] / [74.1Gy] [117Gy]
Table 3.4. Classification of heterogeneous and homogeneous radiation thera-
pies for the low migration case. In all cases, treatment sessions were scheduled along
6 weeks separated by 24 hours intervals except for weekends, where a 72 hours interval is
allowed. Data corresponding to 20 simulations (with different seeds of a random number
generator) are presented. In the heterogeneous therapies, radiation doses are specified
both for the outer (left) and inner (right) tumor regions, each case being indexed from
(1) to (12). The averaged dose for any of the previous cases is labeled with the same
number in the columns corresponding to homogeneous therapies. Within brackets the
total dose of the radiation therapy treatment is also provided. See Tables and Figures
in the Appendix C for further details.
Consider now the same heterogeneous therapies for the case of high migration
and select an inner region where 80% of CSCs are located. Considering these
heterogeneous therapies for each case as before, tumor control is now obtained
only for pa = 0.75 with CSC cycle durations of 96h and 72h. This is due to
the fact that i) the high migration rate permits less contact inhibition, which in
turn allows for rapid re-growth, and ii) there are about 20% of CSCs which only
receive a radiation dose of 2.0Gy. Therefore, to obtain tumor control it is not only
necessary to increase the radiation dose in the inner region, but also in the outer
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one (see Table 3.5 and the Appendix C). The radiation doses of the heterogeneous
therapies required to obtain tumor control are provided for each case of migration
rate considered in Tables 3.4 and 3.5. The respective temporal evolution of the
number of each tumor cell phenotype is shown in Figure 3.8 (A), (C), (E) and (G)
for different values of asymmetric division probability, migration rate and CSC
cycle duration.
Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 96h −−− 2.0Gy − 2.5Gy(1) 2.10Gy(1) 2.5Gy
[63.0Gy] [63.0Gy] [75.0Gy]
72h −−− 2.0Gy − 2.5Gy(2) 2.11Gy(2) 2.5Gy
[63.3Gy] [63.3Gy] [75.0Gy]
48h 2.0Gy − 2.5Gy(3) 2.2Gy − 2.7Gy(4) 2.13Gy(3) / 2.33Gy(4) 2.7Gy
[63.9Gy] [69.9Gy] [63.9Gy] / [69.9Gy] [81.0Gy]
0.50 96h 2.0Gy − 2.9Gy(5) 2.3Gy − 2.9Gy(6) 2.23Gy(5) / 2.45Gy(6) 2.9Gy
[66.9Gy] [73.5Gy] [66.9Gy] / [73.5Gy] [87.0Gy]
72h 2.0Gy − 2.9Gy(7) 2.6Gy − 2.9Gy(8) 2.25Gy(7) / 2.70Gy(8) 2.9Gy
[67.5Gy] [81.0Gy] [67.5Gy] / [81.0Gy] [87.0Gy]
48h 2.0Gy − 2.9Gy(9) 2.8Gy − 3.4Gy(10) 2.29Gy(9) / 3.00Gy(10) 3.4Gy
[68.7Gy] [90.0Gy] [68.7Gy] / [90.0Gy] [102Gy]
0.25 96h 2.0Gy − 3.3Gy(11) 2.4Gy − 3.3Gy(12) 2.36Gy(11) / 2.65Gy(12) 3.3Gy
[70.8Gy] [79.5Gy] [70.8Gy] / [79.5Gy] [99.0Gy]
72h 2.0Gy − 3.3Gy(13) 2.7Gy − 3.3Gy(14) 2.43Gy(13) / 2.90Gy(14) 3.3Gy
[72.9Gy] [87.0Gy] [72.9Gy] / [87.0Gy] [99.0Gy]
48h 2.0Gy − 3.3Gy(15) 3.4Gy − 3.9Gy(16) 2.52Gy(15) / 3.60Gy(16) 3.9Gy
[75.6Gy] [108Gy] [75.6Gy] / [108Gy] [117Gy]
Table 3.5. Classification of heterogeneous and homogeneous radiation ther-
apies for the high migration case. In all cases, treatment sessions were scheduled
along 6 weeks separated by 24 hours intervals except for weekends, where a 72 hours
interval is allowed. Data corresponding to 20 simulations (with different seeds of a ran-
dom number generator) are presented. In the heterogeneous therapies, radiation doses
are specified both for the outer (left) and inner (right) tumor regions, each case being
indexed from (1) to (16). The averaged dose for any of the previous cases is labeled
with the same number in the columns corresponding to homogeneous therapies. Within
brackets the total dose of the radiation therapy treatment is also provided. See Tables
and Figures in the Appendix C for further details.
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Figure 3.8. Comparing heterogeneous and averaged homogeneous radiation therapies in a
heterogeneous tumor for different model parameter sets. Cell survival curves for 20 simulations (with
different seeds of a random number generator) in the cases pa = 0.75 and pa = 0.25 for CSC cycle durations
equal to 96h and 48h with the high and low migration rates are shown. The time evolution for CCs and CSCs is
represented in green and red respectively. (A, C, E, G) Results for heterogeneous therapies consisting of 2.5Gy
and 3.3Gy in the inner sphere and 2.0Gy in the rest of the tumor. (B, D, F, H) Results for the related averaged
homogeneous therapies corresponding to 2.10Gy, 2.23Gy, 2.36Gy and 2.52Gy respectively. (A, B, C, D) Results
for the cases pa = 0.75 and pa = 0.25 with the low migration rate and CSC cycle duration equal to 96h. (E, F,
G, H) Results for the case pa = 0.25 with the high migration rate and CSC cycle durations equal to 96h (E, F)
and 48h (G, H). In all cases 30 sessions are scheduled along 6 weeks, separated by 24 hours intervals except for
weekends, where a 72 hours interval is allowed. Radiation is applied when the total cell count is about 106 cells.
Notice that the vertical coordinate is represented in a logarithmic scale.
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It may appear at first glance that the successful results obtained for heteroge-
neous dosimetries could be a consequence of the overall radiation dose delivered
over the tumor being larger than that administered according the standard irra-
diation protocol (2.0Gy a day, 5 days a week at 24 hours intervals, with weekend
interruptions and 60Gy in total). However, heterogeneous dosimetry turns out
to be crucial to achieve tumor control. In particular, tumor control fails to be
attained when an averaged homogeneous dose (AD) is delivered, corresponding to
the same global radiation energy as in the heterogeneous dosimetry, carried out
along a similar scheduling. The corresponding AD is given by
AD = Din
(
Vin
Vtot
)
+Dout
(
Vout
Vtot
)
, (3.3)
where Vin, Vout are the volume of the internal sphere and the remaining shell
considered; Din, Dout are the radiation doses delivered over the internal and ex-
ternal regions just described, and Vtot is the total volume of the tumor. In the
case of low migration the inner region is that where 100% of CSCs are located
(see Table 3.2 for values of the diameter of this inner region for each case) and the
volume of the outer region is computed with respect to the average diameter of
the tumor at the beginning of the radiotherapy treatment (2680µm). However, for
the case of high migration the inner region is now selected as that where 80% of
CSCs are located (see Table 3.3 for further details). Indeed, since some cells are
now isolated far from the tumor bulk, instead of defining the tumor radius as the
distance from its center of mass to the farthest cell, to compute the averaged dose
the volume of the tumor is now considered as that of the region where 90% of total
cells (CCs and CSCs) are located, where the diameter is about 3120µm (with a
standard deviation of 186µm over 20 simulations performed for each parameter set
considered). The reason for this assumption is that it will yield a higher AD than
that obtained when considering the maximum diameter of the tumor (5294µm),
which will extend to regions sparsely occupied by tumor cells. Hence the averaged
homogeneous therapies thus derived will deliver higher radiation doses than those
that would be obtained if the outer shell were defined as that where all tumor cells
are contained.
The averaged dose (AD) per session according to equation (3.3) is shown in
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Tables 3.4 and 3.5, for each of heterogeneous therapies described before. These AD
vary from 2.10Gy to 2.32Gy for the low migration case and from 2.10Gy to 2.52Gy
in the case of high migration for the asymmetric division probabilities and CSC
cycle durations considered. Notice that the total radiation doses delivered by these
averaged homogeneous therapies are higher than 60Gy (the value corresponding
to the standard irradiation protocol) for all cases. The total radiation doses cor-
responding to these new dosimetries range between 63.0Gy to 69.6Gy for the case
of low migration and 63.0Gy to 75.6Gy for the high migration case. Some of these
results are illustrated in Figure 3.8 (B), (D), (F) and (H). On the other hand, in
Figure 3.9, further details of the time evolution of the tumor colony are provided
during and after an homogeneous radiation therapy delivering an AD = 2.10Gy
for pa = 0.75 and AD = 2.23Gy for pa = 0.25 with the low migration rate and
CSC cycle duration of 96h. The cases pa = 0.25 with the high migration rate
and CSC cycle durations of 96h and 48h, an AD = 2.36Gy and AD = 2.52Gy
respectively are also included. Notice that in the case of high migration (Figure
3.9 (B)) more cells remain isolated at the end of the treatment compared with the
case of low migration (Figure 3.9 (A)). In that Figure, when tumor control is not
achieved, computer simulations are performed until the surviving tumor reaches a
size approximately equal to 106 cells, the number of cells it had before radiotherapy
started.
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Figure 3.9. Time evolution of tumor growth during and after averaged ho-
mogeneous radiation therapies. (A) A homogeneous dose of 2.10Gy for the case
pa = 0.75 is delivered (Top), and a homogeneous dose of 2.23Gy for pa = 0.25 is instead
applied (Bottom), assuming in both cases of (A) the low migration rate and CSC cy-
cle duration equal to 96h. (B) A homogeneous dose of 2.36Gy is delivered (Top) and
a homogeneous dose of 2.52Gy (Bottom) for the case pa = 0.25 with the high migra-
tion rate and CSC cycle durations equal to 96h (Top) and 48h (Bottom). In all cases
(A, B) a standard scheduling (30 sessions along 6 weeks separated by 24 hours inter-
vals except for weekends) was applied. From left to right in sequential order the tumor
before radiotherapy treatment starts, its state after sessions 10, 20 and 30, and three
stages corresponding to recurrence during the period covered (where about 106 cells is
again obtained) are shown. Depicted in dark and light green (respectively, dark and
light red) are proliferating and quiescent CCs (respectively, proliferating and quiescent
CSCs). Dead cells are not represented.
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Tables 3.4 and 3.5 reveal that tumor recurrence occurs in all cases for a ho-
mogeneous therapy delivering the corresponding average dose (AD). Besides, the
number of CSCs in the tumor at the end of the radiotherapy treatment decreases
with pa and CSC cycle duration (see Figure 3.10, and Tables in the Appendix C).
In the case of low migration, for the heterogeneous therapies failing to achieve
tumor control, the number of CSCs remaining alive at the end of the recurrence
tumor stage is 107, 1785 and 4457 respectively, with the corresponding standard
deviations being 8.53, 78.31 and 232.67 (see Figure 3.10 (A) to compare with the
corresponding averaged homogeneous therapies). These values correspond to the
cases pa = 0.75, pa = 0.50 and pa = 0.25 with a CSC cycle duration of 48h. On the
other hand, in Figure 3.10 (B) the number of CSCs at the end of the recurrence
tumor stage is provided in the case of high migration for the heterogeneous thera-
pies delivering 2.5Gy (for the case pa = 0.75), 2.9Gy (for pa = 0.50) and 3.3Gy (for
pa = 0.25) in the inner region, and 2.0Gy in the rest of the tumor. Notice that,
even when tumor control cannot be achieved with the heterogeneous therapies,
the corresponding averaged homogeneous therapies always have more CSCs at the
end of the recurrence tumor stage (see Figure 3.10 (C)). Moreover, in some cases
that number of CSCs is larger than before the treatment started, resulting in more
radioresistant tumors after treatment (see Appendix C for further details).
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Figure 3.10. Estimates on the total number of CSCs at the end of the recurrence
tumor stage for heterogeneous and averaged homogeneous radiation therapies. Num-
ber of CSCs at the end of the recurrence tumor stage (where about 106 cells is again obtained)
and the corresponding standard deviations after performing 20 simulations in each case (with
different seeds of a random number generator) are shown. (A) For averaged homogeneous thera-
pies corresponding to heterogeneous therapies consisting of 2.5Gy, 2.9Gy and 3.3Gy in the inner
sphere and 2.0Gy in the rest of the tumor for the cases pa = 0.75, pa = 0.50 and pa = 0.25
(left, middle, right) assuming the low migration rate and CSC cycle durations equal to 48h, 72h
and 96h (see Table 3.4). (B) For heterogeneous therapies consisting of 2.5Gy, 2.9Gy and 3.3Gy
in the inner sphere and 2.0Gy in the rest of the tumor (Top) and the corresponding averaged
homogeneous therapies (Bottom) for the cases pa = 0.75, pa = 0.50 and pa = 0.25 (left, middle,
right) with the high migration rate and CSC cycle durations equal to 48h, 72h and 96h (see
Table 3.5). In all cases (A, B, C), a standard scheduling (30 sessions along 6 weeks separated
by 24 hours intervals except for weekends) was applied. Notice that the vertical coordinate is
represented in a logarithmic scale. See Tables in the Appendix C for further details.
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Therefore, to achieve full eradication of a tumor consisting of two different
tumor cell phenotypes, heterogeneous dosimetry is crucial. Actually, the choice
of a minimal radiation dose sufficient to achieve tumor control depends on the
value of pa, the CC and CSC cycle durations and on the internal spatial dis-
tribution of CSCs. In Tables 3.4 and 3.5, the heterogeneous radiation therapies
needed to achieve tumor control are described, and the corresponding averaged ho-
mogeneous therapies are also provided. Interestingly, the corresponding averaged
homogeneous therapies in each case fail to obtain tumor control (see also Tables
in the Appendix C). Moreover, homogeneous therapies needed to obtain tumor
control are also provided in Tables 3.4 and 3.5. One readily sees that in all cases
higher total radiation doses are needed for homogeneous than for heterogeneous
therapies.
On the other hand, considering that for all choices of model parameters the
AD is higher than 2.0Gy, this implies that tumor recurrence will also occur for the
standard irradiation protocol (2.0Gy a day, 5 days a week at 24 hours intervals, with
weekend interruptions and 60Gy in total) for each case of pa, migration rate and
CSC cycle duration considered. In terms of the number of remaining CSCs after
treatment is completed, recurrence is certainly weaker when AD is delivered than
for the standard fractionation protocol, as one could expect from the comparative
increase in radiation delivery. Moreover, tumor control cannot be achieved for
each case of pa, migration rate and CSC cycle duration considered even when
the homogeneous therapy delivering the average radiation dose is rescheduled in 7
days a week along 30 sessions at 24 hours intervals, without weekend interruptions
(see Figure 3.11 for some examples of averaged homogeneous therapies with this
fractionation protocol).
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Figure 3.11. Comparing averaged homogeneous radiation therapies without
weekend interruptions. Cell survival curves for 20 simulations (with different seeds
of a random number generator) are shown. (A) Averaged dosimetries consisting of
AD = 2.10Gy for pa = 0.75 and (B) AD = 2.23Gy for pa = 0.25, both for the low
migration case and CSC cycle duration equal to 96h. (C, D) Averaged homogeneous
therapies consisting of AD = 2.36Gy and AD = 2.52Gy for the case pa = 0.25 with the
high migration rate and CSC cycle durations equal to 96h and 48h respectively. The
time evolution of CCs and CSCs are represented in green and red respectively. In all
cases (A, B, C, D), sessions were scheduled 7 days a week separated by 24 hours intervals
along 30 sessions (without weekend interruptions). Notice that the vertical coordinate
is represented in a logarithmic scale.
3.5.2 Hyperfractionation and lower total radiation doses
Since in many clinical scenarios radiation doses are mostly limited by damage in-
flicted at neighboring organs at risk and healthy tissues, it is important to estimate
what amount of tumor control can be achieved when radiation dose distributions
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are kept as low as possible. In what follows, a heterogeneous therapy for which the
average radiation dose is approximately equal to 60Gy, and a case of hyperfrac-
tionation (a type of scheduling consisting of comparatively many sessions, usually
more than 1 per day, with low radiation doses [47], [53], see Section 1.2.2 in Chap-
ter 1; cf. [202] for a specific study on GBM tumors) are considered. As a result, it
will be shown that in these cases a heterogeneous radiation dose distribution also
yields better results than its averaged homogeneous equivalent, even when tumor
control is not achieved.
Consider first the case of low migration, CSC cycle duration equal to 96h and
where the value of the total radiation dose is a bit less than 60Gy for heterogeneous
therapies consisting of 2.3Gy for pa = 0.75, pa = 0.50 and pa = 0.25 within the
largest inner sphere containing 100% of CSCs and 1.8Gy in the rest of the tumor
delivered 5 days a week along 30 sessions at 24 hours intervals with weekend
interruptions. Computer simulations show that these radiation dosimetries fare
better than their averaged homogeneous versions, where total AD lies between
56Gy and 57Gy for the values of pa considered (see Figure 3.12 (A), (B) and (C)).
On the other hand, similar results can be obtained for a lower total radiation dose
when the time lapse between treatment sessions is also shortened. More precisely,
consider the same cases but now for heterogeneous therapies consisting of 1.7Gy
within the largest inner sphere containing 100% of CSCs and 1.2Gy in the rest of
the tumor, delivered in two sessions per day, 5 days a week along 30 sessions 12
hours intervals, with weekend interruptions. While tumor control is not achieved,
tumor radioresistance, measured in terms of the final proportion of CSCs, turns
out to be lower for heterogeneous dosimetries than their averaged versions (see
Figure 3.12 (D), (E) and (F)). Notice that in this case, the total averaged doses
delivered by the heterogeneous dosimetries considered are much smaller than 60Gy
(between 38Gy and 39Gy for the values of pa considered).
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Figure 3.12. Comparing the effects of lower radiation dosimetries with and without
hyperfractionation. Cell survival curves for 20 simulations (with different seeds of a random
number generator) are shown in the case pa = 0.25 for the low migration case and CSC cycle
duration equal to 96h. (Top) From left to right heterogeneous therapies consisting of 2.3Gy
(A) and 1.7Gy (D) in the inner sphere, and 1.8Gy (A) and 1.2Gy (D) in the rest of the tumor
respectively. (Middle) From left to right the averaged homogeneous therapies corresponding to
1.9Gy (B) and 1.3Gy (E) are represented. Radiation dose delivery been made according to 5
days a week, 30 sessions in total, at 24 hours (A, B) and at 12 hours (D, E) intervals with
weekend interruptions. The time evolution of CCs and CSCs is represented in green and red
respectively. (Bottom) Number of CSCs and the corresponding standard deviations at the end of
the recurrence tumor stage (where about 106 cells is again obtained) for heterogeneous (yellow)
and averaged homogeneous (blue) radiation therapies (C, F). Notice that the vertical coordinate
is represented in a logarithmic scale.
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Figure 3.12 shows that there is tumor recurrence in all cases. However, it
turns out that the number of CSCs remaining at the end of the recurrence tumor
stage after radiation therapy is lower than that existing prior to therapy in all
cases. Thus, tumors surviving this therapy can be considered as less radioresistant
than they were before radiation therapy started. An inspection of Figure 3.12 (C)
and (F) quickly shows that in these current cases heterogeneous therapies yield
better results than its averaged homogeneous counterparts previously discussed.
For completeness, estimates on the total number of CSCs after treatments are
concluded and recurrence appears for each case of pa considered are provided (see
Figure 3.12).
3.5.3 Dependence of results on model parameters: some
remarks
To conclude this Section some remarks on the dependence of the model of tumor
growth described, and the results derived from its analysis, on data and parameters
assumed are provided as follows.
To begin with, the results obtained are not restricted to the figure selected
(15%) for the proportion of CSCs within the tumor at the initial stage. In fact,
they continue to hold as long as the more radioresistant tumor cell phenotype
CSC represents a small percentage of the total tumor cell count. A particularly
interesting limit case is that when tumor growth starts from a single CSC. Then
for each value of pa (0.75, 0.50, 0.25), CSC cycle duration (96h, 72h and 48h) and
migration rate kmig (0.025h
−1, 1.75h−1) considered, the number of CSCs present
when tumor has reached a size of about 106 cells (just before radiation treatment
starts) is smaller than that corresponding to the cases considered in this work. For
instance, in the case of CSC cycle duration equal to 48h, pa = 0.25, for the low and
high migration cases the number of CSCs before the treatment starts is about 5956
and 14316 (with standard deviations of 129 and 530 over 20 simulations performed
for each parameter set considered) respectively. The corresponding values for the
case considered in this work are 21953 and 41629 respectively (see Tables 3.2 and
3.3). Moreover, the internal region where CSCs remain confined is smaller (1120µm
and 1840µm with standard deviations of 39.7µm and 71.4µm over 20 simulations
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performed for each parameter set considered, respectively) than that reported in
Tables 3.2 and 3.3. Hence any radiotherapy treatment that achieves tumor control
in the cases considered also does so for tumors staring from a single CSC under
assumptions above.
On the other hand, the assumption that the duration of cell cycle for CSCs
is significantly longer than that of CCs has been used, a hypothesis commonly
assumed in the literature (cf. for instance [142], [163], [164], [165], [166], [167], [168],
[169], [170] and [171]). This fact notwithstanding, the proposed model can be used
to examine also the opposite situation, that is the case where CSC cycle duration
is equal or smaller than that of ordinary CCs. As an example, the cases where
CSC cycle lasts 26 hours (respectively 18 hours), which is equal to (respectively
less than) the 26 hours cell cycle selected for CCs have been considered. As one can
expect, the inner core where most CSCs remain concentrated is now larger than
when slow-cycling CSCs is assumed. In particular, in the case of low migration and
for a CSC cycle duration of 26h, such internal regions (where 100% of CSCs are
located) range from 20% to 83% of the total tumor volume for values of pa equal
to 0.75, 0.50 and 0.25. Besides, when CSC cycle duration is taken to be 18h that
internal volume further expands, ranging now between 23% and 100% of the total
tumor volume. Additional details, including the number of CSCs present when
tumor size reaches about 106 cells and the case of high migration, are provided in
the Appendix C.
A case which has not been addressed in this work is cancer cell plasticity, a
hypothesis that has been advanced to better understand the onset of resistance
after therapy; see for instance [203], [204] and [205]. According to this scenario, in
addition to CSCs giving raise to CCs by asymmetric division, a (supposedly small)
percentage of CCs may transform to a CSC phenotype, possibly as a reaction
to radiation therapy. Although little quantitative information about this process
seems to be available as yet, including such type of process in this model is possible.
To support this statement, a particular example has been studied. Specifically, a
model situation where a small percentage of CCs are transformed to CSCs along
the radiation treatment has been examined. As expected, any increase in the
number of CSCs results in increased malignancy, measured in terms of higher
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resistance to radiation therapy. However, the main conclusion obtained in this
work that heterogeneous, tumor-adapted radiation therapies fare better than their
corresponding averaged homogeneous versions continues to hold. Details on this
study can be found in the Appendix C.
3.6 Discussion
Tumor heterogeneity is being increasingly recognized as a key obstacle to achieve
successful tumor control, either by means of radiotherapy, chemotherapy or
through the use of combined therapies. Indeed, it is well known that tumors at
an advanced stage contain different tumor subpopulations, which might have been
generated as a consequence of sequential mutations of one initial clonogenic line, or
could result from the presence of cancer stem cells. Moreover, it is expected that
such cell phenotypes may considerably differ in their biological and radiobiological
properties, and in particular in their resistance to radiation (cf. for instance [23],
[112], [141], [175], [206], [207]).
Accordingly, it has been proposed that the clinical prognosis of a given tumor
would critically depend on the information that may be gathered about its internal
heterogeneity, and more precisely, about the identification of regions within it with
different sensitivities to a given therapy. In principle, once the spatial distribution
of the various cell phenotypes coexisting in a tumor is known, and the resistance to
therapy of each of these regions had been estimated, personalized strategies com-
plementary to (or as a substitute to) surgery, could be designed to improve chances
of clinical success. The latter can be understood either as total tumor eradication
(the standard paradigm as of today) or as achieving instead a stable, chronically-
controlled tumor burden where less aggressive lines keep at bay more resistant
ones [208]. In either case, significant information towards a personalized treatment
would be inferred from knowledge of the internal, non-homogeneous structure of
a tumor and the resulting differences in therapy resistance corresponding to the
regions thus identified.
In this work, a mathematical model of tumor growth has been proposed to gain
insight about two key issues: how heterogeneity unfolds in a growing tumor, and
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what type of radiation dosimetry is best suited to achieve control in heterogeneous
tumors. Concerning the first issue, it has been described that substantial informa-
tion about the evolution of spatial heterogeneity within a tumor can be retrieved
from knowledge of a few key biological properties of the tumor cell phenotypes in-
volved. In particular, it has been shown that the first place that a difference in cell
cycle duration between a majority of ordinary cancer cells (CCs) and a minority
of comparatively slow-cycling cancer stem cells (CSCs) leads to a concentration
of CSCs in regions that can be a priori estimated. In the cases just discussed,
such regions consist in an internal core within an expanding tumor, but the result
would apply to other geometries as well. In particular, it can be extended to larger
tumors with corrugated shapes and boundaries.
As has already been mentioned, the key assumption that CSCs have longer
replication times than CCs is commonplace in the literature (see [142], [163], [164],
[165], [166], [167], [168], [169], [170] and [171]). As a matter of fact, such assumption
is naturally associated to the consideration of CSCs as a subpopulation of tumor
cells which is able to rescue tumor growth after therapies have been delivered.
This is related to the fact that standard radiation therapies preferentially target
dividing cells (which are more radiosensitive), and thus spare those that have slower
cycles or remain quiescent. Notice that the cell cycle duration could in principle
be estimated, at least in vitro, for all cell phenotypes known to appear in a given
tumor. Importantly, the spatial heterogeneity pattern thus observed does not
depend so much on the precise values of such biological parameters, but rather on
the fact that they are significantly different for the tumor cell phenotypes involved.
As a consequence, the result obtained is robust with respect to fluctuations in cell
cycle duration due to systemic factors.
A second result obtained is that, once information about functional hetero-
geneity had been obtained, tumor-tailored radiation dosimetries can be designed
to improve the treatment outcome. As has been shown, heterogeneous radiation
dosimetries do better than homogeneous ones when regions occupied by different
radioresistant tumor subpopulations can be identified, and this is the case when
more radioresistant phenotypes replicate at a lower pace than less resistant ones.
Again, this is a standard assumption of the CSC theory of tumor resistance to
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therapies. Interestingly, this result holds when the more radioresistant phenotype
is able to sustain unlimited replication as in the case of CSCs, as opposed to the
limited number of replications commonly assumed on CCs. The previous state-
ment holds true, no matter the type of scheduling considered (with or without
weekend interruptions) or the precise result pursued, being it total tumor erad-
ication, controlled recurrence or palliative treatment. It should be noticed that
the comparative advantage of heterogeneous radiation dose distributions deserves
some consideration, since to this day homogeneous dosimetries continue to be those
being commonly implemented worldwide.
It is worth to stress that the model described in this Chapter is quite robust
with respect to changes in data and parameter values. In particular, the con-
clusions arrived in this work remain in force when CSC and CC cycle durations
undergo considerable changes, as long as CSC cycle is significantly slower than that
of CCs. Also, CCs and CSCs migration rates are allowed to undergo substantial
changes (corresponding for instance to slow and fast migration processes) as far as
both tumor cell phenotypes share a similar migration rate. Moreover, the results
obtained continue to hold when changes in the choice of the radiosensitivity pa-
rameters α and β in (3.1) are allowed, or when different fractions of the minority
phenotype (CSC) are assumed. For instance, such results are not confined to the
choice made for the assumed percentage (15%) of CSCs present at an early stage
of tumor growth. They continue to hold if a different figure for that proportion is
taken, as long as CSCs remain a small fraction of the total tumor population at
that stage.
On the other hand, cancer cell plasticity has recently received considerable
attention [203], [204], [205]. As a consequence, a particular example where in
addition to CCs being generated by CSCs with asymmetric division, a small per-
centage of CCs are transformed to CSCs as a consequence of radioresistance to
therapy has been investigated. The main result obtained in this work that hetero-
geneous, tumor-adapted radiation therapies fare better than their corresponding
averaged homogeneous versions continues to hold in this case.
To conclude a discussion on some of the limitations of this work, as well as on
possible extensions thereof is provided as follows. To begin with, more research
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is needed to understand the possible mechanisms that can be responsible for slow
cycling of CSCs. Particularly relevant in this context would be to ascertain if
slow cycling can, at least in some cases, be established as an intrinsic property of
CSCs or if it could alternatively be induced by systemic feedback in the course
of tumor growth. Interestingly, even if CSCs are assumed to cycle faster than
CCs, the proposed model still shows that heterogeneous dosimetries adapted to
the resulting tumor heterogeneity continue to outperform standard homogenous
therapies currently in use.
A general conclusion that follows from this study is that detailed informa-
tion about intratumoral heterogeneity is needed in order to implement efficient
dose-painting techniques in clinical practice. In particular, in this work a clear de-
pendence on tumor heterogeneity of the radiation doses needed to achieve tumor
control has been obtained. In fact, the inner tumor regions where more radioresis-
tant tumor cell phenotype remains confined are shown to strongly depend on CSC
cycle duration and their probability of asymmetric division. In the particularly
unfavorable assumption of fast CSCs cycling, this region may rank from 20% to
100% of the total tumor volume. In this latter situation, a worst-case scenario
corresponding to a high and homogeneous radiation dose being prescribed and
only limited by neighboring organs at risk tolerance, is recovered that corresponds
to current clinical practice. The results obtained in this work suggest that such
situation could be considerably improved in many cases if and when sufficient in-
formation about key different biological and radiobiological properties of the tumor
cell phenotypes present in a given tumor is available, be it either by estimating
patient-specific parameters or by means of medical imaging techniques.
Finally, it looks feasible from a mathematical viewpoint to address within this
framework situations where larger tumors are considered, a number of cell pheno-
types coexist there due to mutations, and other effects (immune response, nutrient
limitation, etc.) are accounted for. For example, the modeling framework selected
in this work permits simulations to be scaled up to cubic centimeter sizes, though
at the expense of lower spatial and functional resolution, and more computing re-
sources. It can also be used to construct hybrid models, zooming in at the cell
scale in regions of interest. In particular, it has be chosen to represent each cell
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individually to exclude averaging effects when studying the relation between tumor
heterogeneity and simulated radiation outcomes. However, this work could provide
a starting point towards the study of the more general situations described above.
105
Chapter4
A decision-support system to select
dosimetry plans in radiotherapy
“. . . The lack of real contact between mathematics and biology is either a tragedy,
a scandal, or a challenge, it is hard to decide which . . .”
Gian-Carlo Rota (1932-1999)
4.1 Abstract
Radiotherapy treatment plans are selected by radiophysicists and clinicians out of
a small number of tentative plans simulated on a commercial treatment planning
system (TPS). In this work, a decision-aid procedure to assist in the choice of the
plan to be applied has been proposed. This is done as follows. For any tentative
plan, three different estimates of radiation dose distributions are defined on the
planning target volume, nearby organs at risk and healthy tissue respectively.
These are then combined to build a figure of merit, the Dose Distribution Index
(DDI), which provides a score for any such tentative plans. To do that, only dose
volume histograms (DVHs) obtained from TPSs and the radiation dose prescribed
on the tumor are used. DDI provides a straightforward, user-friendly tool to
compare different radiation dosimetry plans with similarly looking DVHs. In fact,
small differences in the number, incidence angles or intensities of radiation beams,
yield significantly different scores for each of the partial indexes in theDDI. On the
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other hand, DDI can be computed for any type of treatment planning system in
use, irrespective of tumor type and localization, and allows to compare dosimetry
plans obtained from different commercial planning systems or corresponding to
different irradiation techniques.
In particular, using DDI several tentative plans for a given radiotherapy pa-
tient, each corresponding to a different radiation dose distribution, can be quan-
titatively compared. In order to test this methodology, the plan suggested by the
DDI was compared with those actually implemented in a number of centrally-
located brain tumor patients. For any of them, three different planning strategies
were considered, out of which one was selected and eventually delivered. The DDI
was then computed for any of those alternative choices, and a considerable degree
of coincidence was observed. Besides, the reason for possible discrepancies, when
they occurred, was discussed. To further assess the information provided by this
tool, a sequence of hypothetical treatment plans for one prostate cancer patient was
also examined, and a clear correlation between DDI scores and clinical assessment
was observed.
4.2 Introduction
A key question in radiotherapy clinical practice is how to deliver by means of
the devices actually in use (linear particle accelerators, LINACs) a radiation dose
distribution that meets clinical requirements in a satisfactory manner. To that
end, a LINAC commercial treatment planning system (TPS) is used, on which
several tentative treatment plans for any diagnosed patient are tried, one of which
is eventually selected. This last is expected to achieve best tumor control, and to
induce little side effects on neighboring critical regions. However, TPSs are not
equipped with standard decision-aid tools to quantify the difference between two
tentative plans, nor the impact of small modifications on any of the tentative plans
considered. The choice of a dosimetry plan is therefore made after examination of
a few plans, or of successive modifications of a unique tentative plan, simulated in
a TPS. Therefore, in the absence of widely accepted quantitative criteria, different
persons may possibly make different choices from the same set of dose volume
histograms (DVHs). As a consequence, different specialists may suggest different
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treatment plans for a given patient, which makes difficult to establish a standard
planning procedure to compare radiotherapy results. In fact, the differences in
DVHs and isodose curves corresponding to different tentative plans are usually
small, and thus a merely subjective selection made among them may not be easy
to justify (see Figure 4.1 below and Figure 2.1 in Chapter 2). Therefore the
development of user-friendly, computer-assisted decision tools could be quite useful
as a benchmark quality test for clinical decisions.
Figure 4.1. From left to right: magnetic resonance images (MRI) of radiation iso-
dose curves corresponding to two different external beam radiotherapy tentative plans
for a same patient. [This image is used under permission of the Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain].
As discussed in Chapter 1, the search for a single figure of merit to quantify
the quality of a radiotherapy treatment plan has been actively pursued, with only
partial success to this day. During that process, several figures have been proposed
to assess dosimetry plans, paying attention to radiation dose coverage, conformity
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and dose gradient as separate or combined overall scores (see for instance [27], [28],
[29], [30], [31], [32], [33], [34], [35], [36], [37] and [38]). However, all such figures
have been reported to suffer from different limitations. In particular, the indexes
proposed may introduce false positives (cf. [27], [29], [32] for a detailed discussion
on HI and CI), are not sensitive to small modifications sequentially introduced
(a common situation in the planning process), depend on many parameters (cf.
[31], [33], [37], [39]), provide ambiguous scoring due to averaging effects [34], are
difficult to extend for any type of TPS, and often are not easy to implement [38].
In this Chapter a decision-aid tool to assist in the choice of a radiotherapy
treatment plan is proposed. Such tool uses only data extracted from the DVHs
provided by commercial TPSs and the radiation dose prescribed on the PTV.
Specifically, the DDI consists in a global score that will be formulated in Section
4.3. In Section 4.4 the DDI is computed in a series of clinical cases as part of a
retrospective study. These correspond to centrally-located brain tumors, situated
at internal regions close to several organs at risk (OARs), and for which different
tentative treatment plans were simulated by means of a TPS: iPlanRT Dose v4.1
TPS (BrainLAB AG, Germany). In each situation, three tentative plans were
simulated for each patient, one of which was eventually selected. Such plans will
be graded by means of the DDI and that which scores best will be selected and
then compared with the actually implemented treatment plan. While considerable
agreement between both choices is observed, discrepancies are also noticed, and
some underlying patterns are identified when this occurs. On the other hand, to
further assess the information provided by the DDI, a sequence of hypothetical
treatment plans for one prostate cancer patient is also discussed. In this case,
any such plan can be clinically evaluated in an easy way, and a good agreement
between clinical assessment and DDI scores is observed. Finally in Section 4.5
a user-friendly graphic interface to implement the DDI in a TPS is presented.
In fact, by means of this computer application, radiophysicists can compare and
analyze different tentative plans in a straightforward way, and comparison output
data can be displayed and saved for future statistic analysis. A discussion on the
main results can be found in a concluding Section 4.6.
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4.3 A decision-aid tool: the Dose Distribution
Index
As mentioned above, differences between tentative treatment plans are often small.
Moreover, the large amount of parameters to be considered during the planning
process renders deciding among simulated alternatives a very difficult task. In this
Section a decision-aid system, consisting of a Dose Distribution Index (DDI) to
provide a quantitative estimate on any tentative treatment plan, is formulated. In
this manner, different plans can be compared in a precise way. This quantitative
index (DDI) accounts for the main dosimetry features (radiation dose coverage,
conformity and homogeneity) considered in clinical practice and allows to quan-
titatively compare the results of even minor changes introduced in a tentative
dosimetry plan. One can at once realize the separate impact on PTV, OARs and
HT of any such modification, and use this information as a guidance to improve
any given tentative plan.
For convenience of the reader, before defining the Dose Distribution Index, a
table describing the parameters used in its formulation is provided (see Table 4.1).
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Symbol Description
Dp Prescription radiation dose on the PTV
Dp% Percentage of the Dp
DM Maximum dose received for each structure involved
Dm Maximum dose received at least by 100% of the PTV
N Number of OARs involved
|PTV | Volume of the planning target
|OARVi| Volume of the ith OAR
|HTV | Volume of the HT
VT (D) DVH curve of the PTV
VO,i(D) DVH curve of the ith OAR
VH(D) DVH curve of the HT
wO,i Weight of the ith OAR term
wT Weight of the PTV subindex
wO Weight of the OARs subindex
wH Weight of the HT subindex
Table 4.1. Quantities used to define the DDI.
In particular, DDI is defined as a weighted sum of three main terms, which
respectively measure radiation dose distributions within the PTV, OARs and HT
for a given tentative treatment plan. The first of those terms estimates how well
the proposed radiation dose distribution covers the PTV. In fact, it computes the
ratio between the area under the dose-volume curves for the DVH considered, and
that corresponding to the ideal case of constant prescription dose (Dp) uniformly
delivered over the PTV (see Figure 4.2). Such a perfect conformation provides
the best coverage of the PTV and would yield a value of one for that ratio. In
this way, an estimate is obtained of the deviation with respect the case of perfect
conformation over the PTV, which corresponds to Dm = Dp = DM . On the
other hand, the curvature in the DVH may be useful to compare different critical
dosimetry points. For that reason, a factor (Dm/DM) is also introduced. Thus,
the PTV term (IT ) for a tentative plan is defined as follows
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IT =
∣∣∣∣∣∣∣∣∣1−


DM∫
0
VT (D) dD
Dp · |PTV |
 ·
(
Dm
DM
)
∣∣∣∣∣∣∣∣∣ . (4.1)
Figure 4.2. A DVH corresponding to a PTV where some of the parameters in Table
4.1 are indicated.
Notice that an optimal treatment plan over the PTV would yield IT = 0. This
case corresponds to a homogeneously irradiated tumor with a prescription dose
Dp, which is the aim in current clinical practice.
On the other hand, in the case of OARs and HT considered in the second
and third terms at the DDI, the idea is quite similar, but now the ideal cases
correspond to a situation where the area under the DVH is close to zero, meaning
that the radiation dose received by these critical structures is very low (see Figure
4.3). Moreover, the ratio (DM/Dp%) is included in order to weight the radiation
dose received by OARs and HT against a fixed percentage of the prescribed dose
(Dp%) on the PTV. Clearly, one aims at situations when these ratios are also close
to zero. The subindexes for OARs (4.2) and HT (4.3) will be referred as IO and
IH respectively, and are defined as follows
113
IO =
1
N
N∑
i=1
wO,i ·

DM∫
0
VO,i(D) dD
Dp% · |OARVi|
 ·
(
DM
Dp%
) (4.2)
and
IH =

DM∫
0
VH(D) dD
Dp% · |HTV |
 ·
(
DM
Dp%
)
. (4.3)
Figure 4.3. DVHs corresponding to an OAR or HT where some of the parameters in
Table 4.1 are indicated.
In what concerns OARs and HT terms, an optimal treatment plan would yield
IO = IH = 0, which would result in no irradiation on such critical structures.
These three subindexes (4.1)-(4.3) are combined to obtain the Dose Distribution
Index defined as follows
DDI = wT · IT + wO · IO + wH · IH , (4.4)
where wT , wO and wH are weight parameters to enhance the relative importance
of each term in (4.1), (4.2) and (4.3) respectively. Notice that different weights may
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also be associated to different OARs in (4.2). An ideal treatment plan would give
DDI = 0, which corresponds to perfect irradiation on the PTV and no irradiation
at all over the OARs and HT. It should be noted that DDI could be easily extended
to include several PTVs, similarly to what has been done for the OARs in (4.2).
For instance, this may be the case when a heterogeneous PTV is considered and
non-homogeneous radiation doses are required on it [19].
In order to evaluate how the DDI would work in clinical practice, a retro-
spective study has been performed over a number of clinical cases already treated
in Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. In this
study, 30 patients diagnosed with centrally-located brain tumors (14 Meningioma,
10 Neuroma and 6 Adenocarcinoma) were selected. In all cases, several OARs are
closely located to the PTV. For any patient, three tentative plans were prepared
and recorded during the ordinary treatment planning process over the same TPS:
iPlan RT Dose 4.1.1 (BrainLAB AG, Germany). Out of the three tentative plans
considered, one was selected and delivered. This tentative plan will be referred in
the following as the applied plan (AP ). For any fixed choice of weight parameters,
the plan achieving the lowest DDI value is obtained, (the DDI plan, referred as
DDIp). Then the selected AP and the DDIp were compared. The corresponding
study is described below.
4.4 Results: comparing different dosimetries of
clinical cases
A first result is that if all weight parameters in (4.2) and (4.4) are set all equal to one
(so that dose impact on PTV, OARs and HT are considered as equally important),
AP and DDIp agree in 18 out of the 30 cases considered. This suggests that in the
remaining 12 cases different importance has been assigned to different anatomical
structures during the planning process. To make this point precise, the cases where
AP and DDIp did not coincide were examined. In 11 of these 12 cases AP can
be shown to agree with a DDIp if values of weights in (4.4) are not assumed to
be all equal to one. Thus AP and DDIp will still coincide in most of such cases if
dose impact on PTV, OARs and HT are no longer assumed as equally important.
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As shown in Table 4.2 if two such parameters are equal to one, a value of the
third weight can be obtained such that the corresponding DDIp agrees with that
actually applied in 11 of the 12 cases under consideration. There remains a case
where no such weight combination exists, although AP and DDIp eventually agree
if two (not just one) of the weight parameters in (4.4) are allowed to be different
from one.
wT 1.0 1.0 1.5 1.0 1.5 1.0 2.0 1.0 1.0 1.1 1.0
wO 2.5 1.0 1.0 1.0 1.0 0.5 1.0 0.5 1.0 1.0 0.5
wH 1.0 0.5 1.0 2.0 1.0 1.0 1.0 1.0 0.5 1.0 1.0
Table 4.2. A list of possible values of weight parameters in (4.4) for which DDIp and
AP agree when only two of them are set equal to one.
It should be noted that the choice of weights in Table 4.2 does not need to
be unique. Therefore the same dosimetry plan can be selected upon different
assumptions on the relative importance attributed to impact achieved on PTV,
OARs and HT.
To illustrate further the use of the DDI to monitor tentative treatment plans,
the following case is now examined. A patient with prostate cancer has been
selected, for whom four different tentative plans are examined. Specifically, the
following cases have been sequentially considered i) two parallel and opposite beam
fields, ii) three beam fields, iii) five beam fields and iv) seven beam fields, and DDI
values were computed for any of them. In all situations, conformal beam technique
was used to clearly observe the dose distribution changes for the different tentative
plans, and to avoid optimization compensation possibly introduced by intensity-
modulated radiation therapy (IMRT) techniques than can blur this test. The
calculation was run using a commercial TPS: XiO 4.62.00 (CMS-ELEKTA). For
simplicity, only some of the organs at risk involved (Bladder, Rectum and Penile
Bulb) as well as the PTV (see Figure 4.4) will be considered. As can be expected,
when the number of fields increases the score of these tentative plans (measured
by means of the corresponding term in (4.4)) over the OARs decreases.
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Figure 4.4. A CT scan of a patient diagnosed with prostate cancer, where Bladder
(red), Rectum (orange) and PTV (purple) are represented. [This image is used under permission
of the Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain].
The first case (Plan A), where only two opposite fields have been used, produces
the greatest effect on the PTV, but turns out to be the worst with respect to OARs
(see Figure 4.5). As the number of fields increases, radiation effects on the OARs
are sequentially reduced, but so is the effect on the PTV.
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Figure 4.5. Representation of OARs and the PTV for a patient diagnosed with prostate
cancer (Bladder (red), Rectum (orange) and PTV (purple)). Isodose curves (correspond-
ing respectively to 30%, 50%, 70%, 85%, 90% and 95% of the prescription dose (Dp))
for each tentative plan: A) two parallel and opposite fields, B) three fields, C) five fields
and D) seven fields are provided. [This image is used under permission of the Hospital Universitario
Puerta de Hierro Majadahonda, Madrid, Spain].
An inspection of the DVHs for each tentative plan shows that if the effect on
the PTV is given total priority, the best choice corresponds to Plan A, followed (in
this order) by Plans B, C and D (see Figure 4.6). On the contrary, when lowering
effects on OARs were given highest priority; the best choice would be Plan D,
followed by Plans C, B and A, respectively (see Figure 4.7).
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Figure 4.6. (Left) DVHs of the PTV for each tentative treatment plan. (Right) A mag-
nification of previous DVHs to better display effects corresponding to higher radiation
doses. Notice that the tentative treatment plan with larger effect on the PTV is Plan A
followed by Plan B, Plan C and Plan D respectively.
Figure 4.7. DVHs corresponding to OARs and HT for each tentative treatment plan
in the case considered. Notice that the tentative treatment plan with less effect on the
OARs and HT is Plan D followed by Plan C, Plan B and Plan A respectively.
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Finally, in Table 4.3 the values of the proposed DDI in (4.4) and each term
(4.1)-(4.3) for these tentative plans are given. In particular, when all weights in
(4.2) and (4.4) are considered equal to one the best tentative plan turns out to be
Plan D, which produces lowest effect on OARs, but has the lowest effect on the
PTV as well. However, if tumor control (hence impact over the PTV) is retained
as the primary goal, the best choice is Plan A. In fact, Table 4.3 shows that the
values provided by each term in (4.4) are consistent with information provided by
the corresponding DVHs.
IT,i IO,i IH,i DDI
Plan A 0.0437 1.8105 0.2685 2.1226
Plan B 0.0580 1.5697 0.1872 1.8149
Plan C 0.0672 1.5859 0.1216 1.7746
Plan D 0.0705 1.4527 0.1092 1.6324
Table 4.3. Values of each term (4.1), (4.2) and (4.1) and the DDI (4.4) for the four
tentative plans (when all weights are equal to one in (4.2) and (4.4)) of the example
considered.
It should be mentioned that these results are part of a preliminary study to
check the performance of the DDI on different clinical situations. Currently, a
more exhaustive investigation of the performance of this tool in current clinical
practice is being conducted. To do that, a user-friendly graphic interface has been
created, where clinicians and radiophysicists can easily compare several tentative
treatment plans in daily clinical practice. In the next Section more details about
this software are provided.
4.5 A user-friendly graphic interface
In order to make simpler the use of the Dose Distribution Index in current clinical
practice, a computer application has been programmed. This software, referred as
DDIapp for simplicity, is a tool to compare tentative plans defined on a commercial
TPS. DDIapp only uses the DVHs and the Dp on the PTV as external data
defined in the planning process. The functionality of this decision-aid tool can
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be accessed by a graphical user-interface (GUI) that includes, as its main feature,
visualization and analysis of the comparison results (see Figure 4.8). The intuitive
graphical interface of DDIapp follows a natural workflow and does not require
programming for its use. In the following, this user-friendly software to compare
different tentative plans is described and its main features are highlighted.
Figure 4.8. DDIapp graphical user interface (GUI).
To begin with, the first step to useDDIapp is to import the data files containing
the information of the DVHs of each tentative plan that will be compared. In
general, TPSs are equipped with options to export the DVHs of any tentative
plan in different output formats, which are used as input data in the DDIapp.
As required by radiophysicists, DDIapp is able to interpret these formats without
requiring an edition of these files by the user. This simple feature is very useful to
save time and make the comparison process easier. It should be noted that DDI
is designed to compare tentative plans prepared for a same patient. Thus such
plans should have the same number of structures, and be planned considering the
same Dp on the PTV. Once the information of the DVHs has been introduced,
the user has to provide the parameters of the DDI and the Dp. In addition, some
dose volume constraints can be defined in order to account for further clinical
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requirements as explained below. Then the comparison results are obtained, and
can be visualized and saved for further discussion.
The graphical user interface of DDIapp provides a number of options to assist
radiophysicists and clinicians in the process of analyzing tentative treatment plans
(see Figure 4.9).
Figure 4.9. DDIapp graphical user interface and the representation of modules: data
files import (A), parameters editor (B) and comparison viewer (C). The dose volume
histograms viewer (D) and export result files (E) options are also provided.
The main features of the DDIapp are described as follows:
A. Data files import: At this moment, DDIapp is able to interpret the DVH
data files provided by different TPSs currently in use in Hospital Universitario
Puerta de Hierro. DVHs can be exported both in an accumulative or differential
form, which can be handled by DDIapp without requiring an edition of these files
by the user. Therefore, different tentative plans for a same patient defined in any
of such TPSs can be compared.
B. Parameters editor: Once the DVH data files have been loaded, all struc-
tures defined on the corresponding tentative plans are listed. At that moment, the
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user should provide the value of all parameters involved in the comparison pro-
cess. To begin with, the HT and PTV have to be selected. Then, the Dp defined
in the planning process has to be provided. Moreover, the weights used in the
definition of the DDI (see (4.2) and (4.4)) for each OAR, HT and PTV can be
selected to consider different clinical requirements. In addition, for each tentative
plan and each structure involved a dose volume constraint can be incorporated.
For instance, it may be required that 95% of the PTV should receive less than a
given radiation dose. These constraints do not have influence in the calculation of
the DDI. In fact, by means of dose volume constraints radiophysicists can pay
attention to relevant aspects on the DVH plots and decide which tentative plan (if
any) satisfies such constraints.
C. Comparison viewer: The comparison results are represented in two forms.
In the first, the values of the PTV (4.1), OARs (4.2) and HT (4.3) terms, and the
DDI (4.4) are provided. Then, the tentative plans can be sorted by each of these
terms and compared. On the other hand, for each tentative plan a description of
the dose volume constraints (if required) is provided. In particular, to repeat the
process changing any of the parameters or to add another tentative plan, there is
no need to re-enter all the information. Only the parameters that the user wants
to modify should be fed in.
D. Dose volume histograms visualization tool: For user convenience,
DDIapp is equipped with a tool that provides a visualization of the DVHs of
tentative plans being compared (see Figure 4.10). DVHs can be viewed in an
accumulative or differential form. On the other hand, for comparison purposes
several DVHs for different tentative plans can be superposed to better realize the
differences between them.
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Figure 4.10. Dose volume histograms visualization tool (see also Figure 4.9).
E. Exporting result files: To save the workspace for future uses, an addi-
tional tool is provided (see Figure 4.11), where a file with the whole information
of the current process can be saved. In a similar way, DDIapp can restore these
workspace files starting the process exactly in the same point.
The programming language used to implement this software was C++, which
has a wide range of compilers that run on many different platforms that support it.
Moreover, codes that exclusively use the C++ standard library can be executed on
many environments. On the other hand, procedures to interpret more DVH output
files generated from different TPSs can be included in a simple way keeping to the
same general process.
In summary, this user graphic interface provides all features of the DDI in
an easy and simple way. The radiophysics department of Hospital Universitario
Puerta de Hierro is currently testing this software, an exhaustive and detailed
study of its use in current radiotherapy clinical practice is being prepared. The
results obtained from this study will be reported in future works.
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Figure 4.11. Exporting result files (see also Figure 4.9).
4.6 Discussion
The availability of commercial treatment planning systems allows radiophysicists
and radiation oncology departments to virtually explore different dosimetry plans
for each radiotherapy patient. In any such plan, detailed information concerning
DVHs and isodose curves is provided. However, TPSs are not equipped with
standard decision-aid tools to quantify the impact of small modifications on the
tentative plans considered. The choice of a dosimetry plan is therefore made after
examination of a few tentative plans, or of successive modifications of a unique
plan, simulated in a commercial TPS.
Bearing these facts in mind, in this Chapter a decision-aid tool (DDI) has been
presented to assist clinical personnel to estimate the consequences of modifications,
however small, on any tentative plan under consideration. The decision-support
tool thus provided is easy to handle and uses exclusively the information of DVHs
and the Dp on the PTV exported from a TPS. It also permits simultaneously con-
sidering the particular results of the different subindexes of the DDI corresponding
to different radiation dose distributions and the DVHs involved.
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It should be remarked that DDI is not meant to be a replacement for per-
sonal decisions along the treatment planning process. Instead, it is expected to
provide a better assessment of the impact of such decisions over the anatomical
and pathological regions considered. In particular, the DDI will not tell the plan-
ning person what his/her choice of dosimetry plan should be, nor what criteria
should be assumed to produce such plan. Instead, DDI provides precise estimates
on the differences between priorities made and the tentative plans thus resulting.
Actually, for any given patient, different practitioners may pursue different, and
occasionally conflicting goals: prioritizing impact on PTV in some cases, insisting
on palliative considerations and therefore on saving OARs and HT in others. DDI
is not intended to change their priorities, but to help them to precisely assess the
consequences of their choices. On the other hand, it should be stressed that com-
puting the DDI is straightforward, and can be easily done and displayed on a TPS
simultaneously to the plotting of the corresponding DVHs. Moreover, the DDI
is very sensitive to small dosimetry variations, is easily implemented and can be
obtained for any type of TPS. It may also be used to compare plans obtained from
different TPSs. Furthermore, the proposed DDI can be derived for any irradiation
source (photons, protons, etc.) or radiotherapy technique (IMRT, 3DCRT, etc.)
that provide DVHs of the radiation dose distributions for the tentative plans being
simulated.
To give an idea of what DDI can actually accomplish, a retrospective study
has been presented, corresponding to 30 patients diagnosed with centrally-located
brain tumors. In each case, three tentative plans were simulated and recorded, out
of which one was eventually delivered. Then, for a given set of weight parameters
the applied plan (AP ) and that providing the lowest DDI score (DDIp), were
compared. Moreover, a clinical case of prostate cancer has been also considered
and variations on the impact of tentative plans on PTV, OARs and HT have been
monitored by the DDI as the number of fields considered changes. In view of the
previous results, it appears that the implementation of the DDI in any type of
TPS being used in clinical centers could improve reliability standards in selecting
treatment plans.
Finally, the DDI proposed in this Chapter can be combined with the mathe-
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matical model described in Chapter 2 to improve the radiotherapy planning pro-
cess. In fact, these tools are aid-decision systems, which permit to define and
compare different radiation dose distributions, which is one of the main tasks in
clinical practice. In particular, having discussed on a precise definition of prescrip-
tion radiation dose distributions as proposed in Chapter 2, it is natural to wonder
how one could prepare a radiotherapy treatment plan where the dose distribution
is as close as possible to an optimal prescription dose. While it is not possible to
provide a general solution to that problem, this user-friendly tool can be used to
decide, out of a given number of tentative plans, which one is closer to delivering
the radiation dose distribution deemed optimal in each case.
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Chapter5
Conclusions
“. . . But there is another reason for the high repute of mathematics: it is
mathematics that offers the exact natural sciences a certain measure of security
which, without mathematics, they could not attain . . .”
Albert Einstein (1879-1955)
Since the discovery of X-rays more than one hundred years ago, use of ionizing
radiation in medicine has become pervasive, both to assist in diagnosis and as a
treatment choice for tumor patients. In particular, radiotherapy is now a common
clinical technique to treat solid tumors. The treatment of these diseases, and that
of cancer patients in general, represents a major challenge on scientific and social
terms. Considerable scientific and technological advances made over the last years
have led to a significant reduction in tumor morbidity. However, tumor recurrence
after therapy, as well as treatment of tumors at advanced or disseminated stages
remains a critical problem in clinical practice.
On the other hand large efforts have been devoted to the development of math-
ematical models to assist in the radiotherapy treatment planning process. In par-
ticular, several models based on physical and radiobiological principles have been
proposed, which have permitted to improve radiotherapy performance. However,
when preparing a treatment plan in current practice, a number of difficulties re-
lated to the choice of prescription dose and the manner in which this has to be
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delivered have to be overcome.
In this memoir some mathematical models and computer-based methods have
been proposed to assist clinicians and radiophysicists during the treatment plan-
ning process. To begin with, in Chapter 2 a mathematical model was pro-
posed to select optimal radiation dose distributions as solutions (minimizers) of
a constrained optimization problem satisfying common clinical and technical con-
straints. To illustrate this approach, several clinical cases were considered, and a
comparison of the proposed optimal dose distributions with those actually deliv-
ered was performed. As a result, when compared with actual dosimetries delivered
in such clinical cases, the proposed optimal dose distributions are shown to be
better options, and can thus be considered optimal choices against which tentative
treatment plans should be compared during the radiotherapy planning process. In
fact, these results strongly suggest that solutions of this mathematical model can
be instrumental in deriving good quality tests to select radiotherapy treatment
plans in rather general clinical situations. On the other hand, analysis of the de-
pendence of such minimizers on model parameters allows to propose a strategy to
select radiation dose distributions, under the assumption that key radiobiological
parameters for tumors and organs at risk involved are only partially known, a
situation which is quite common in clinical practice.
In Chapter 3 the effect of tumor heterogeneity in radiotherapy treatment out-
comes was investigated. To that end, a mathematical model for heterogeneous
tumor growth was considered where two tumor cell phenotypes are present, which
strongly differ in their respective biological and radiobiological properties. In par-
ticular, as a consequence of those differences, the spatial distribution of such phe-
notypes and hence of the resulting tumor heterogeneity can be predicted as growth
proceeds. Using such heterogeneity information the effects of different heteroge-
neous (dose painting) therapies have been investigated. It has been shown that
heterogeneous dosimetries can be selected to enhance tumor control by boosting
radiation in the region occupied by the more radioresistant tumor cell phenotype.
Consequently, it has been observed that such heterogeneous radiation dosimetries
fare always better than their homogeneous counterparts that are currently used in
clinical practice.
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In Chapter 4 a mathematical aid-decision tool to compare and evaluate radio-
therapy tentative treatment plans has been proposed. Such tool uses only data
extracted from the dose volume histograms provided by commercial treatment
planning systems and the prescribed radiation dose on the tumor. In particular,
to assess the information provided by the proposed aid-system, a number of actual
clinical cases were investigated in retrospect. In addition, a computer application
has been implemented, where clinicians and radiophysicists can easily compare and
analyze different tentative plans. It should be stressed that this tool can be easily
incorporated on any commercial treatment planning system and used to assess
any radiotherapy technique that provides dose volume histograms of the tentative
plans being simulated.
Summing up, the proposed mathematical models are expected to provide some
help towards improving radiotherapy clinical practice, a goal that has been always
present during this study.
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AppendixA
Numerical discretization of
variational problems
A.1 A general functional defined in an infinite
dimensional function space
In this Appendix, a detailed numerical discretization of a class of general problems
formulated in the field of Calculus of Variations is presented. See for instance [118]
and [119] for further details of such problems. In particular, this discretization is
used to numerically solve the problem (2.6)–(2.11) formulated in Chapter 2.
To begin with, let us consider a general functional J(v) defined in an infinite
dimensional function space X , that is
J(v) =
∫
Ω
f(x, v(x),∇v(x)) dx,
where f is a sufficiently smooth function, so that the corresponding integral makes
sense. The problem of finding the minimizer function u ∈ X , for which J(u) ≤ J(v)
for all functions v ∈ X defined in Ω and x ∈ Ω, can be briefly expressed in the
following form
J(u) = min
u∈X
J(v), (A.1)
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where in what follows, solutions of the problem (A.1) will be referred as minimizers
for short.
Unfortunately, most of this type of problems do not have an analytic expression
of the minimizer function u ∈ X , even though its existence and uniqueness are
known in advance, as well as many of its properties. Therefore, it will be necessary
to resort efficient numerical techniques and optimization methods in order to ap-
proximate u ∈ X . The simplest way to do that is to consider a finite dimensional
function space, or better yet, a family (Vh)0<h<h0 of finite dimensional function
spaces that, as h → 0, better approximate the elements of X . In particular, the
procedure to numerically approximate minimizers of the problem (A.1) will be
presented and discussed through this Appendix.
In what follows, it will be going from the formulation of most general problems
towards main aspects to numerically solve the problem (2.6)–(2.11) (referred as
(P) for short). For this purpose, the formulation of the Finite Element Method
(FEM) (cf. for instance [128], [127] and [126]) and an optimization method are
considered. Then, Sections A.2 - A.6 are devoted to present the definitions and nu-
merical procedures used to find solutions (minimizers) of the problem (P). While
doing so, Section A.7 is focused on the numerical discretization and the corre-
sponding mathematical formulation. Moreover, particular attention is paid to the
key issues related with the computational implementation, as well as the existence
and uniqueness properties of solutions of the resulting discrete problem.
A.2 The finite element method for nonlinear
functionals
To start, let us first consider the problem of finding the function u defined in the
infinite dimensional function space
X ≡ W 1,∞(Ω) = {v ∈ L∞(Ω) : ∂vxi ∈ L∞(Ω), i = 1, ..., n} , (A.2)
for Ω ⊂ R3, such that u minimizes the following functional
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J(v) =
∫
Ω
|∇v(x)|2 dx +
∫
Ω
f(v(x)) dx, (A.3)
where x ∈ R3, J(u) ≤ J(v) for all v ∈ X defined in Ω and f : Ω → Rn is a
nonlinear function.
Then, to approximate the minimizers of functional J(v) in (A.3), a finite dimen-
sional function space Vh of dimension nh has been considered, which is an approxi-
mation of the infinite dimensional function space for which J(v) makes sense, that
is, X in (A.2). Let {ϕ1, . . . , ϕnh} be a basis of Vh, then for any function vh ∈ Vh,
vh can be written as a unique linear combination of the elements of such basis,
that is
vh(x) =
nh∑
j=1
vjϕ(x). (A.4)
As it is customary, the first term of the functional (A.3) can be expressed as a(v, w)
for functions v, w ∈ X , where a is the symmetric bilinear form given by
a(v, w) =
∫
Ω
∇v(x) · ∇w(x) dx. (A.5)
As consequence, in view of (A.4) the bilinear form a(v, w) can be expressed as
follows
a(vh, wh) = a
(
nh∑
i=1
viϕi,
nh∑
j=1
wjϕj
)
=
nh∑
i,j=1
via(ϕi, ϕj)wj,
for the corresponding functions vh, wh ∈ Vh.
On the other hand, denoting by Ah = (aij)1≤i,j≤nh the symmetric square matrix of
dimension (nh × nh), usually referred as the stiffness matrix, with elements
aij = a(ϕi, ϕj) =
∫
Ω
∇ϕi(x) · ∇ϕj(x) dx, 1 ≤ i, j ≤ nh,
that is, the matrix of the bilinear form a(vh, wh) on the basis {ϕ1, . . . , ϕnh}, then
it is possible to express the following
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a(vh, wh) = v
T
hAhwh,
where for any function vh ∈ Vh, vh ∈ Rnh denotes the vector of values
vh =

vh(x1)
...
vh(xnh)
 .
In the same way, the second term of the functional (A.3) can be expressed as
follows
Fh(vh) =
∫
Ω
f
(
nh∑
j=1
vjϕj(x)
)
dx,
where Fh : Rnh → R and vh ∈ Vh.
Therefore, for any function vh ∈ Vh the value of J(vh) can be expressed in the
following form
J(vh) = v
T
hAhvh + Fh.
A.3 The finite dimensional function spaces and
the corresponding nodal basis functions
In this Section, a definition of the finite dimensional function spaces Vh and the
expression of their nodal basis functions {ϕ1, ..., ϕnh} are provided. To do that,
the first step is to consider a three-dimensional triangulation
Th = {τi}nti=1
of the domain Ω ⊂ R3, with nn vertices and nt elements (for instance, tetrahedrons
in R3). The subindex h refers to the diameter of the triangulation, defined as the
length of the longest edge of all tetrahedrons, that is, the longest distance between
two vertices on Th. It should be noted that, a triangulation of Ω is a partition
of this domain into elements, in this case tetrahedrons. On its turn, tetrahedrons
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must cover the closure of Ω but no more, and must fulfill the following rule: “if two
tetrahedrons have some intersection, it is either on common vertex or a common
full face”. In particular, two different tetrahedrons do not overlap.
The finite dimensional function spaces Vh considered in this work have been the
well-known piecewise linear elements, which are continuous functions in Ω, such
that are linear on each tetrahedron τ ∈ Th and given by
Vh =
{
v ∈ C(τ) : v|τ ∈ P1(τ), ∀τ ∈ Th
}
,
where P1 represents the set of polynomials of degree less than or equal to one.
Observe that, if the values on the vertices of the triangulation Th are fixed, then
there exists a unique function vh ∈ Th with those values on such vertices. Therefore,
an element of Th is uniquely determined by its values on the set of vertices of the
triangulation.
The next step is to show the expression of the nodal basis functions {ϕ1, . . . , ϕnh}
in terms of the independent variable x ∈ Ω, which satisfy the following property
ϕi(xj) = δij =
1 if i = j0 if i 6= j . (A.6)
Since the nodal basis functions have been defined elementwise, let us consider an
arbitrary tetrahedron τ ∈ Th as represented in Figure A.1, where the coordinates
of its vertices are as follows
x1 =

x1
y1
z1
 x2 =

x2
y2
z2
 x3 =

x3
y3
z3
 x4 =

x4
y4
z4
 .
Then, for instance, the basis function ϕ4 associated to the vertex x4 on the tetra-
hedron τ can be defined by means of the equation of the plane p4(x, y, z) = 0 that
passes through the nonaligned remaining three vertices x1, x2 and x3, which is as
follows
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x4
⌧
Figure A.1. Representation of an arbitrary tetrahedron τ with vertices x1, x2, x3
and x4 on a triangulation Th.
p4(x, y, z) ≡
∣∣∣∣∣∣∣∣
x− x1 x2 − x1 x3 − x1
y − y1 y2 − y1 y3 − y1
z − z1 z2 − z1 z3 − z1
∣∣∣∣∣∣∣∣ = 0,
where | · | denotes the determinant of any arbitrary square matrix. Notice that
equation p4(x, y, z) is a linear function, equal to zero in the vertices x1, x2 and x3,
and nonzero in x4. Thus, dividing the equation p4(x, y, z) = 0 by the value of the
corresponding function evaluated on x4 results in a linear function equal to one in
x4 and zero in the remaining vertices, that is
ϕ4(x, y, z) =
p4(x, y, z)
p4(x4, y4, z4)
(A.7)
and expressed in terms of its coordinates as follows
ϕ4(x, y, z) =
∣∣∣∣∣∣∣∣
x− x1 x2 − x1 x3 − x1
y − y1 y2 − y1 y3 − y1
z − z1 z2 − z1 z3 − z1
∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
x4 − x1 x2 − x1 x3 − x1
y4 − y1 y2 − y1 y3 − y1
z4 − z1 z2 − z1 z3 − z1
∣∣∣∣∣∣∣∣
. (A.8)
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Moreover, observe that the basis function ϕ4 satisfies the property (A.6). Similarly,
it is possible to obtain the expression of the basis functions ϕ1, ϕ2 and ϕ3 on the
arbitrary tetrahedron τ ∈ Th. Notice also that, in this way the expressions of
the nodal basis functions on every tetrahedron τ in the triangulation Th can be
obtained.
A.4 Computation of integrals on a triangulation
This Section is devoted to introduce the procedure to approximate an integral
defined in Ω by means of the triangulation Th = {τi}nti=1 in the finite dimensional
function space Vh. The key idea is to replace the original integral by a finite sum
of integrals over each tetrahedron τ ∈ Th. To do that, let us recall the bilinear
form a(v, w) for functions v, w ∈ X of equation (A.5) given by
a(v, w) =
∫
Ω
∇v(x) · ∇w(x) dx =
∫
Ω
(vxwx + vywy + vzwz) dxdy dz,
where this bilinear form can be expressed as a finite sum of integrals over each
tetrahedron of the triangulation Th as follows
a(v, w) =
nt∑
j=1
∫
τj
(vxwx + vywy + vzwz) dxdy dz
 . (A.9)
Denoting by aτ (v, w) the bilinear form restricted to a tetrahedron τ ∈ Th, that is
aτ (v, w) =
∫
τ
∇v(x) · ∇w(x) dx, (A.10)
then the bilinear form a(v, w) of equation (A.9) can be expressed as follows
a(v, w) =
nt∑
j=1
aτj(v, w). (A.11)
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As a result, notice that the stiffness matrix Ah = (a(ϕi, ϕj))1≤i,j≤nn of dimension
(nn × nn) can be written in the following form
Ah = Aτ1 + Aτ2 + . . .+ Aτnt , (A.12)
where Aτk for (k = 1, . . . , nt) is the matrix of the bilinear form aτk(v, w), that is
Aτk = (aτk(ϕi, ϕj))1≤i,j≤nn .
On the other hand, the second term of the functional (A.3) given by
F (v) =
∫
Ω
f(v(x)) dx,
can also be expressed as the sum of the contributions of the tetrahedrons τ in the
triangulation Th to the corresponding integral defined in Ω, which is then given by
F (v) =
nt∑
j=1
∫
τj
f (v(x)) dx =
nt∑
j=1
Fτj(v), (A.13)
where
Fτ (v) =
∫
τ
f (v(x)) dx. (A.14)
Therefore, the problem of computing an integral defined in Ω is reduced to compute
the contributions to such integral of the tetrahedrons in the triangulation Th. In
particular, in what follows, the way to compute the integrals (A.10) and (A.14) on
an arbitrary tetrahedron τ ∈ Th is described.
A.5 Assembling the stiffness matrix
As pointed out in the previous Section, the stiffness matrix Ah can be decomposed
in a finite sum of the matrices Aτj for (j = 1, . . . , nt) in the triangulation Th =
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{τi}ti=1 (see (A.12) for further details). Therefore, the way to obtain a matrix Aτ
of the bilinear form aτ for an arbitrary tetrahedron τ ∈ Th is now outlined. To do
that, let us consider an arbitrary tetrahedron τ with vertices x1, x2, x3 and x4,
and the function v ∈ Vh restricted to τ . Let us also consider the corresponding
nodal basis functions ϕ1, ϕ2, ϕ3 and ϕ4 associated to these vertices. Thus, taking
into account that v is linear in τ , means that
v(x) =
4∑
i=1
v(xi)ϕi(x),
where by introducing the vector
v =

v(x1)
v(x2)
v(x3)
v(x4)
 (A.15)
and the mapping whose components are the nodal basis functions given by
ϕ̂(x) =

ϕ1(x)
ϕ2(x)
ϕ3(x)
ϕ4(x)
 , x ∈ τ,
then the function v(x) can be expressed as follows
v(x) = vT ϕ̂(x), x ∈ τ.
Therefore, in order to compute the integral of the bilinear form aτ (v, v) defined in
(A.10), the partial derivatives of v(x) = vTϕ(x) with respect to x, y and z should
be also computed, and these are
vx = v
T ϕ̂x, vy = v
T ϕ̂y, vz = v
T ϕ̂z, (A.16)
where
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ϕ̂x =

∂xϕ1
∂xϕ2
∂xϕ3
∂xϕ4
 , ϕ̂y =

∂yϕ1
∂yϕ2
∂yϕ3
∂yϕ4
 , ϕ̂z =

∂zϕ1
∂zϕ2
∂zϕ3
∂zϕ4
 .
Then, substituting (A.16) into the bilinear form aτ (v, v) in (A.10) gives the follow-
ing
aτ (v, v) =
∫
τ
((vT ϕ̂x)
2 + (vT ϕ̂y)
2 + (vT ϕ̂z)
2) dxdy dz. (A.17)
On the other hand, taking into account that for each point x ∈ τ the expression
(vT ϕ̂x) is a scalar value, then
vT ϕ̂x = (v
T ϕ̂x)
T = ϕ̂Tx v,
where in the last equality, the property that the transpose of a scalar value is equal
to itself has been used. Thus, the square of this last expression can be written as
follows
(vT ϕ̂x)
2 = (vT ϕ̂x)(ϕ̂
T
x v) = v
T ϕ̂xϕ̂
T
x v. (A.18)
Arguing similarly for the remaining terms under the integral sign in (A.17), then
aτ (v, v) = v
TEv, (A.19)
where the matrix E, which is usually known as the elementary matrix, is given by
E =
∫
τ
(
ϕ̂xϕ̂
T
x + ϕ̂yϕ̂
T
y + ϕ̂zϕ̂
T
z
)
dxdy dz. (A.20)
Notice that, for each tetrahedron τ ∈ Th there are only four nonzero nodal basis
functions, so the dimension of the matrix E is (4× 4). Observe also that
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E =

aτ (ϕ1, ϕ1) aτ (ϕ1, ϕ2) aτ (ϕ1, ϕ3) aτ (ϕ1, ϕ4)
aτ (ϕ2, ϕ1) aτ (ϕ2, ϕ2) aτ (ϕ2, ϕ3) aτ (ϕ2, ϕ4)
aτ (ϕ3, ϕ1) aτ (ϕ3, ϕ2) aτ (ϕ3, ϕ3) aτ (ϕ3, ϕ4)
aτ (ϕ4, ϕ1) aτ (ϕ4, ϕ2) aτ (ϕ4, ϕ3) aτ (ϕ4, ϕ4)
 , (A.21)
that is, the elements of the matrix E are the values of aτ in those basis functions
that are nonzero in the tetrahedron τ .
Indeed, the matrix E can be computed by a change of variables to the reference
tetrahedron τ0 (see Figure A.2), where τ0 is the unit tetrahedron defined by one
point in the origin and one on each coordinate axis in a cartesian grid at the
value one. This change of variables has been implemented by means of an affine
transformation Ψ.
⌘
⇣
⇠ x
y
z
 
⇠1
⇠2
⇠3
⇠4
x1
x2
x3
x4
⌧⌧0
Figure A.2. A schematic representation of an affine transformation Ψ which allows
to express an arbitrary tetrahedron τ with vertices x1, x2, x3 and x4 in the coordinate
system (x, y, z) (right) in terms of the reference tetrahedron τ0 with vertices ξ1, ξ2, ξ3
and ξ4 in the coordinate system (ξ, η, ζ) (left).
More precisely, let us consider the reference tetrahedron τ0, which is defined by
the following vertices ξ1, ξ2, ξ3 and ξ4 in the coordinate system (ξ, η, ζ) given by
ξ1 =

0
0
0
 , ξ2 =

1
0
0
 , ξ3 =

0
1
0
 , ξ4 =

0
0
1
 .
Then, the vertices x1, x2, x3 and x4 of an arbitrary tetrahedron τ can be obtained
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from the reference tetrahedron τ0 by means of the affine transformation Ψ(ξ) in
the following form
ξ 7→ x = Ψ(ξ) = x1 + [x2 − x1,x3 − x1,x4 − x1]ξ (A.22)
or expressed in terms of their components as follows
ξ =

ξ
η
ζ
 7→ x =

x
y
z
 =

x1
y1
z1
+

x2 − x1 x3 − x1 x4 − x1
y2 − y1 y3 − y1 y4 − y1
z2 − z1 z3 − z1 z4 − z1


ξ
η
ζ
 .
Notice that, the differential of Ψ(ξ) with respect to ξ is the constant square matrix
given by
DΨ =

xξ xη xζ
yξ yη yζ
zξ zη zζ
 =

x2 − x1 x3 − x1 x4 − x1
y2 − y1 y3 − y1 y4 − y1
z2 − z1 z3 − z1 z4 − z1
 ,
where hence the inverse matrix of DΨ is expressed as follows
DΨ−1 =

ξx ξy ξz
ηx ηy ηz
ζx ζy ζz
 ,
which is also constant. In particular, the entries of the matrix DΨ−1 are easily
computed by the Cramer’s rule. For instance, ξx =
(y3−y1)(z4−z1)−(z3−z1)(y4−y1)
J
,
where J = |DΨ| is the determinant of the Jacobian matrix given by
J = (x2 − x1)(y3 − y1)(z4 − z1) + (x3 − x1)(y4 − y1)(z2 − z1)+
(x4 − x1)(y2 − y1)(z3 − z1)− (x4 − x1)(y3 − y1)(z2 − z1)−
(x3 − x1)(y2 − y1)(z4 − z1)− (x2 − x1)(y4 − y1)(z3 − z1).
On the other hand, denoting by Ni(ξ) for (1 ≤ i ≤ 4) the nodal basis functions
on the coordinate system (ξ, η, ζ) for the reference tetrahedron τ0, and by N̂ the
following mapping
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N̂ (ξ) =

N1(ξ)
N2(ξ)
N3(ξ)
N4(ξ)
 , ξ ∈ τ0,
then, a simple calculation (recall the expression of the basis function in (A.7)–
(A.8)) provides that
N̂ (ξ) =

1− ξ − η − ζ
ξ
η
ζ
 . (A.23)
Moreover, the affine transformation Ψ(ξ) allows to express the nodal basis func-
tions ϕ̂(x) with respect to the reference tetrahedron τ0 as follows
ϕ̂(x) = N̂ (ξ) ◦Ψ−1, (A.24)
so that, applying the chain rule in (A.24), the differential of the nodal basis func-
tions ϕ̂(x) with respect to x can be written in the following form
ϕ̂x = N̂ξξx + N̂ηηx + N̂ζζx,
ϕ̂y = N̂ξξy + N̂ηηy + N̂ζζy,
ϕ̂z = N̂ξξz + N̂ηηz + N̂ζζz,
which implies that
ϕ̂xϕ̂
T
x = ξ
2
x(N̂ξN̂ Tξ ) + η2x(N̂ηN̂ Tη ) + ζ2x(N̂ζN̂ Tζ ) + ξxηx(N̂ξN̂ Tη +
N̂ηN̂ Tξ ) + ξxζx(N̂ξN̂ Tζ + N̂ζN̂ Tξ ) + ηxζx(N̂ηN̂ Tζ + N̂ζN̂ Tη ),
ϕ̂yϕ̂
T
y = ξ
2
y(N̂ξN̂ Tξ ) + η2y(N̂ηN̂ Tη ) + ζ2y (N̂ζN̂ Tζ ) + ξyηy(N̂ξN̂ Tη + (A.25)
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N̂ηN̂ Tξ ) + ξyζy(N̂ξN̂ Tζ + N̂ζN̂ Tξ ) + ηyζy(N̂ηN̂ Tζ + N̂ζN̂ Tη ),
ϕ̂zϕ̂
T
z = ξ
2
z (N̂ξN̂ Tξ ) + η2z(N̂ηN̂ Tη ) + ζ2z (N̂ζN̂ Tζ ) + ξzηz(N̂ξN̂ Tη +
N̂ηN̂ Tξ ) + ξzζz(N̂ξN̂ Tζ + N̂ζN̂ Tξ ) + ηzζz(N̂ηN̂ Tζ + N̂ζN̂ Tη ).
Notice that, N̂ξ, N̂η and N̂ζ are constant vectors obtained by deriving the expres-
sion (A.23) with respect to ξ, η and ζ respectively, which are as follows
N̂ξ =

−1
1
0
0
 , N̂η =

−1
0
1
0
 , N̂ζ =

−1
0
0
1
 .
Thus, expression (A.25) can be substituted into the bilinear form aτ (v, v) in (A.20),
which can be expressed in terms of the reference tetrahedron τ0 as follows
∫
τ
(
ϕ̂xϕ̂
T
x + ϕ̂yϕ̂
T
y + ϕ̂zϕ̂
T
z
)
dx =
c1
∫
τ0
N̂ξN̂ Tξ dξ + c2
∫
τ0
N̂ηN̂ Tη dξ + c3
∫
τ0
N̂ζN̂ Tζ dξ +
c4
∫
τ0
(N̂ξN̂ Tη + N̂ηN̂ Tξ ) dξ + (A.26)
c5
∫
τ0
(N̂ξN̂ Tζ + N̂ζN̂ Tξ ) dξ +
c6
∫
τ0
(N̂ηN̂ Tζ + N̂ζN̂ Tη ) dξ,
where the constants ci for (i = 1, . . . , 6) are given by
c1 = |J |(ξ2x + ξ2y + ξ2z ),
c2 = |J |(η2x + η2y + η2z),
c3 = |J |(ζ2x + ζ2y + ζ2z ),
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c4 = |J |(ξxηx + ξyηy + ξzηz),
c5 = |J |(ξxζx + ξyζy + ξzζz),
c6 = |J |(ζxηx + ζyηy + ζzηz)
and |J | is the absolute value of the determinant of the Jacobian matrix. Since N̂ξ,
N̂η and N̂ζ are constant vectors and the integral over τ0 of the constant function
one is the volume of τ0, which is equal to 1/6 (see [209] for further details), then
the integrals in the right hand of (A.26) denoted by S1, . . . , S6 respectively, are the
following
S1 =
∫
τ0
N̂ξN̂ Tξ dξ =
1
6
N̂ξN̂ Tξ ,
S2 =
∫
τ0
N̂ηN̂ Tη dξ =
1
6
N̂ηN̂ Tη ,
S3 =
∫
τ0
N̂ζN̂ Tζ dξ =
1
6
N̂ζN̂ Tζ ,
S4 =
∫
τ0
(N̂ξN̂ Tη + N̂ηN̂ Tξ ) dξ =
1
6
(N̂ξN̂ Tη + N̂ηN̂ Tξ ),
S5 =
∫
τ0
(N̂ξN̂ Tζ + N̂ζN̂ Tξ ) dξ =
1
6
(N̂ξN̂ Tζ + N̂ζN̂ Tξ ),
S6 =
∫
τ0
(N̂ηN̂ Tζ + N̂ζN̂ Tη ) dξ =
1
6
(N̂ηN̂ Tζ + N̂ζN̂ Tη ).
Therefore, the elementary matrix E can be computed by a linear combination of
the constants ci and matrices Si for (i = 1, . . . , 6) in the following form
E =
6∑
i=1
ciSi.
Finally, it should be noted that the matrix Aτ of an arbitrary tetrahedron τ ∈ Th
with vertices xi, xj, xk and xl can be obtained from the corresponding elementary
matrix E. Thus, the stiffness matrix Ah in (A.12) can be sequentially assem-
bled as a sum of the matrices Aτ of tetrahedrons τ ∈ Th. See Figure A.3 for a
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representation of the eventually nonzero elements of a matrix Aτ .
( )
i
i
j
j
k
k
l
l
Figure A.3. Representation of the eventually nonzero elements of the matrix Aτ ,
corresponding to the tetrahedron τ with vertices xi, xj , xk and xl.
A.6 Computation of integrals of a general non-
linear functional
Similarly to computations described in the previous Section, using the affine trans-
formation Ψ(ξ) in (A.22) and the nodal basis functions N̂ (ξ) in (A.23), the value
of the integral in (A.14) over an arbitrary tetrahedron τ ∈ Th can be computed
as an integral on the reference tetrahedron τ0 by means of the change of variables
given by
Fτ (v) =
∫
τ
f
(
vT ϕ̂(x)
)
dx = |J |
∫
τ0
f
(
vT N̂ (ξ)
)
dξ,
where |J | is the absolute value of the determinant of the Jacobian matrix.
However, quite frequently these integrals cannot be expressed in terms of elemen-
tary functions, so that, a quadrature formula (a method to approximate the value
of integrals) can be used to approximate their values [210], [211]. In this case,
a quadrature formula of s = 15 nodes [c1, . . . , cs] and the corresponding nonneg-
ative weights [w1, . . . , ws] to approximate the value of an integral
∫
τ0
g dξ, which
integrates exactly all polynomials of degree less than and equal to five, has been
considered. The values of the corresponding nodes and weights for this quadrature
formula are given in Table A.1.
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Therefore, by means of the quadrature formula described above, a definite integral
on the reference tetrahedron τ0 can be approximated in the following form
∫
τ0
g(ξ) dξ ≈
s∑
j=0
wjg(cj) = [w1, . . . , ws]

g(c1)
...
g(cs)
 .
Then, an approximation of the value of Fτ (v) can be obtained as follows
Fτ (v) ≈ |J |
s∑
i=1
wif
(
vT N̂ (ci)
)
. (A.27)
In particular, notice that the value of F (v) in (A.13) can be approximated by a
sum of the contributions of the tetrahedrons τ ∈ Th by means of the expression
(A.27).
A.7 Computation of the functional and con-
straints
The goal of this Section is to describe the discrete formulation of the variational
problem (2.6)–(2.11) in the finite dimensional function space Vh defined by piece-
wise linear continuous functions (the well-known Lagrange elements), where a tri-
angulation Th = {τi}nti=1 of the domain Ω ∈ R3 has been considered.
As before, the key idea is to express the integrals defined on Ω in terms of the
tetrahedrons of the triangulation Th. Let us begin denoting by T1 the first term
of the functional (2.6), which is given by
T1 ≡
∫
Ω
XΩiSFi(D(x)) dx =
∫
Ωi
(
e−αiD(x)−βiD(x)
2
)
dx.
Then, the value of T1 can be obtained by a finite sum of integrals over each
tetrahedron τ ⊂ Ωi, that is
150
T1 =
∑
τ⊂Ωi
∫
τ
e−αiD(x)−βiD(x)
2
dx =
∑
τ⊂Ωi
T1τ , (A.28)
where
T1τ =
∫
τ
e−αiD(x)−βiD(x)
2
dx. (A.29)
In a similar way, the second term of the functional (2.6) can be expressed as follows
T2 ≡
∫
Ωj
(
1− e−αjD(x)−βjD(x)2
)
dx =
∑
τ⊂Ωj
T2τ , (A.30)
where
T2τ =
∫
τ
(
1− e−αjD(x)−βjD(x)2
)
dx. (A.31)
On the other hand, it should be noted that the discrete formulation of the last
term of the functional (2.6) in the finite dimensional function space Vh has been
described in the previous Sections (see (A.11) in Section A.4 for further details).
Therefore, in order to obtain a whole discrete formulation of the problem (P)
defined by (2.6)–(2.11), the inequality constraints (2.10) and (2.11) should be
also expressed in the finite dimensional function space Vh. Similarly, the gradi-
ent vectors and Hessian matrices should be computed for the functional (2.6) and
constraints (2.7), (2.10) and (2.11) of the problem (P) to look for the minimizer
function through an optimization algorithm. In particular, the following Sections
are devoted to provide a detailed description of these issues. Finally, existence and
uniqueness properties of solutions of the problem (P) in the discrete formulation
are also discussed.
A.7.1 Computation of the gradient vector and Hessian ma-
trix of the nonlinear functional
To begin with, let τ ∈ Th be an arbitrary tetrahedron with vertices x1, x2, x3
and x4, and d ∈ Vh the linear function restricted to τ , which is expressed as
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d(x) = dT ϕ̂(x) for x ∈ τ , where d ∈ R4 is the vector whose components are the
values of the function d(x) at the vertices of τ , that is
d =

d(x1)
d(x2)
d(x3)
d(x4)
 .
Then, using the affine transformation Ψ(ξ) in (A.22), the integrals of T1τ in (A.29)
and T2τ in (A.31) can be expressed in terms of the reference tetrahedron τ0 on the
nodal basis functions N̂ (ξ) and approximated by means of the quadrature formula
as follows
T1τ ≈ |J |
s∑
k=1
wk e
−αi(dT N̂ (ck))−βi(dT N̂ (ck))2 ,
(A.32)
T2τ ≈ |J |
s∑
k=1
wk
(
1− e−αj(dT N̂ (ck))−βj(dT N̂ (ck))2
)
.
On the other hand, the gradient vector and Hessian matrix of T1 in (A.28) and T2
in (A.30) can be assembled from the first and the second derivatives of T1τ and
T2τ in (A.32) with respect to d for all tetrahedron τ ∈ Ωi and τ ∈ Ωj respectively.
In what follows, the expressions of such gradient vectors and Hessian matrices are
described.
The differential of T1τ with respect to d is given by
(T1τ )d = |J |
s∑
k=1
wk e
−αi(dT N̂ (ck))−βi(dT N̂ (ck))2
(
−αi − 2βi(dT N̂ (ck))
)
N̂ T (ck)
and similarly, the differential of T2τ can be expressed as follows
(T2τ )d = |J |
s∑
k=1
wk
(
1− e−αj(dT N̂ (ck))−βj(dT N̂ (ck))2
)(
αj + 2βj(d
T N̂ (ck))
)
N̂ T (ck).
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On the other hand, the Hessian matrix of T1τ and T2τ are given by
(T1τ )d,d = |J |
s∑
k=1
wk e
−αi(dT N̂ (ck))−βi(dT N̂ (ck))2
((
αi + 2βi(d
T N̂ (ck))
)2
− 2βi
)
N̂ (ck)N̂ T (ck)
and
(T2τ )d,d = |J |
s∑
k=1
wk
(
1− e−αj(dT N̂ (ck))−βj(dT N̂ (ck))2
)(
2βj −
(
αj + 2βj(d
T N̂ (ck))
)2)
N̂ (ck)N̂ T (ck).
To conclude this Section, observe that the gradient vector and Hessian matrix of
the last term in the functional (2.6) restricted to an arbitrary tetrahedron τ can
be easily obtained from (A.19) in Section A.5, which are respectively
(aτ (d, d))d = 2Aτd,
where Aτ = E, being E the matrix defined in (A.21), and
(aτ (d, d))d,d = 2Aτ .
A.7.2 The constraint on the gradient
The constraint on the gradient (2.7) should be also formulated in the finite di-
mensional function space Vh respect to every tetrahedron τ of the triangula-
tion Th. To do that, for an arbitrary tetrahedron τ ∈ Th, let us consider
the linear function d(x) = dT ϕ̂(x) for x ∈ τ , where as before d denotes the
vector d = [d(x1), d(x2), d(x3), d(x4)]
T ∈ R4 and ϕ̂ the mapping whose com-
ponents are the nodal basis functions associated to the vertices of τ , that is,
ϕ̂(x) = [ϕ1(x), ϕ2(x), ϕ3(x), ϕ4(x)]
T . Then, the constraint (2.7) can be written
as follows
|∇d(x)| ≤ C1 ⇒
√
(dT ϕ̂x(x))2 + (d
T ϕ̂y(x))2 + (d
T ϕ̂z(x))2 ≤ C1,
where using the property (A.18) in Section A.5 can be expressed in the following
form
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dT (ϕ̂xϕ̂
T
x + ϕ̂yϕ̂
T
y + ϕ̂zϕ̂
T
z )d ≤ C21 , (A.33)
which can be easily computed by means of the affine transformation Ψ(ξ) in (A.22)
to the reference tetrahedron τ0 in the nodal basis functions N̂ (ξ) in (A.23).
Then, the gradient vector is the first derivative of inequality (A.33) with respect
to d and given by
2(ϕ̂xϕ̂
T
x + ϕ̂yϕ̂
T
y + ϕ̂zϕ̂
T
z )d,
where hence the Hessian matrix is the second derivative of (A.33) and defined as
follows
2(ϕ̂xϕ̂
T
x + ϕ̂yϕ̂
T
y + ϕ̂zϕ̂
T
z ).
A.7.3 The volumetric constraints
In particular, this Section is devoted to present the discretization in the finite di-
mensional function space Vh, as well as the procedure to compute the gradient vec-
tor and Hessian matrix, of the volumetric constraints (2.10)–(2.11). As described
before, the gradient vector and Hessian matrix are assembled from the contribu-
tions of the tetrahedrons τ in the triangulation Th. For the sake of simplicity, let
us only consider the volumetric constraint (2.10) given by
|{x ∈ Ωi : D(x) > CVi}| ≥ δi|Ωi|, (A.34)
where it should be noted that the arguments presented in this Section can be
similarly used for the volumetric constraint (2.11).
As a matter of fact, the volumetric constraint (A.34) can be interpreted as the
portion of the volume |Ωi| that receives a radiation dose higher than CVi must be
at least the δi percent of the total volume |Ωi| for (0 ≤ δi ≤ 1). Therefore, the
volume |Ωi| and the portion of |Ωi| that receives a radiation dose higher than CVi
(denoted in what follows as |Ω̂i|) should be computed.
The volume |Ωi| can be computed by the finite sum of the volume of the tetra-
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hedrons in Ωi. Thus, for an arbitrary tetrahedron τ ∈ Ωi in the triangulation Th
with vertices x1, x2, x3 and x4, the volume |τ | can be computed by means of the
determinant of the matrix, whose columns are x2 − x1, x3 − x1 and x4 − x1, and
denoted by [x2 − x1,x3 − x1,x4 − x1], as follows
|τ | = |det([x2 − x1,x3 − x1,x4 − x1])|
6
.
In a similar way, the volume |Ω̂i| can be computed by the finite sum of the portions
of the volume that receive a radiation dose higher than CVi of the tetrahedrons
in Ωi. To do that, let us take the same arbitrary tetrahedron τ ∈ Ωi defined
above, and let d(x) = dT ϕ̂(x) be a linear function in τ , and d = [d1, d2, d3, d4]
T be
the constant vector whose components are the values of the radiation dose in the
vertices of τ , that is, di = d(xi) for (1 ≤ i ≤ 4). Then, the following four general
cases in terms of the radiation dose in the vertices of τ can be considered:
1. No vertex of τ receives a radiation dose higher than CVi .
2. Every vertex of τ receives a radiation dose higher than CVi .
3. Only one vertex (respectively, the opposite three vertices) of τ receives a
radiation dose higher than CVi (see Figure A.4).
4. Exactly two vertices (respectively, the opposite two vertices) of τ receive a
radiation dose higher than CVi (see Figure A.5).
In the first case, the portion of τ that receives a radiation dose higher than CVi is
equal to zero, while in the second case is the total volume, |τ |. Since that in both
cases the radiation dose in all vertices is higher or lower than CVi respectively, the
contribution of this tetrahedron τ to the gradient vector and Hessian matrix of the
volumetric constraint (A.34) is zero.
Let us now consider the third case, where only one vertex of a tetrahedron τ
receives a radiation dose higher than CVi , say for instance x1. Then, the portion of
τ that receives a radiation dose higher than CVi is the volume of the tetrahedron
with vertices x1, p12, p13 and p14 (see Figure A.6), where p12, p13 and p14 are the
points on the edges between x1 and the remaining three vertices respectively, for
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Figure A.4. Representation of the possible combinations where only one vertex (re-
spectively, the opposite three vertices) of τ receives a radiation dose higher than CVi .
Notice that, in the points pij for (1 ≤ i, j ≤ 4 and i 6= j) the radiation doses are equal
to CVi .
p12
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p13 p13
p14 p14
p23
p23
p24 p24
p34 p34
x1 x1 x1
x2 x2 x2
x3 x3 x3
x4
x4 x4
Figure A.5. Representation of the possible combinations where exactly two vertices
(respectively, the opposite two vertices) of τ receive a radiation dose higher than CVi .
Notice that, in the points pij for (1 ≤ i, j ≤ 4 and i 6= j) the radiation doses are equal
to CVi .
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which the radiation doses are equal to CVi . Observe that, the equations of these
points are given by
p12 = x1 +
CVi − d1
d2 − d1 (x2 − x1),
p13 = x1 +
CVi − d1
d3 − d1 (x3 − x1),
p14 = x1 +
CVi − d1
d4 − d1 (x4 − x1),
where, for instance, the equation of the point p12 ∈ [x1,x2] is obtained as follows.
Let x = x1 + t(x2 − x1) be the parametric equation of the line passing through
points x1 and x2, where d2 ≤ CVi < d1. Then, the radiation dose in the line [x1,x2]
is equal to CVi when d1 + t(d2 − d1) = CVi holds, which implies that the value of
the parameter t is
CVi−d1
d2−d1 . Then, p12 = x1 +
CVi−d1
d2−d1 (x2 − x1). Notice that, the
equations of p13 and p14 are obtained in a similar way.
Therefore, the contribution to |Ω̂i| of the tetrahedron τ is computed as follows
Vc ≡ |(p12−x1) (p13−x1) (p14−x1)|6 =
(
CVi−d1
d2−d1
)
·
(
CVi−d1
d3−d1
)
·
(
CVi−d1
d4−d1
)
· |τ |, (A.35)
where Vc is the volume of the tetrahedron with vertices x1, p12, p13 and p14.
Analogously, if the vertices x2, x3 and x4 receive a radiation dose higher than CVi
and x1 less than CVi , the portion of the volume |τ | that receives a radiation dose
higher than CVi is given by (|τ | − Vc) (see Figure A.6).
The next step is to describe the form of the gradient vector restricted to an arbi-
trary tetrahedron τ , which satisfies the third case stated above. To obtain it, the
first derivative of equation (A.35) with respect to d should be computed, which is
given by
∂d1 (Vc) = |τ | ·
(
1
CVi − d1
)
·
[(
CVi − d2
d2 − d1
)
+
(
CVi − d3
d2 − d1
)
+
(
CVi − d4
d2 − d1
)]
,
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Figure A.6. Representation of the combination where only the node x1 receives a
radiation dose higher than CVi , or the vertices x2, x3 and x4 receive a radiation dose
higher than CVi and x1 less than CVi . Notice that, in the points pij for (i = 1 and j =
2, 3, 4) the radiation doses are equal to CVi .
∂d2 (Vc) = |τ | ·
(
1
CVi − d1
)
·
(
−CVi − d1
d2 − d1
)
,
∂d3 (Vc) = |τ | ·
(
1
CVi − d1
)
·
(
−CVi − d1
d3 − d1
)
,
∂d4 (Vc) = |τ | ·
(
1
CVi − d1
)
·
(
−CVi − d1
d4 − d1
)
.
Notice that, the Hessian matrix can be easily obtained from the second derivative
of equation (A.35) with respect to d. In summary, for any other combination of
vertices as shown in Figure A.4, the calculation of the portion of the volume |τ |
that receives a radiation dose higher than CVi , as well as the gradient vector and
Hessian matrix, can be obtained in a similar way.
Finally, let us consider the last case where exactly two vertices of τ receive a
radiation dose higher than CVi , for instance x1 and x2 (see Figure A.7). Then,
the portion of the volume |τ | that receives a radiation dose higher than CVi is
the volume of the polyhedron given by x1, x2, p13, p14, p23 and p24, where p13,
p14, p23 and p24 are the points on the edges between vertices x1, x2 and x3, x4
respectively, for which the radiation dose is equal to CVi . Notice that, the volume
of this polyhedron can be computed by the sum of the volume of the following three
tetrahedrons with vertices x2, p14, p23 and p24; x1, x2, p14 and p23; and x1, p13,
p14 and p23 respectively (see Figure A.7). Therefore, in this case the contribution
to |Ω̂i| of the tetrahedron τ can be computed as follows
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( |(p14 − x2) (p23 − x2) (p24 − x2)|
6
)
+
( |(x2 − x1) (p14 − x1) (p23 − x1)|
6
)
+
( |(p13 − x1) (p14 − x1) (p23 − x1)|
6
)
, (A.36)
where
p13 = x1 +
CVi −D1
D3 −D1 (x3 − x1),
p14 = x1 +
CVi −D1
D4 −D1 (x4 − x1),
p23 = x2 +
CVi −D2
D3 −D2 (x3 − x2),
p24 = x2 +
CVi −D2
D4 −D3 (x4 − x3).
x
y
z
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p24
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Figure A.7. Representation of the combination where exactly two vertices x1 and
x2 receive a radiation dose higher than CVi . Notice that, in the points pij for (i =
1, 2 and j = 3, 4) the radiation doses are equal to CVi and the polyhedron with vertices
x1, x2, p13, p14, p23 and p24 can be divided in the following three tetrahedrons with
vertices x2, p14, p23 and p24; x1, x2, p14 and p23; and x1, p13, p14 and p23.
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To conclude, observe that the gradient vector and Hessian matrix for this case
can be computed from equation (A.36) in a similar way as that discussed for the
previous case. In particular, notice that for any other combination of this case as
shown in Figure A.5 the calculations are similar.
A.7.4 Existence and uniqueness of solutions in the finite
dimensional function space
Let us take the positive radiosensitivity parameters (α, β) of the LQ model de-
scribed in Chapter 1 and the function f(d(x)) defined as follows
f(d(x)) = e−αd(x)−βd(x)
2
.
Then, it is easy to check that f(d(x)) is a strictly convex function in the interval
C2 ≤ d(x) ≤ C3,
if the following condition is satisfied
C2 >
(
− α
2β
+
√
1
2β
)
, (A.37)
and the function (1− f(d(x))) is also strictly convex if, on the contrary,
C3 <
(
− α
2β
+
√
1
2β
)
. (A.38)
See the proof of Theorem 3 in Chapter 2 for further details.
Therefore, by means of the affine transformation Ψ(ξ) in (A.22) the linear function
d ∈ Vh in an arbitrary tetrahedron τ ∈ Th with vertices x1, x2, x3 and x4 can be
expressed in the reference tetrahedron τ0 as follows
d(x) = dT N̂ (ξ), x ∈ τ, ξ ∈ τ0,
where d = [d(x1), d(x2), d(x3), d(x4)]
T ∈ R4 and the components of N̂ (ξ) are the
nodal basis functions on τ0 given by
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N (ξ) =

1− ξ − η − ζ
ξ
η
ζ
 , ξ =

ξ
η
ζ
 ∈ τ0,
so that, the components of the constant vector d are the values of d ∈ Vh at the
vertices of τ0.
Let us now consider the nonnegative weights [w1, . . . , ws] of a quadrature formula
based on s nodes [c1, . . . , cs], which is assumed to integrate exactly all polynomials
of degree at least two (see Table A.1 in Section A.6). Then, it is possible to prove
that the expression
I(d(x)) =
s∑
i=1
wif(d
T N̂ (ci)), (A.39)
which is an approximation of the integral∫
τ0
f(dT N̂ (ξ)) dξ,
is a convex function of d if condition (A.37) holds, which is particularly satisfied if
d(x1), d(x2), d(x3), d(x4) >
(
− α
2β
+
√
1
2β
)
.
In addition, notice that the arguments developed below can also be used to show
that
1− I(d(x)) =
s∑
i=1
wi
(
1− f(dT N̂ (ci))
)
is convex if condition (A.38) holds.
In order to prove these results, the differential
(
f(dTN)
)
d
of f(dTN) with respect
to d should be computed, where the vector N represents any of the vectors N̂ (ci)
for (i = 1, . . . , s). Thus, applying the chain rule, then
(
f(dTN)
)
d
= f(dTN)
(−α− 2β(dTN)) (dTN)
d
,
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where
(
dTN
)
d
is the differential of
(
dTN
)
with respect to d, which is given by
(
dTN
)
d
= NT .
Therefore, the differential
(
f(dTN)
)
d
is obtained as follows
(
f(dTN)
)
d
= f(dTN)
(−α− 2β(dTN))NT
and the Hessian is expressed in the following form
f(dTN)
((
α + 2β(dTN)
)2 − 2β)NNT .
Since f(dTN) = e(−α(d
TN)−β(dTN)2) > 0 and (NNT ) is a rank one positive semidef-
inite matrix, then Hessian of f(dTN) is positive semidefinite if
(
α + 2β(dTN)
)2 − 2β > 0,
which holds if (A.37) is satisfied.
Therefore, the Hessian of I(d(x)), which is given by
(I(d(x)))d,d =
s∑
i=1
wif(d
T N̂ (ci))
((
α + 2β(dT N̂ (ci))
)2
− 2β
)
N̂ (ci) N̂ (ci)T , (A.40)
is positive definite if for every vector v ∈ R4 with v 6= 0, then
vT
(
s∑
i=1
wif(d
T N̂ (ci))
((
α + 2β(dT N̂ (ci))
)2
− 2β
)
N̂ (ci) N̂ (ci)T
)
v > 0,
that is, if
s∑
i=1
wif(d
T N̂ (ci))
((
α + 2β(dT N̂ (ci))
)2
− 2β
)(
vT N̂ (ci)
)2
> 0,
where
(
vT N̂ (ci)
)2
= vT
(
N̂ (ci) N̂ (ci)T
)
v (see equation (A.18) for further de-
tails).
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Therefore, as argued before, if (A.37) holds then
(
α + 2β(dT N̂ (ci))
)2
−2β > 0, so
that, vT
(
(I(d(x)))d,d
)
v ≥ 0. Then, vT
(
(I(d(x)))d,d
)
v = 0, which implies that
(
vT N̂ (ci)
)2
= 0, i = 1, . . . , s
and
s∑
i=1
wi
(
vT N̂ (ci)
)2
= 0. (A.41)
But since that, the quadrature formula considered integrates exactly all polyno-
mials of degree at least two, then the expression on the left-hand side of (A.41)
coincides with ∫
τ0
(
vT N̂ (ξ)
)2
dξ,
where this integral can only be zero if and only if vT N̂ (ξ) = 0 for all ξ ∈ τ0, which
being vT N̂ (ξ) = 0 a linear function of ξ can only hold if v = 0. Thus, the Hessian
(I(d(x)))d,d (A.40) is positive definite and the function I(d(x)) (A.39) is convex.
To conclude this Section, it should be noted that the last term of the functional
(2.6) is not strictly convex, because the second derivative is equal to zero for
constant functions. However, the sum of all terms of such functional is strictly
convex, due to its nonlinear terms are strictly convex as described above.
A.7.5 Computational implementation
Before concluding this Appendix, some comments on the programming routines are
appropriate. It should be noted that errors in the implementation of subroutines
involving the gradient and the Hessian of objective functions are common and often
difficult to detect. Therefore, it is essential to check these routines before applying
optimization algorithms. For this purpose, a test has been developed using the
Taylor expansion to check the implementation of the gradient and the Hessian of
the functional and constraints involved in the problem (P).
In order to briefly explain this procedure, let us consider a Taylor expansion of a
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function f(x) : Rn → R around a given point x0 ∈ Rn, which is formulated at
x0 + x1 for  > 0 and x1 ∈ Rn, that is
f(x0 + x1) = f(x0) + g(x0)
Tx1 +
(
2
2
)
xT1H(x0)x1 +O(
3)
where g and H are the gradient and the Hessian, respectively. Notice that, if
only the gradient is tested, the second-order Taylor term is set to zero, and the
truncation error is O(2).
This test was performed by computing the Taylor approximation at smaller and
smaller values of  and checking whether the truncation errors are as expected,
O(2) and O(3) if the approximation is correct up to the gradient and the Hessian
terms, respectively. Then, for the ith step, 
i
=
i−1
10
is taken, and to verify if indeed
the truncation errors decrease as they should (in order 10−2 for the gradient and
10−3 for the Hessian). Observe that the truncation error for the ith step is given
by ∣∣∣∣f(x0 + i x1)− f(x0)− i g(x0)Tx1 − (2i2
)
xT1H(x0)x1
∣∣∣∣ .
Notice that a small error in the code of these subroutines would produce much
different values in the truncation errors. In particular, this test is useful to detect
errors that are common in the implementation and very difficult to detect without
this procedure.
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AppendixB
Computer simulations for minimizers
of a constrained optimization
problem
B.1 Comparison with a clinical case: additional
results
In this Appendix different computer simulations as a complement to the results
discussed in Chapter 2 are described.
To begin with, dose volume histograms (DVHs) for different values of the radiosen-
sitivity parameter α for the case considered in Section 2.5 are provided. More
precisely, DVHs for numerical simulations where w1 = wj = 1 (see Figure B.1),
and w1 = 10 and wj = 1 (see Figure B.2) for (2 ≤ j ≤ m + 1) in the functional
(2.6) are presented. The remaining parameters are selected as described in Tables
2.2 and 2.4 in Chapter 2 respectively (see Sections 2.5.3 and 2.5.5).
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Figure B.1. From top to bottom dose volume histograms (DVHs) for each OAR,
healthy tissue (Brain tissue) and the PTV corresponding to numerical simulations of the
case w1 = wj = 1 (2 ≤ j ≤ m+ 1) for α = 0.95Gy−1, α = 0.55Gy−1 and α = 0.10Gy−1
respectively.
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Figure B.2. From top to bottom dose volume histograms (DVHs) for each OAR,
healthy tissue (Brain tissue) and the PTV corresponding to numerical simulations of
the case w1 = 10 and wj = 1 (2 ≤ j ≤ m + 1) for α = 0.95Gy−1, α = 0.55Gy−1 and
α = 0.10Gy−1 respectively.
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An inspection of Figures B.1 and B.2 reveals the dependence of the model mini-
mizers with respect to parameters w1 and α. As described in Chapter 2 and shown
in Figure B.1 for the case w1 = wj = 1 with (2 ≤ j ≤ m + 1) the minimizer
provides in all cases low radiation doses on the organs at risk (OARs) and healthy
tissue (Brain tissue), but also low radiation dose conformation for the isodose cor-
responding to 95% of the prescription dose on the planning target volume (PTV),
than that obtained with the applied treatment plan (see Table 2.2 in Chapter 2).
On the other hand, when the weight corresponding to the PTV dosimetry increases
(say, when w1 = 10 and wj = 1 for (2 ≤ j ≤ m + 1)) the radiation coverage on
the tumor also increases, and so does the radiation doses delivered to OARs and
healthy tissue (HT). However, in all cases the maximum radiation dose on the
OARs and HT is lower than that delivered with the applied treatment plan (see
Figure B.2 and Table 2.4 in Chapter 2). Moreover, for all values of the parameter
α considered the coverage of the PTV is also better. Therefore, these simulations
support the strategy suggested in Section 2.5 to select an optimal radiation dose
distribution as a standard for comparison with radiotherapy tentative treatment
plans.
B.2 Description of results for different clinical
cases
To continue, numerical simulations corresponding to the remaining nine clinical
cases included in this study of patients diagnosed with centrally-located brain tu-
mors (Meningioma) are provided, of which a single case has been discussed in
detail in Chapter 2. These will be referred to as Case 2 to 10 in the sequel. All
of them were treated in the same Hospital and treatment planning system (TPS)
with Intensity Modulated Radiation Therapy (IMRT). For any of them a total pre-
scription dose of 50.4Gy, scheduled in 28 daily sessions, 5 days a week, of 1.8Gy
with weekend interruptions, was planned and delivered. For any patient a recon-
struction of the PTV and OARs, drawn from the TPS used during the treatment
planning process is provided. Furthermore, DVHs corresponding respectively to
i) the radiation dose distribution actually applied and ii) that corresponding to
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one minimizer obtained as described in Sections 2.3 and 2.5 are given. Concerning
the latter, parameters are selected as follows: w1 = 10 for the PTV dosimetry,
wj = 1 with (2 ≤ j ≤ m + 1) for OARs and HT (Brain tissue) terms in (2.6),
set α/β = 3.7Gy as before and then pick α = 0.55Gy−1. As to the bounds (2.7)
and (2.8), (2.7) is selected as in the case considered in Section 2.5, and values
C2 = 0.0Gy, C3 = 1.8Gy in (2.8) are also taken in agreement with clinical require-
ments. For simplicity, only solutions to (2.6)-(2.8) are considered.
A description of the clinical cases considered is provided below. Notice that all
studies made share some common properties. In particular, the Homogeneity Index
(HI) (see equation (2.2) in Chapter 2) of the proposed minimizers is always equal to
one (the optimal homogeneity case on the PTV), whereas for most of the actually
applied treatments the corresponding value is different from one. On the other
hand, the portion of the PTV receiving the prescribed radiation dose (1.8Gy)
and the value of the Conformity Index (CI) (see equation (2.3) in Chapter 2) for
the isodose corresponding to 95% of the prescription radiation dose on the PTV
are always better or equal for the proposed minimizer when compared with the
applied treatments. Finally, such minimizers always induce lower side effects on
OARs than the applied treatments considered (see Tables and Figures below).
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CASE 2:
Figure B.3. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
Figure B.4. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.5. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.6. Dose volume histograms (DVHs) of the applied (left) and minimizer (right)
radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the PTV.
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Parameter Applied Minimizer
PTVDM 1.86Gy 1.80Gy
DPTV 100% 1.5524Gy 1.6389Gy
PTVDp 71.58% 91.88%
CIDp95% 0.97 0.98
Brain Tissue* 1.8143Gy 1.6832Gy
Cochlea (Left)* 1.5226Gy 1.3015Gy
Brain Stem* 1.5524Gy 1.2874Gy
VII* 1.5337Gy 1.3570Gy
Trigeminal Nerve (Left)* 1.6173Gy 1.2932Gy
Table B.1. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
CASE 3:
Figure B.7. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
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Figure B.8. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.9. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.10. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
Parameter Applied Minimizer
PTVDM 1.90Gy 1.80Gy
DPTV 100% 1.6626Gy 1.6274Gy
PTVDp 78.68% 92.14%
CIDp95% 0.98 0.98
Brain Tissue* 1.8876Gy 1.7094Gy
Hypophysis* 1.5043Gy 1.4479Gy
Optic Nerve (Left)* 1.7583Gy 1.4256Gy
Optic Chiasm* 1.4748Gy 1.3813Gy
Table B.2. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
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CASE 4:
Figure B.11. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
Figure B.12. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.13. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.14. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
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Parameter Applied Minimizer
PTVDM 1.80Gy 1.80Gy
DPTV 100% 1.6334Gy 1.6489Gy
PTVDp 2.56% 92.18%
CIDp95% 0.95 0.98
Brain Tissue* 1.7782Gy 1.6651Gy
VII-VIII (Right)* 1.7452Gy 1.4580Gy
Cochlea (Right)* 1.4682Gy 1.3813Gy
Trigeminal Nerve (Right)* 1.7168Gy 1.3975Gy
Brain Stem* 1.6885Gy 1.3203Gy
Table B.3. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
CASE 5:
Figure B.15. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
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Figure B.16. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.17. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.18. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
Parameter Applied Minimizer
PTVDM 1.75Gy 1.80Gy
DPTV 100% 1.6948Gy 1.6570Gy
PTVDp 0% 94.69%
CIDp95% 0.98 0.99
Brain Tissue* 1.7402Gy 1.6651Gy
Brain Stem* 1.6871Gy 1.3146Gy
Optic Chiasm* 1.7148Gy 1.2951Gy
Cochlea (Left)* 1.6754Gy 1.2730Gy
VII-VIII* 1.7056Gy 1.3976Gy
Optic Tract (Left)* 1.7202Gy 1.4299Gy
Optic Tract (Right)* 1.6995Gy 1.2817Gy
Table B.4. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
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CASE 6:
Figure B.19. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
Figure B.20. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.21. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.22. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
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Parameter Applied Minimizer
PTVDM 1.81Gy 1.80Gy
DPTV 100% 1.6226Gy 1.6108Gy
PTVDp 6.45% 88.69%
CIDp95% 0.97 0.98
Brain Tissue* 1.8049Gy 1.6832Gy
Brain Stem* 1.7037Gy 1.3942Gy
Optic Nerve (Left)* 1.6409Gy 1.3789Gy
Hypothalamus* 1.5879Gy 1.4437Gy
Optic Chiasm* 1.7337Gy 1.5022Gy
Trigeminal Nerve (Left)* 1.7967Gy 1.4218Gy
Hypophysis* 1.7767Gy 1.4037Gy
Table B.5. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
CASE 7:
Figure B.23. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
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Figure B.24. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.25. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.26. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
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Parameter Applied Minimizer
PTVDM 1.76Gy 1.80Gy
DPTV 100% 1.6814Gy 1.6733Gy
PTVDp 0% 92.47%
CIDp95% 0.96 0.99
Brain Tissue* 1.7323Gy 1.6852Gy
Brain Stem* 1.5563Gy 1.3842Gy
Optic Nerve (Right)* 1.5909Gy 1.2946Gy
Hypothalamus* 1.5632Gy 1.3489Gy
Hypophysis* 1.6439Gy 1.3955Gy
Optic Chiasm* 1.5748Gy 1.4437Gy
Trigeminal Nerve (Right)* 1.6616Gy 1.3651Gy
Optic Tract (Right)* 1.7146Gy 1.5928Gy
Table B.6. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
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CASE 8:
Figure B.27. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
Figure B.28. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.29. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.30. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
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Parameter Applied Minimizer
PTVDM 1.77Gy 1.80Gy
DPTV 100% 1.6865Gy 1.6651Gy
PTVDp 0% 96.36%
CIDp95% 0.96 0.99
Brain Tissue* 1.7402Gy 1.6832Gy
Optic Nerve (Right)* 1.7165Gy 1.4261Gy
Hypophysis* 1.6808Gy 1.3789Gy
Optic Chiasm* 1.6271Gy 1.3560Gy
V* 1.7344Gy 1.3994Gy
Lacrimal Gland (Right)* 1.6794Gy 1.2823Gy
Retina (Right)* 1.6629Gy 1.3441Gy
Table B.7. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
CASE 9:
Figure B.31. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
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Figure B.32. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.33. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.34. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
Parameter Applied Minimizer
PTVDM 1.84Gy 1.80Gy
DPTV 100% 1.6657Gy 1.6109Gy
PTVDp 19.93% 93.87%
CIDp95% 0.97 0.98
Brain Tissue* 1.7952Gy 1.6571Gy
Brain Stem* 1.7212Gy 1.3813Gy
Optic Nerve (Left)* 1.6671Gy 1.3894Gy
Hypothalamus* 1.6983Gy 1.3670Gy
Optic Chiasm* 1.7135Gy 1.4399Gy
Cochlea (Left)* 1.6876Gy 1.4157Gy
Table B.8. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
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CASE 10:
Figure B.35. From left to right a three-dimensional domain reconstruction for the case
considered, the three-dimensional Delaunay triangulation created over the whole domain
of simulation, and the representation of the PTV and OARs involved.
Figure B.36. Three-dimensional reconstruction of the PTV and OARs involved. Notice
that the PTV is represented in red.
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Figure B.37. A comparison of the applied radiation dose distribution (left) and the
minimizer radiation dose distribution (right). From left to right the radiation dose
distributions (3D) over the PTV and OARs.
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Figure B.38. Dose volume histograms (DVHs) of the applied (left) and minimizer
(right) radiation dose distributions for each OAR, healthy tissue (Brain tissue) and the
PTV.
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Parameter Applied Minimizer
PTVDM 1.80Gy 1.80Gy
DPTV 100% 1.6954Gy 1.6128Gy
PTVDp 0% 92.14%
CIDp95% 0.99 0.98
Brain Tissue* 1.7767Gy 1.6433Gy
Optic Nerve (Left)* 1.7687Gy 1.4394Gy
Optic Chiasm* 1.7246Gy 1.4189Gy
Hypophysis* 1.7507Gy 1.3624Gy
Table B.9. A comparison of the applied radiation dose distribution (second column)
and the minimizer radiation dose distribution (third column). (PTVDM ) Maximum
radiation dose received by the PTV. (DPTV 100%) Maximum radiation dose received at
least by 100% of the PTV. (PTVDp) Percentage of the PTV receiving the prescribed
radiation dose (1.8Gy). (CIDp95%) Conformity Index (CI) for the isodose corresponding
to 95% of the prescription radiation dose on the PTV. (*) Maximum radiation dose
received by the OARs considered.
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AppendixC
Model of tumor growth and
radiotherapy treatments: details of
computer simulations and additional
results
C.1 Details of computer simulations
In this Section, details of computer simulations of the model of tumor growth and
radiotherapy treatments considered in Chapter 3 are described. Moreover, the
flowchart of a cell in the model of tumor growth and the pseudo-code guidelines of
the algorithm implemented are also provided.
C.1.1 Cell processes and model parameters
In Chapter 3 a three-dimensional (3D) cellular automata (CA) model for tumor
growth has been developed, where each cell is considered as an individual agent
(cf. for instance [144], [191] and [192]). For computer simulations of the model
of tumor growth, a three-dimensional Voronoi tessellation is implemented, where
each lattice point will host only one cell at any time. The construction points
of the Voronoi tessellation are defined by first generating a regular cubic lattice
with lattice constant a, and then placing exactly one point at an arbitrary position
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within each cube of that lattice (resulting in an unstructured lattice with no rota-
tional or translational symmetry, thus avoiding symmetry artifacts). Constant a
is chosen such that the average volume of a Voronoi cell, E[V ] = a3, corresponds
to that of a biological cell, V = (pi/6)d3. In this work the average cell diameter
d will be assumed equal to 20µm (i.e. a = (pi/6)1/3 d = 16.12µm). Thus, the
domain of computer simulations is divided into 200 × 200 × 200 lattice points,
which corresponds to a total volume of about 33.51mm3. Actually, the modeling
framework selected permits simulations to be scaled up to cubic centimeter sizes,
though at the expense of lower spatial and functional resolution. Alternatively,
hybrid models might be used, zooming in at the cell scale in regions of interest.
However, a CA model representing each cell individually has been chosen to bet-
ter understand the relation between tumor heterogeneity and simulated radiation
treatment outcomes.
This model accounts for heterogeneous tumor growth. Specifically, two different
tumor cell phenotypes (called, cancer cell (CC) and cancer stem cell (CSC)), which
have markedly different biological and radiobiological properties, are allowed to
coexist. The initial configuration of computer simulations is composed by 105
cells, out of which approximately 85% are CCs and 15% are CSCs. Tumor growth
is kept track of until a size of about 106 cells is reached. At this time, the impact
of different (homogeneous and heterogeneous) radiation therapies is simulated and
discussed. In the case of tumor recurrence after radiation therapy, regrowth is
allowed until a size of about 106 cells is attained, and then computer simulations
are stopped.
The cell processes considered in the model of tumor growth are summarized as
follows:
◦ Cell Division (symmetric or asymmetric): Cell replication on the lattice
depends on the doubling time of the tumor cell phenotypes involved (τ). In the
multi-cellular model the cell cycle is mimicked by a chain of Poisson processes.
A Poisson process implies exponentially distributed waiting times. Moreover, a
chain of m consecutive Poisson processes leads to an Erlang-distributed waiting
time of the whole chain [213]. The integer parameter m determines the sharpness
of the distribution around the average waiting time. This enables the model to
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capture a variety of different cell cycle time distribution shapes from exponentially
distributed cell cycle times (m = 1) to very sharp Erlang-distributed cell cycle
times (m → ∞). In this case, the cell cycle is modeled as such a chain of 4
consecutive cell cycle phases (G1, S, G2 and M) which themselves are subdivided
into a number of subprocesses (mG1, mS, mG2, mM). Each of the cell cycle phases
has an average duration (τG1, τS, τG2, τM). This construction permits to control the
average duration τp as well as the sharpness of the distribution of τp for each phase
p individually (see Figure C.1). Beginning in cycle step i = 1, a cell progresses in
the cell cycle from i to i + 1 with rate mp/τp, where p is the associated cell cycle
phase. When i = mG1 +mS +mG2 +mM , the cell divides and both daughter cells
reenter in the cell cycle with i = 1.
In the proposed model of tumor growth, division of CCs is always supposed to
be symmetric giving two identical daughter cells and with a limited replication
capability. However, CSCs will be assumed to sustain either symmetric or asym-
metric division, in which case one CSC and one CC will result from replication.
Proliferation is only possible for cells located at a point having at least one free
neighbor in the lattice (which is randomly chosen for replication). During cell
division, the daughter cell is placed on this randomly selected free neighbor site.
A cell with no free neighbors temporarily loses its ability to divide and becomes
quiescent due to contact inhibition. The quiescence state is abandoned as soon as
one of the surrounding lattice points becomes free. The duration of cell cycle for
CCs is assumed to be significantly shorter than that of CSCs (see Table 3.1).
◦ Migration: In this work, both tumor cell phenotypes considered are able to
move to a randomly chosen free neighbor site with same (hopping) rate kmig.
Indeed, two different migration rates have been considered, a comparatively low
rate obtained from the cell diffusion constant (cf. for instance [144] and [214])
and a higher rate as estimated in vitro in [111] for a Glioblastoma Multiforme
(GBM) cell line (see Table 3.1). The cell diffusion rate is estimated as D =
6.5 × 10−11 cm2/s − 4.7 × 10−12 cm2/s (see Table of parameters in [144]). The
diffusion coefficient depends on the properties of the cell and the surrounding
media. Since D = l2λ (λ = hopping rate = kmig) and l the hopping distance (=
cell diameter), then considering a cell diameter of 20µm, this implies that λ =
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D/l2 = D ·2.5×105 cm2 = 2.5×10−7 s−1−1.5×10−5 s−1 = 0.009 h−1−0.054 h−1.
Therefore, for the low migration case, a kmig = 0.025 h
−1 has been selected, which
is in the range estimated. On the other hand, for the high migration case, a
kmig = 1.75 h
−1 has been assumed. Similar estimates of this last migration rate
have been independently derived for a GBM cell line in [111] and references therein.
◦ Death by radiation: The effect of radiation on tumor cells (in terms of the
corresponding surviving cell fraction) is estimated by means of the standard Linear
Quadratic (LQ) model (see Section 3.3.2 in Chapter 3 and [53], [54], [55], [56]).
In this work has been considered that CSCs are more resistant to radiation than
CCs. Moreover, for any of these two tumor cell phenotypes, quiescent cells are
more radioresistant than proliferating ones. When a radiation dose is delivered
on the tumor, four estimates on dying fractions (corresponding to proliferating /
quiescent CC phenotype and to proliferating / quiescent CSC phenotype) for the
total tumor volume or for the inner and outer tumor regions are computed and a
corresponding amount of cells (randomly chosen) is then declared as being dead.
◦ Apoptosis (programmed cell death): In this model, both tumor cell phe-
notypes considered are subject to apoptosis, a programmed cell death. When this
process occurs, cells activate the apoptotic pathway, which will lead to cell shrink-
age, nuclear fragmentation, chromatin condensation, chromosomal DNA fragmen-
tation and cell fragmentation into apoptotic bodies. The corresponding process is
accounted for in the model of tumor growth by changing from a proliferating or
quiescent state to an apoptotic state (cell death) at a rate kapt (see Table 3.1).
◦ Lysis: Disposal of cellular debris resulting from apoptosis is carried out by a
lysis process [193], for which a lysis rate klys = 0.035 h
−1 (about 30h) has been as-
sumed (see Table 3.1). This rate is about 10-fold less than phagocytosis (digestion
of cellular debris by macrophages) observed in vivo [194], but within the range
reported for in vitro cultures (0.002 h−1 for Hybridoma VO 208 cell line [195] to
0.07 h−1 for Fibrobacter succinogenes [196]). It should be noted in this context
that tumor growth within the size limits considered in this work is closer to in
vitro cultures than to in vivo situations. Lysis is mimicked in the model of tumor
growth by means of a Poisson process, which removes dead cells from the lattice.
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C.1.2 Time evolution of the system
A version of the Gillespie algorithm [197] has been implemented and adapted to
the cell population system considered in this work. To this end, some explanations
are in order. The class of processes that cells can perform will be indexed by µ,
say proliferation, migration, apoptosis and lysis. The related process rate, denoted
by rµ needs not be constant for all cells. For example, proliferating rates depend
on the tumor cell phenotypes considered. Therefore, a process Pc,µ is specified by
its process class µ, but also by the cell c where it takes place. For instance, if µ
represents proliferation, the corresponding replication process can be summarized
as follows
Pc,µ : c− [rc,µ]→ 2c,
where rc,µ is the rate at which the cell c implements the process µ (in this example,
proliferation) and 2c represents the two daughter cells arising from c.
The algorithm describing the temporal evolution of the system is shortly described
in the pseudo-code provided in Section C.1.3 (see also Figure C.1 for further de-
tails). Lines within braces at each step refer to the procedure sketched at the end
of the description.
• Step 0 (lines 1 to 10 - Initialization): Read the initial set of cells (C) and
the list of all possible processes at this stage of the system (P ) from a data file
(see lines 1 and 2). The initial tumor stage is composed by 105 cells, where about
85% are CCs and the remaining 15% are CSCs randomly distributed. Set the time
variable t to zero and initialize the unit-interval uniform random number generator
(URN) (see lines 3 and 4). When a size of about 106 cells is reached, a radiotherapy
treatment is applied. Then the frequency and total number of sessions (rsf and
ns), the dying cell fraction for each tumor cell phenotype (CC and CSC) after each
session, and the respective cell states (proliferating and quiescent) are computed
(see input parameters and lines 5 to 9). Moreover, the maximum number of cells
allowed (mnc) in computer simulations is also defined. On the other hand, the
proportion of CSCs (pin) to define the inner region for the case of high migration,
when heterogeneous therapies are delivered, should be established (80% in the
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simulations performed). Notice that, for the case of low migration, pin is equal to
100% which corresponds with the inner region where all CSCs are located.
• Steps 1 to 5 (lines 11 to 79 - Time evolution): A step-by-step time
evolution is processed within the global loop. The following Steps 1 to 5 are
repeated until the system reaches the end time tmax of simulation, when there are
no more processes to execute (for instance, all cells are dead) or the maximum
number of cells considered is reached (mnc = 10
6) at the end of the recurrence
tumor stage after radiation therapy.
• Step 1 (line 12 - Rates): Calculate and store as rΣ the sum of rates rc,µ of all
processes Pc,µ ∈ P .
• Step 2 (lines 13 and 14 - Time increment): Generate a random number u1
using the unit-interval uniform random number generator (URN), and calculate
the time increment τ = − ln(u1)
rΣ
.
• Step 3 (lines 15 to 23 - Process selection): The process Pb,v to perform
during this iteration is chosen randomly from the list of all processes P taking into
account that the probability of each process Pc,µ ∈ P to be chosen is proportional
to its rate rc,µ. As proposed by Gillespie [197], this can be done as follows: gen-
erate a second random number u2 using the unit-interval uniform random number
generator (URN). Then step-by-step sum up as r
′
Σ the rates rc,µ of all processes
Pc,µ ∈ P until the condition r′Σ− rc,µ < u2 · rΣ ≤ r′Σ is satisfied. Then store Pc,µ as
the selected process in Pb,v.
• Step 4 (lines 24 and 25 - Update): Increase the time t by τ , and adjust
the cell set to account for what has happened during process Pb,v (e.g. remove
cells, add cells, move cells and/or change environment of a cell). Update the list of
possible processes according to the new cell set (e.g. add/remove processes after
an environmental change).
• Step 5 (lines 26 to 78 - Radiation therapy): Radiation therapy starts
when the tumor reaches a size greater than or equal to mnc. Radiation is delivered
over the time corresponding with the number and frequency of sessions selected.
Notice that in the case of weekend interruptions the variable rsf should be incre-
mented in 72 hours after weekly consecutive sessions, and afterwards this period
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will be changed back to the initial frequency of sessions. For homogeneous thera-
pies a number of cells is randomly selected on the whole tumor corresponding with
the dying cell fraction of proliferating and quiescent states for CCs and CSCs re-
spectively. However, for heterogeneous therapies this selection is separately made
within the inner sphere and in the rest of the tumor, and the dying cell fractions
are computed for the corresponding radiation dose delivered on each region. At
the end of each session, the cell state of this set of cells is updated to dead. Alter-
natively, one might introduce the death process by radiation as a rate. However,
a common and accepted assumption is that this process is very fast, in which case
the algorithm chosen is much more efficient.
C.1.3 Pseudo-code guidelines
In this Section the pseudo-code guidelines of the algorithm implemented is de-
scribed (see Section C.1.2 above for further details).
Input parameters:
tmax := maximum duration of simulations
rsf := frequency of radiation sessions
ns := total number of radiation sessions
mnc := maximum number of cells allowed in simulations
pin := proportion of CSCs to define the inner region (for heterogeneous
therapies with the high migration rate)
Initialization:
1 – Input the initial set of cells C := {c | c is a cell within the volume V
where c ∈ {CC,CSC}}
2 – Determine the processes array P := {Pc,µ | if c ∈ C and c is reactant of µ}
3 – Set t := 0
4 – Initialize URN
5 – Initialize the dying cell fraction for each tumor cell phenotype (CC and CSC)
and cell state (proliferating and quiescent), where D is the radiation dose for
homogeneous therapies:
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Figure C.1. The flowchart of a cell in the model of tumor growth. (A) The
flowchart illustrates how the accessible states and rates for the respective transition for
a configuration of N cells, both CCs and CSCs, are determined algorithmically in the
computer program. Here, M = mG1 + mS + mG2 + mM . The possible transitions are
investigated cell by cell. For each cell (i = 1, . . . , N) all processes that cell i can perform
are determined and saved in a list. If cell i is dead, it can only undergo lysis with rate klys.
Accordingly, the rate ri,1 with which cell i can change its state becomes equal to the lysis
rate. Notice that this includes cells of tumor phenotype CC which reached its maximum
number of cell cycles and consequently die. If cell i is alive, apoptosis is added as every
cell can undergo apoptosis in the model, so that ri,1 = kapt. If in addition a lattice site
is free next to the cell, it may migrate, so ri,2 = ri,1 + kmig. In this way the total ri,µ of
cell i is computed, and all intermediate values, (ri,1, ri,2, ...) are saved. The total rate
at which the current cell configuration changes is then given by rtot =
∑N
i=0 ri,µi,max .
(B) To select a process, a random number ξ is chosen in [0, rtot), and that process p of
cell k is performed, for which either
∑k−1
i=1 ri,µi,max + rk,p ≤ ξ <
∑k−1
i=1 ri,µi,max + rk,p+1,
or p = µk,max and
∑k
i=1 ri,µi,max ≤ ξ <
∑k
i=1 ri,µi,max + rk+1,1. Concerning radiation
effects, cells are picked randomly and killed according to the corresponding surviving
cell fraction estimate.
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6 – Set pCC :=
(
1− e−ξp1(αD+βD2)
)
7 – Set qCC :=
(
1− e−ξq1(αD+βD2)
)
8 – Set pCSC :=
(
1− e−ξp2(αD+βD2)
)
9 – Set qCSC :=
(
1− e−ξq2(αD+βD2)
)
# Notice that in the case of heterogeneous therapies, Din and Dout should
be defined with the corresponding dying cell fractions for each tumor cell
phenotype (CC and CSC) and cell state (proliferating and quiescent)
respectively.
10 – Define rrad, srad, ds and dr (auxiliary variables):
Set rrad := false # conditional: start irradiation
Set srad := false # conditional: stop irradiation
Set ds := 0 # delivered number of radiation sessions
Set dr := 0 # radius partitions to define the inner region (for
heterogeneous therapies with the high migration rate)
11 – REPEAT
Sum over all process rates:
12 – Calculate rΣ :=
∑
Pc,µ∈P rc,µ
Calculate time step τ :
13 – Generate u1 from URN
14 – Take τ := − ln(u1)
rΣ
Select process Pb,v regarding to its probability Pb,v =
rb,v
rΣ
:
15 – Generate u2 from URN
16 – Set r
′
Σ := 0
17 – for all Pc,µ ∈ P do
18 – if (r
′
Σ < u2 · rΣ ≤ r′Σ + rc,µ) then
Select cell b and process class v:
19 – b := c
20 – v := µ
21 – end if
22 – Put r
′
Σ := r
′
Σ + rc,µ
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23 – end for
Execute process Pb,v:
24 – Put t := t+ τ
25 – Adjust C and P according to Pb,v
Applying radiation therapy:
26 – if ((length(C) ≥ mnc) or (rrad == true) and (srad == false)) then
27 – if ((ds == 0) or ((t− ts) == rsf ))
(taking into account weekend interruptions if it is the case) then
28 – if (ds == 0) then
Compute the center-of-mass:
29 – mx :=
∑
c∈C xi
length(C)
; my :=
∑
c∈C yi
length(C)
; mz :=
∑
c∈C zi
length(C)
Compute the diameter of tumor regions:
30 – Set rout := 0
31 – Set rin := 0
32 – for all c ∈ C do
33 – cd :=
√
(cx −mx)2 + (cy −my)2 + (cz −mz)2
34 – if (cd > rout) then
35 – rout := cd
36 – end if
37 – end for
38 – if (Heterogeneous therapy) then
39 – NCSC := Compute the number of CSCs in C
40 – if (Low migration rate) then
41 – for all c ∈ C and c is CSC do
42 – cd :=
√
(cx −mx)2 + (cy −my)2 + (cz −mz)2
43 – if (cd > rin) then
44 – rin := cd
45 – end if
46 – end for
47 – else # High migration rate
48 – for (i = dr; i > 0; i−−) do
49 – Set cin := 0
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50 – for all c ∈ C and c is CSC do
51 – cd :=
√
(cx −mx)2 + (cy −my)2 + (cz −mz)2
52 – if (cd ≤ (rout/dr) ∗ i) then
53 – cin := cin + 1
54 – end if
55 – end for
56 – if (cin ≥ pin ∗NCSC) then
57 – rin := (rout/dr) ∗ i
58 – break
59 – end if
60 – end for
61 – end if
62 – end if
63 – end if
For homogeneous therapies select randomly on the
whole tumor:
64 – A number of proliferating CCs corresponding to:
pCC
65 – A number of quiescent CCs corresponding to:
qCC
66 – A number of proliferating CSCs corresponding to:
pCSC
67 – A number of quiescent CSCs corresponding to:
qCSC
# Notice that for heterogeneous therapies this selection is separately
made within the inner sphere (center-of-mass to rin) and in the
rest of the tumor (rin to rout) for the corresponding radiation dose
delivered on each region (Din and Dout) respectively
68 – Change cell state of the selected set of cells to dead
69 – Adjust P for all selected cells
70 – ds := ds + 1
71 – rrad := true
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72 – if (ds == ns) then
73 – rrad := false
74 – srad := true
75 – end if
76 – ts := t # update time of the last delivered treatment session
77 – end if
78 – end if
79 – UNTIL (t ≥ tmax) or (P = ∅) or ((length(C) ≥ mnc) and (srad == true))
C.2 Additional results: radiotherapy treatments
and number of CSCs at the pre-treatment
and recurrence tumor stages
In this Section, additional results for heterogeneous and homogeneous radiation
therapies considered in Chapter 3 are presented and other model properties are
investigated.
C.2.1 Heterogeneous vs. homogeneous therapies for the
low and high migration cases
To begin with, in Tables C.1 and C.2 (to be compared to Tables 3.4 and 3.5 in
Chapter 3 respectively) the number of CSCs at the recurrence tumor stage (with
the corresponding standard deviation) for heterogeneous and the corresponding
averaged homogeneous radiation therapies considered in Chapter 3 are provided.
Moreover, heterogeneous and homogeneous radiation therapies required to achieve
tumor control are also shown. This is done for the values of pa (0.75, 0.50 and
0.25), CSC cycle duration (96h, 72h and 48h) and migration rate kmig (0.025h
−1,
1.75h−1) considered in Table 3.1.
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Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 96h −−− 2.0Gy − 2.5Gy(1) 2.10Gy(1) 2.5Gy
(83/7.87)
72h −−− 2.0Gy − 2.5Gy(2) 2.10Gy(2) 2.5Gy
(264/14.82)
48h 2.0Gy − 2.5Gy(3) 2.0Gy − 2.7Gy(4) 2.10Gy(3)/2.12Gy(4) 2.7Gy
(107/8.53) (603/41.22)/(514/13.65)
0.50 96h −−− 2.0Gy − 2.9Gy(5) 2.15Gy(5) 2.9Gy
(814/37.57)
72h −−− 2.0Gy − 2.9Gy(6) 2.17Gy(6) 2.9Gy
(2130/86.68)
48h 2.0Gy − 2.9Gy(7) 2.0Gy − 3.4Gy(8) 2.19Gy(7)/2.30Gy(8) 3.4Gy
(1785/78.31) (16757/243.46)/(12208/456.08)
0.25 96h −−− 2.0Gy − 3.3Gy(9) 2.23Gy(9) 3.3Gy
(3961/171.88)
72h −−− 2.0Gy − 3.3Gy(10) 2.27Gy(10) 3.3Gy
(14495/274.86)
48h 2.0Gy − 3.3Gy(11) 2.0Gy − 3.9Gy(12) 2.32Gy(11)/2.47Gy(12) 3.9Gy
(4457/232.67) (113546/1393.2)/(96346/1141.3)
Table C.1. Classification of heterogeneous and homogeneous radiation thera-
pies for the low migration case. In all cases, treatment sessions were scheduled along
6 weeks separated by 24 hours intervals except for weekends, where a 72 hours interval is
allowed. Data corresponding to 20 simulations (with different seeds of a random number
generator) are presented. In the heterogeneous therapies, radiation doses are specified
both for the outer (left) and inner (right) tumor regions, each case being indexed from (1)
to (12). The averaged dose for any of the previous cases is labeled with the same number
in the columns corresponding to homogeneous therapies. Within braces, the number of
CSCs at the recurrence tumor stage and the corresponding standard deviation are also
provided. See Figure 3.10 (A) in Chapter 3 where some of these results are shown.
C.2.2 Consequences of assuming that CSCs cycle faster
than CCs
So far, the standard assumption that the duration of cell cycle for CSCs is signif-
icantly longer than that of CCs has been considered (cf. for instance [142], [163],
[164], [165], [166], [167], [168], [169], [170] and [171]). For completeness, some re-
sults provided by this model of tumor growth under the opposite situation that
CSCs cycle faster than CCs are shortly described. To do that, consider the cases
where CSC cycle lasts 26 hours (respectively 18 hours) which is equal to (respec-
tively less than) the 26 hours cell cycle selected for CCs. In Tables C.3 and C.4 (see
also Figures C.2, C.3 and C.4), estimates of the tumor inner region diameter and
number of CSCs before radiation treatment starts are provided, both for the low
and high migration cases and values of pa equal to 0.75, 0.50 and 0.25 respectively.
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Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 96h −−− 2.0Gy − 2.5Gy(1) 2.10Gy(1) 2.5Gy
(135/11.88)
72h −−− 2.0Gy − 2.5Gy(2) 2.11Gy(2) 2.5Gy
(216/9.24)
48h 2.0Gy − 2.5Gy(3) 2.2Gy − 2.7Gy(4) 2.13Gy(3)/2.33Gy(4) 2.7Gy
(294/16.73) (536/37.21)/(267/10.61)
0.50 96h 2.0Gy − 2.9Gy(5) 2.3Gy − 2.9Gy(6) 2.23Gy(5)/2.45Gy(6) 2.9Gy
(349/21.89) (634/43.73)/(251/13.86)
72h 2.0Gy − 2.9Gy(7) 2.6Gy − 2.9Gy(8) 2.25Gy(7)/2.70Gy(8) 2.9Gy
(815/36.70) (1579/85.56)/(466/29.65)
48h 2.0Gy − 2.9Gy(9) 2.8Gy − 3.4Gy(10) 2.29Gy(9)/3.00Gy(10) 3.4Gy
(12712/455.01) (19344/447.66)/(1582/48.38)
0.25 96h 2.0Gy − 3.3Gy(11) 2.4Gy − 3.3Gy(12) 2.36Gy(11)/2.65Gy(12) 3.3Gy
(1448/71.75) (2419/160.03)/(769/59.82)
72h 2.0Gy − 3.3Gy(13) 2.7Gy − 3.3Gy(14) 2.43Gy(13)/2.90Gy(14) 3.3Gy
(2646/136.52) (11318/335.88)/(2020/77.78)
48h 2.0Gy − 3.3Gy(15) 3.4Gy − 3.9Gy(16) 2.52Gy(15)/3.60Gy(16) 3.9Gy
(78073/3054.90) (191730/3747.03)/(7716/174.66)
Table C.2. Classification of heterogeneous and homogeneous radiation ther-
apies for the high migration case. In all cases, treatment sessions were scheduled
along 6 weeks separated by 24 hours intervals except for weekends, where a 72 hours
interval is allowed. Data corresponding to 20 simulations (with different seeds of a ran-
dom number generator) are presented. In the heterogeneous therapies, radiation doses
are specified both for the outer (left) and inner (right) tumor regions, each case being
indexed from (1) to (16). The averaged dose for any of the previous cases is labeled
with the same number in the columns corresponding to homogeneous therapies. Within
braces, the number of CSCs at the recurrence tumor stage and the corresponding stan-
dard deviation are also provided. See Figure 3.10 (B) in Chapter 3 where some of these
results are shown.
As expected, in these cases the inner core where most CSCs remain concentrated
is now larger than when slow-cycling CSCs is assumed, see Tables C.3 and C.4 (to
be compared to Tables 3.2 and 3.3 in Chapter 3). In particular, it should be noted
that in the slow-cycling CSCs case for the low migration case such inner regions,
where 100% of CSCs are located, ranged from 15% to 25% of the total tumor
volume. For the case of high migration the volume where at least 80% of CSCs are
located ranged from 21% to 40% of the volume where 90% of total cells (CCs and
CSCs) are located. Notice that, as reported in Chapter 3, the average diameter of
the tumor for the low migration case is about 2680µm, while for the high migration
case the average diameter of the region where 90% of total cells (CCs and CSCs)
are located is about 3120µm (with standard deviations of 56µm and 186µm over
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20 simulation performed for each parameter set considered respectively).
When the assumption that CSCs cycle faster than CCs is made, then the values of
the average diameter of the tumor and the region where the 90% of total cells (CCs
and CSCs) are located for the low and high migration cases respectively, are exactly
those recalled above. This is due to the fact that computer simulations are executed
for the same maximum number of cells (106) keeping the same migration rates.
However, in the case of low migration now considered and CSC cycle duration equal
to 26h (respectively 18h) tumor inner regions range from 20% to 83% (respectively
22% to 100%) of the total tumor volume (see Table C.3, and Figures C.2 (A) and
C.3 (A)). For the case of high migration and CSC cycle duration equal to 26h
(respectively 18h) these inner regions further expand, so that the volume where
80% of CSCs remain confined ranges now from 28% to 44% (respectively 33% to
51%) of the volume where 90% of total cells (CCs and CSCs) are located (see Table
C.4, and Figures C.2 (B) and C.3 (B)).
pa = 0.75 pa = 0.50 pa = 0.25
τcsc Diameter CSCs Diameter CSCs Diameter CSCs
26h 1567.3 µm 18217 1826.2 µm 21417 2516.3 µm 29873
[57.16 µm] [71.82] [78.22 µm] [145.66] [37.87 µm] [765.80]
18h 1623.5 µm 19151 2412.9 µm 27846 2678.3 µm 84134
[63.48 µm] [75.48] [67.77 µm] [573.03] [48.75 µm] [3104.15]
Table C.3. Estimates of the tumor inner region diameter and number of CSCs
before irradiation for the low migration case and fast-cycling CSCs. Diameter
is that of an inner sphere where 100% of CSCs are located. CSCs number is computed
before radiation therapy treatment starts. Within brackets the corresponding standard
deviations are also provided. Data corresponding to 20 simulations (with different seeds
of a random number generator) for each case considered. See also Figures C.2 (A), C.3
(A) and C.4 (A) where these results are shown.
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pa = 0.75 pa = 0.50 pa = 0.25
τcsc Diameter CSCs Diameter CSCs Diameter CSCs
26h 2048.1 µm 23084 2195.0 µm 38081 2365.7 µm 64786
[72.81 µm] [485.90] [84.28 µm] [1227.08] [69.15 µm] [2086.43]
18h 2156.5 µm 25791 2284.4 µm 54628 2495.4 µm 124584
[62.38 µm] [584.35] [93.49 µm] [1502.97] [71.36 µm] [2339.59]
Table C.4. Estimates of the tumor inner region diameter and number of CSCs
before irradiation for the high migration case and fast-cycling CSCs. Diameter
is that of an inner sphere where 80% of CSCs are located. CSCs number is computed
before radiation therapy treatment starts. Within brackets the corresponding standard
deviations are also provided. Data corresponding to 20 simulations (with different seeds
of a random number generator) for each case considered. See also Figures C.2 (B), C.3
(B) and C.4 (B) where these results are shown.
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Figure C.2. Representation of the tumor inner region diameter for the low
and high migration cases. Diameters of the tumor inner region at the pre-treatment
stage (where about 106 cells are present) and the corresponding standard deviations
after performing 20 simulations in each case (with different seeds of a random number
generator) are shown. Results are provided for the cases pa = 0.75, pa = 0.50 and
pa = 0.25 (left, middle, right) and CSC cycle durations equal to 18h, 26h, 48h, 72h and
96h. (A) Diameters of the tumor inner sphere where 100% of CSCs are located for the
low migration case. (B) Diameters of the tumor inner sphere where 80% of CSCs are
located for the high migration case. See Tables 3.2 and 3.3 in Chapter 3, and Tables C.3
and C.4 above.
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Figure C.3. Representation of the volume proportion of the inner region
respect to the volume of the outer region for the low and high migration
cases. Volume of the tumor inner region at the pre-treatment stage (where about
106 cells are present) and the corresponding standard deviations after performing 20
simulations in each case (with different seeds of a random number generator) are shown.
Results are provided for the cases pa = 0.75, pa = 0.50 and pa = 0.25 (left, middle, right)
and CSC cycle durations equal to 18h, 26h, 48h, 72h and 96h. (A) Volume proportion
of the tumor inner sphere where 100% of CSCs are located for the low migration case
with respect to the total tumor volume (2680µm). (B) Volume proportion of the tumor
inner sphere where 80% of CSCs are located for the high migration case with respect to
the region where 90% of total cells (CCs and CSCs) are located (3120µm). See Tables
3.2 and 3.3 in Chapter 3, and Tables C.3 and C.4 above.
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Figure C.4. Representation of the number of CSCs before irradiation for the
low and high migration cases. Number of CSCs at the pre-treatment stage (where
about 106 cells are present) and the corresponding standard deviations after performing
20 simulations in each case (with different seeds of a random number generator) are
shown. Results are provided for the cases pa = 0.75, pa = 0.50 and pa = 0.25 (left,
middle, right), CSC cycle durations equal to 18h, 26h, 48h, 72h and 96h, for the low (A)
and high (B) migration cases. See Tables 3.2 and 3.3 in Chapter 3, and Tables C.3 and
C.4 above.
To complete this discussion related to the fast-cycling CSCs situation, some results
concerning the performance of heterogeneous and the corresponding averaged ho-
mogeneous radiation therapies for CSC cycle durations equal to 26h and 18h are
provided in Tables C.5 and C.6 (see also Figures C.5 and C.6) respectively. More-
over, the number of CSCs at the recurrence tumor stages and radiation doses for
heterogeneous and homogeneous therapies needed to obtain tumor control are also
shown.
As it turns out, as CSC cycle duration and pa decrease, the standard fractionation
(30 sessions delivered 5 days a week at 24 hours intervals with weekend inter-
ruptions) is not enough to treat the resulting tumors with clinically acceptable
radiation doses. In both cases, heterogeneous and homogeneous radiation ther-
apies and for some model parameter sets a fractionation protocol delivered in 7
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days a week along 30 sessions at 24 hours intervals is advisable instead. Moreover,
in the worst scenario, which corresponds to CSC cycle duration equal to 18h and
pa = 0.25, the total radiation dose needed to achieve tumor control whit any of
these fractionation protocols is too high to be considered as a treatment option.
However, an inspection of Tables C.5 and C.6 (see Figures C.5 and C.6) reveals
that for all model parameter sets used, heterogeneous radiation therapies yield
better results than their averaged homogeneous counterparts.
Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 26h 2.0Gy − 2.5Gy(1) 2.0Gy − 3.2Gy(2) 2.10Gy(1)/2.24Gy(2) 3.2Gy
[63Gy]† [67.2Gy]† [63Gy]†/[67.2Gy]† [96Gy]†
(3085/116.59) (11904/232.85)/(7913/224.15)
18h 2.0Gy − 2.5Gy(3) 2.0Gy − 3.9Gy(4) 2.11Gy(3)/2.42Gy(4) 3.9Gy
[63.3Gy]† [72.6Gy]† [63.3Gy]†/[72.6Gy]† [117Gy]†
(26579/586.17) (57890/951.47)/(34675/854.97)
0.50 26h 2.0Gy − 2.9Gy(5) 2.0Gy − 4.3Gy(6) 2.28Gy(5)/2.73Gy(6) 4.3Gy
[68.4Gy]† [81.9Gy]† [68.4Gy]†/[81.9Gy]† [129Gy]†
(96626/1776.42) (182051/3485.87)/(123683/2601.55)
18h 2.0Gy − 2.9Gy(7) 2.0Gy − 4.9Gy(8) 2.66Gy(7)/4.12Gy(8) 4.9Gy
[79.8Gy]‡ [123.6Gy]‡ [79.8Gy]‡/[123.6Gy]‡ [147Gy]‡
(241936/7613.76) (357911/9430.74)/(30377/1859.44)
0.25 26h 2.0Gy − 3.3Gy(9) 2.0Gy − 4.7Gy(10) 3.10Gy(9)/4.23Gy(10) 4.7Gy
[93Gy]‡ [126.9Gy]‡ [93Gy]‡/[126.9Gy]‡ [141Gy]‡
(192613/5840.14) (331871/9068.78)/(52201/3183.69)
18h −−− −−− −−− −−−
Table C.5. Performance of heterogeneous and homogeneous radiation thera-
pies for the low migration case and fast-cycling CSCs. Data corresponding to 20
simulations (with different seeds of a random number generator) are presented. Treat-
ment sessions were scheduled along 6 weeks (30 sessions) separated by 24 hours intervals
except for weekends, where a 72 hours interval is allowed (†) and 7 days a week along 30
sessions at 24 hours intervals (without weekend interruptions) (‡). In the heterogeneous
therapies, radiation doses are specified both for the outer (left) and inner (right) tumor
regions, each case being indexed from (1) to (10). The averaged dose for any of the
previous cases is labeled with the same number in the columns corresponding to homo-
geneous therapies. In brackets the total dose of the radiation therapy treatment and
within braces the number of CSCs at the recurrence tumor stage with the corresponding
standard deviation. See also Figure C.5 where some of these results are shown.
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Figure C.5. Total number of fast-cycling CSCs at the end of the recurrence
tumor stage for heterogeneous and averaged homogeneous radiation therapies
with the low migration rate. Number of CSCs at the end of the recurrence tumor
stage (where about 106 cells are again present) and the corresponding standard deviations
after performing 20 simulations in each case (with different seeds of a random number
generator) are shown. (A) For heterogeneous therapies that do not achieve tumor control
and (B) for the corresponding averaged homogeneous therapies considered in Table C.5
for the cases pa = 0.75, pa = 0.50 and pa = 0.25 (left, middle, right). The low migration
rate and CSC cycle durations equal to 18h and 26h have been assumed. Notice that
the vertical coordinate is represented in a logarithmic scale. See Table C.5 for further
details.
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Heterogeneous therapy Homogeneous therapy
pa τcsc No Control Control No Control Control
0.75 26h 2.0Gy − 2.5Gy(1) 2.8Gy − 3.4Gy(2) 2.14Gy(1)/2.97Gy(2) 3.4Gy
[64.2Gy]† [89.1Gy]† [64.2Gy]†/[89.1Gy]† [102Gy]†
(11050/484.08) (18967/326.68)/(2269/189.34)
18h 2.0Gy − 2.5Gy(3) 3.6Gy − 4.3Gy(4) 2.17Gy(3)/3.83Gy(4) 4.3Gy
[65.1Gy]† [114.9Gy]† [65.1Gy]†/[114.9Gy]† [129Gy]†
(159982/5495.70) (197218/5508.36)/(3826/319.69)
0.50 26h 2.0Gy − 2.9Gy(5) 3.5Gy − 4.1Gy(6) 2.31Gy(5)/3.70Gy(6) 4.1Gy
[69.3Gy]‡ [111Gy]‡ [69.3Gy]‡/[111Gy]‡ [123Gy]‡
(218770/5954.86) (282412/6544.93)/(9844/562.32)
18h 2.0Gy − 2.9Gy(7) 4.4Gy − 4.9Gy(8) 2.35Gy(7)/4.60Gy(8) 4.9Gy
[70.5Gy]‡ [138Gy]‡ [70.5Gy]‡/[138Gy]‡ [147Gy]‡
(594483/8063.34) (831328/18256.43)/(48205/2468.33)
0.25 26h 2.0Gy − 3.3Gy(9) 4.3Gy − 4.8Gy(10) 2.57Gy(9)/4.52Gy(10) 4.8Gy
[77.1Gy]‡ [135.6Gy]‡ [77.1Gy]‡/[135.6Gy]‡ [144Gy]‡
(689546/11268.43) (896248/19376.56)/(96035/4090.75)
18h −−− −−− −−− −−−
Table C.6. Performance of heterogeneous and homogeneous radiation ther-
apies for the high migration case and fast-cycling CSCs. Data corresponding
to 20 simulations (with different seeds of a random number generator) are presented.
Treatment sessions were scheduled along 6 weeks (30 sessions) separated by 24 hours
intervals except for weekends, where a 72 hours interval is allowed (†) and 7 days a
week along 30 sessions at 24 hours intervals (without weekend interruptions) (‡). In the
heterogeneous therapies, radiation doses are specified both for the outer (left) and inner
(right) tumor regions, each case being indexed from (1) to (10). The averaged dose for
any of the previous cases is labeled with the same number in the columns corresponding
to homogeneous therapies. In brackets the total dose of the radiation therapy treat-
ment and within braces the number of CSCs at the recurrence tumor stage with the
corresponding standard deviation. See also Figure C.6 where some of these results are
shown.
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Figure C.6. Total number of fast-cycling CSCs at the end of the recurrence
tumor stage for heterogeneous and averaged homogeneous radiation therapies
with the high migration rate. Number of CSCs at the end of the recurrence tumor
stage (where about 106 cells are again present) and the corresponding standard deviations
after performing 20 simulations in each case (with different seeds of a random number
generator) are shown. (A) For heterogeneous therapies that do not achieve tumor control
and (B) for the corresponding averaged homogeneous therapies considered in Table C.6
for the cases pa = 0.75, pa = 0.50 and pa = 0.25 (left, middle, right). The high migration
rate and CSC cycle durations equal to 18h and 26h have been assumed. Notice that
the vertical coordinate is represented in a logarithmic scale. See Table C.6 for further
details.
C.2.3 A particular case of cancer cell plasticity
To conclude this Appendix, an example of cancer cell plasticity is described, a
hypothesis that has been proposed to better understand the onset of resistance
after therapy (cf. for instance [203], [204] and [205]). To address this issue, suppose
that in addition to CSCs giving raise to CCs by asymmetric division, a (assumed
small) percentage of CCs may transform to a CSC phenotype, possibly as a reaction
to radiation therapy. In particular, consider the cases of CSC cycle duration equal
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to 48h and pa equal to 0.75 and 0.25, both for the low and high migration cases
respectively. Then, assume that a small percentage of CCs (5%) are transformed
to CSCs after sessions 5, 15 and 25 of a standard fractionation protocol (5 days
a week along 30 sessions at 24 hours intervals except for weekends, where a 72
hours interval is allowed). As one can expect, any increase in the number of CSCs
results in increased malignancy, measured in terms of higher radioresistance to
therapy. However, the conclusion obtained that heterogeneous, tumor-adapted
radiation therapies fare better than their corresponding averaged, homogeneous
versions continues to hold. To show that, in Table C.7 (respectively, Table C.8) a
comparison is provided of the same cases with and without the cancer cell plasticity
effect for the low (respectively high) migration case. See also Figures C.7 and C.8
where some results provided in Tables C.7 and C.8 are shown respectively.
Heterogeneous therapy Homogeneous therapy
pa No Control Control No Control Control
0.75 No CC Plasticity −−− 2.0Gy − 2.7Gy(1) 2.12Gy(1) 2.7Gy
[63.6Gy] [63.6Gy] [81Gy]
(514/13.65)
CC Plasticity 2.0Gy − 2.7Gy(2) 2.4Gy − 3.2Gy(3) 2.12Gy(2)/2.54Gy(3) 3.2Gy
[63.6Gy] [76.2Gy] [63.6Gy]/[76.2Gy] [96Gy]
(771/24.37) (1256/43.42)/(197/26.14)
0.25 No CC Plasticity −−− 2.0Gy − 3.9Gy(4) 2.47Gy(4) 3.9Gy
[74.1Gy] [74.1Gy] [117Gy]
(96346/1141.30)
CC Plasticity 2.0Gy − 3.9Gy(5) 3.2Gy − 4.3Gy(6) 2.47Gy(5)/3.47Gy(6) 4.3Gy
[74.1Gy] [104.1Gy] [74.1Gy]/[104.1Gy] [129Gy]
(143242/4084.60) (297794/6467.14)/(5144/280.49)
Table C.7. Estimating cancer cell plasticity effects for the low migration case
and CSC cycle duration equal to 48 hours. In all cases, treatment sessions were
scheduled along 6 weeks separated by 24 hours intervals except for weekends, where a
72 hours interval is allowed. Data corresponding to 20 simulations (with different seeds
of a random number generator) are presented. In the heterogeneous therapies, radiation
doses are specified both for the outer (left) and inner (right) tumor regions, each case
being indexed from (1) to (6). The averaged dose for any of the previous cases is labeled
with the same number in the columns corresponding to homogeneous therapies. In
brackets the total dose of the radiation therapy treatment and within braces the number
of CSCs at the recurrence tumor stage with the corresponding standard deviation. See
also Figure C.7 where some of these results are shown.
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Figure C.7. Cancer cell plasticity effects on the total number of CSCs at the
end of the recurrence tumor stage for heterogeneous and averaged homoge-
neous radiation therapies. The low migration rate and CSC cycle duration equal
to 48h have been assumed. Number of CSCs at the end of the recurrence tumor stage
(where about 106 cells are again present) and the corresponding standard deviations
after performing 20 simulations in each case (with different seeds of a random number
generator) are shown. Results are provided for radiation therapies with and without cell
plasticity effects. (A) For heterogeneous therapies that do not achieve tumor control and
(B) for the corresponding averaged homogeneous therapies considered in Table C.7 for
the cases pa = 0.75 and pa = 0.25 (left and right). Notice that the vertical coordinate is
represented in a logarithmic scale. See Table C.7 for further details.
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Heterogeneous therapy Homogeneous therapy
pa No Control Control No Control Control
0.75 No CC Plasticity −−− 2.2Gy − 2.7Gy(1) 2.33Gy(1) 2.7Gy
[69.9Gy] [69.9Gy] [81Gy]
(267/10.61)
CC Plasticity 2.2Gy − 2.7Gy(2) 2.6Gy − 3.2Gy(3) 2.33Gy(2)/2.75Gy(3) 3.2Gy
[69.9Gy] [82.5Gy] [69.9Gy]/[82.5Gy] [96Gy]
(953/37.45) (2487/92.83)/(526/34.56)
0.25 No CC Plasticity −−− 3.4Gy − 3.9Gy(4) 3.60Gy(4) 3.9Gy
[108Gy] [108Gy] [117Gy]
(7716/174.66)
CC Plasticity 3.4Gy − 3.9Gy(5) 3.7Gy − 4.3Gy(6) 3.60Gy(5)/3.94Gy(6) 4.3Gy
[108Gy] [118.2Gy] [108Gy]/[118.2Gy] [129Gy]
(8116/251.09) (17212/592.21)/(3501/278.34)
Table C.8. Estimating cancer cell plasticity effects for the high migration
case and CSC cycle duration equal to 48 hours. In all cases, treatment sessions
were scheduled along 6 weeks separated by 24 hours intervals except for weekends, where
a 72 hours interval is allowed. Data corresponding to 20 simulations (with different seeds
of a random number generator) are presented. In the heterogeneous therapies, doses are
specified both for the outer (left) and inner (right) tumor regions, each case being indexed
from (1) to (6). The averaged dose for any of the previous cases is labeled with the same
number in the columns corresponding to homogeneous therapies. In brackets the total
dose of the radiation therapy treatment and within braces the number of CSCs at the
recurrence tumor stage with the corresponding standard deviation. See also Figure C.8
where some of these results are shown.
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Figure C.8. Cancer cell plasticity effects on the total number of CSCs at the
end of the recurrence tumor stage for heterogeneous and averaged homoge-
neous radiation therapies. The high migration rate and CSC cycle duration equal
to 48h have been assumed. Number of CSCs at the end of the recurrence tumor stage
(where about 106 cells are again present) and the corresponding standard deviations
after performing 20 simulations in each case (with different seeds of a random number
generator) are shown. Results are provided for radiation therapies with and without cell
plasticity effects. (A) For heterogeneous therapies that do not achieve tumor control and
(B) for the corresponding averaged homogeneous therapies considered in Table C.8 for
the cases pa = 0.75 and pa = 0.25 (left and right). Notice that the vertical coordinate is
represented in a logarithmic scale. See Table C.8 for further details.
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